Šw‰ï•ñ
ƒgƒbƒv‚Ö
–ß‚é

(Šw‰ï)

2019

‘æ226‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@12ŒŽ21“ú

ƒAƒUƒVƒ`ƒWƒ“‚ð“Š—^’†‚ÉMycobacterium abscessus‚É‚æ‚é”dŽí«”ñŒ‹Šj«RŽ_‹ÛÇ‚ð”­Ç‚µ‚½œ‘ˆÙŒ`¬ÇŒóŒQ
’F@®ŽqA’ç@”ü“ÞŽqA’†ŽÉ—m•ãA‹g“c‘SGA‹g‘º‘ì˜NA—Ñ@—ÇŽ÷A’†”ö—²•¶AŽRªF‹v

 

61th ASH (American Society of Hematology)
‚n‚’‚Œ‚‚Ž‚„‚@12ŒŽ7“úE10“ú
4492
Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation
Tanizawa N, Koh H, Okamura H, Shiro K, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H
2030
Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide
Ido K, Koh H, Okamura H, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H
4159
Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Takahashi N, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Hino M
4587
Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood
Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Goto T, Kohno A, Ozeki K, Onishi Y, Fukuhara N, Fujii N, Yokoyama H, Kasai M, Iida H, Kanemura N, Endo T, Ago H, Onizuka M, Iyama S, Nawa Y, Nakamae M, Nagata Y, Kurahashi S, Tomiya Y, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, Murata M

 

‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ï@

“Œ‹ž@10ŒŽ11“ú-13“ú
OS1-7C-1
Real-world outcomes of ixazomib: a multicenter retrospective analysis from Kansai Myeloma Forum
Teruhito Takakuwa(KMF), Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Aya Nakaya, Shinichi Fuchida, Hirohiko Shibayama, Mitsuhiro Matsuda, Yutaka Shimazu, Yoko Adachi, Satoru Kosugi, Hitoji Uchiyama, Hirokazu Tanaka, Hitoshi Hanamoto, Yuji Shimura, Junya Kanda, Yoshiyuki Onda, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
OS1-13C-1
Development of personalized survival prediction curves in allogeneic HCT using machine learning
Hiroshi Okamura, Mika Nakamae, Makoto Moriguchi, Yusuke Okayama, Nao Tanizawa, Yumi Tagaito, Tetsuya Hayashi, Kazuki Sakatoku, Kentaro Ido, Naonori Harada, Satoru Nanno, Yasuhiro Nakashima, Hideo Koh, Takahiko Nakane, Asao Hirose, Kohei Yabusaki, Masayuki Hino, Hirohisa Nakamae
OS2-9D-1
Retrospective multi-centers study of AYA-MM

‚`ya Nakaya(KMF), Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, Ryosuke Yamamura, Yutaka Shimazu, Hirokazu Tanaka, Shinichi Fuchida, Yuji Shimura, Miki Kiyota, Katsuya Wada, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Kensuke Ohta, Chihiro Shimazaki, Masayuki Hino, Akifumi Takaori, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
OS3-14B-3
Phase I study of bortezomib-added GVHD prophylaxis for allo-HCT from HLA mismatched unrelated donor

Takahiko Nakane, Hiroshi Okamura, Yumi Tagaito, Shiro Koh, Yousuke Makuuchi, Satoru Nanno, Takuro Yoshimura, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
OS2-7C-2
Aggressive ATL prospective cohort study: CB and haploidentical transplantation may be feasible

Ayumu Ito, Nobuaki Nakano, Takashi Tanaka, Shigeo Fuji, Junya Makiyama, Yoshitaka Inoue, Ilseung Choi, Hirohisa Nakamae, Koji Nagafuji, Ken Takase, Shinichiro Machida, Tsutomu Takahashi, Yasushi Sawayama, Tomohiko Kamimura, Koji Kato, Toshiro Kawakita, Masao Ogata, Rika Sakai, Souichi Shiratori, Yoshihiro Inamoto, Kaoru Uchimaru, Atae Utsunomiya, Takahiro Fukuda
OS2-14D-1
Impact of pre-transplant donor-specific anti-HLA antibodies in cord blood transplantation

Shigeo Fuji, Kumi Oshima, Kazuteru Ohashi, Masashi Sawa, Takeshi Saito, Tetsuya Eto, Masatsugu Tanaka, Makoto Onizuka, Hirohisa Nakamae, Souichi Shiratori, Yukiyasu Ozawa, Michihiro Hidaka, Tokiko Nagamura, Hidenori Tanaka, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masao Ogata

OS3-8A-2
Unit selection for umbilical cord blood transplantation for adults with AML in complete remission

Masamitsu Yanada, Takaaki Konuma, Yachiyo Kuwatsuka, Tadakazu Kondo, Takahito Kawata, Satoshi Takahashi, Naoyuki Uchida, Shigesaburo Miyakoshi, Masatsugu Tanaka, Yukiyasu Ozawa, Masashi Sawa, Hirohisa Nakamae, Nobuyuki Aotsuka, Junya Kanda, Minoko Takanashi, Yoshinobu Kanda, Yoshiko Atsuta, Shingo Yano

OS2-7A-4
Clinicopathological analysis of HIV associated lymphoma at Osaka City General Hospital

Minako Tsutsumii‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j
, Takafumi Nakao, Yosuke Nakaya, Masahiro Yoshida, Takuro Yoshimura, Yoshiki Hayashi, Takeshi Inoue, Takahisa Yamane

OS2-7B-1
Importance of diagnosis-to-treatment interval in newly diagnosed Japanese patients with DLBCL

Masahiro Yoshidai‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Yosuke Nakaya, Minako Tsutsumi, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takahisa Yamane
OS1-15C-5
Clinical decision analysis with machine learning in relapse and refractory multiple myeloma

Shiro Kohi¶’·‰ï•{’†•a‰@j, Kumiyo Nakai, Yusuke Kizawa, Hiroyoshi Ichihara, Shoji Ine, Atsuko Mugitani
OS1-15D-5
Retrospective analysis of the safety and efficacy of thalidomide for myeloma in single institution
Yumi Kimurai‘åã•{϶‰ï’†’Õa‰@j,Teruhito Takakuwa, Moe Nomura, Ippei Otomaru, Taku Araki, Akiko Miura, Yotaro Fujitani, Ryosuke Yamamura
OS1-15D-6
A single-institute experience of pomalidomide for relapsed and refractory multiple myeloma patients

Teruhito Takakuwai‘åã•{϶‰ï’†’Õa‰@j, Taku Araki, Moe Nomura, Yumi Kimura, Ippei Otomaru, Akiko Miura, Yotaro Fujitani, Ryosuke Yamamura
OS3-12C-3
Clinicopathologic prognostic factors of gastrointestinal CMV disease after allogeneic HCT

Masatomo Kuno, Takashi Tanaka, Akiko Maeshima, Hirokazu Taniguchi, Kinuko Tajima, Wataru Takeda, Tsuneaki Hirakawa, Ayumu Ito, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Takahiro Fukuda

PS3-23-3
Case of successful treatment of cryptococcal meningitis by voriconazole complicated by ATL

Kiryang Kohi‘åã“S“¹•a‰@j, Dai Momose, Shiro Koh, Masahiro Manabe, Yasuyoshi Sugano, Masayuki Hino

PS2-16-8
‚qetrospective study of ibrutinib therapy for patients with CLL / SLL and MCL
Mirei Horiuchii‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Takafumi Nakao, Hirohisa Nakamae, Manabu Hirai, Hiroyoshi Ichihara, Kensuke Ohta, Dai Momose, Akiko Miura, Takahisa Yamane
PS2-14-1
Effective treatment of acute B-lymphoblastic leukemia with PDGFRB-EBF1 fusion treated by imatinib
Mirei Horiuchii‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Masahiro Yoshida, Minako Tsutsumi, Yosuke Nakaya, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Kai Yamasaki, Takane Aoyama, Takahisa Yamane
PS2-18-3
Delayed diagnosis of Epstein-Barr virus-positive mucocutaneous ulcer: a case report

Takuro Yoshimurai‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Minako Tsutsumi, Yosuke Nakaya, Naoko Tatsumi, Masahiro Yoshida, Yoshiki Hayashi, Takafumi Nakao, Takahisa Yamane
PS3-11-1
 HHV-8 positive multicentric Castleman disease featuring germinotropic plasmablastic proliferation
Yosuke Nakayai‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Minako Tsutsumi, Masahiro Yoshida, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takeshi Inoue, Takahisa Yamane

PS2-23-8
Elotuzumab therapy combined with lenalidomide and dexamethasone for patients with multiple myeloma

Moe Nomurai‘åã•{϶‰ï’†’Õa‰@j, Teruhito Takakuwa, Yumi Kimura, Ippei Otomaru, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura

PS2-24-5
Retrospective analysis of carfilzomib combination therapy for multiple myeloma at our hospital

Ippei Otomarui‘åã•{϶‰ï’†’Õa‰@j, Teruhito Takakuwa, Moe Nomura, Yumi Kimura, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura
PS3-2-6
Comparison of first-line with second-line treatment of anagrelide for essential thrombocythemia

Teruhito Takakuwai‘åã•{϶‰ï’†’Õa‰@j, Moe Nomura, Yumi Kimura, Ippei Otomaru, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura
PS2-13-2
Analysis of treatment selection and prognosis of high-risk myelodysplastic syndrome patients

Yusuke Kizawai¶’·‰ï•{’†•a‰@j, Shiro Koh, Soichiro Nakako, Mitsuharu Hashimura, Hiroyoshi Ichihara, Shoji Ine, Atsuko Mugitani
PS2-9-1
Report of 2 CML patients who discontinued TKI and have achieved pregnancy and childbirth

Kumiyo Nakaii¶’·‰ï•{’†•a‰@j, Shoji Ine, Yusuke Kizawa, Shiro Koh, Hiroyoshi Ichihara, Atsuko Mugitani

 

‘æ225‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@9ŒŽ21“ú

Œ´”­«ƒ}ƒNƒƒOƒƒuƒŠƒ“ŒŒÇ‚ÌŒo‰ß’†‚ÉŒã“V«ŒŒ—F•a‚`‚ð”­Ç‚µ‚½‚P—á
–Ø‘º—F”üA’†“ˆN”ŽA‰ªŽR—T‰îA‰ª‘º_ŽjC“ì–ì@’qC’†ªF•FAN@G’jC’†‘O”Ž‹vC“ú–ì‰ë”VA”õŒã^“o

 

“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
“Þ—Ç@7ŒŽ6“ú-7“ú
ŒŒ‰t“à‰ÈˆãŽt‚ɑ΂·‚é×–E•ª—Þ‹³ˆç‚ɂ‚¢‚ÄAŒŸ¸Žº‚ÌŽæ‚è‘g‚Ý[‘æ1•ü[
’r–{@ÊA¡ˆäd—ÇA•“c^ˆêA‹v•Û“c@_A’†‘O”ü‰ÀA“ú–ì‰ë”V
‚s×–EƒŠƒ“ƒp‰è‹…«ƒŠƒ“ƒpŽî‚É”­Ç‚µ‚½ˆÚAŒãƒŠƒ“ƒp‘B«Ž¾Š³
¡ˆäd—ÇA’r–{@ÊA•“c^ˆêA‹v•Û“c@_A’†‘O”ü‰ÀA“ú–ì‰ë”V

‘½”­«œ‘Žî‚É‚¨‚¯‚é×–EŒ`‘Ô•ª—Þ‚Æ—\Œã‚Æ‚ÌŠÖ˜A«‚ÌŒŸ“¢
•ŸŽR’qŽqAr–Ø‘ñA‚ŒK‹PlA‹v“ç–¾ä»AŠC]“cˆÇ“ÞA’†‘ºPmA[“cŒb—˜“ÞAŽR‘º—º‰î

 

‘æ111‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï

‘åã@6ŒŽ‚Q‚X“ú

‹äB‚Å”­Ç‚µ‚½ƒAƒOƒŒƒbƒVƒuNK ×–E”’ŒŒ•a‚Ì1—á
XŒû@TA’†“ˆN”ŽA‰ª‘º_ŽjA“ì–ì@’qAN@G’j@’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VA‘åàV­•F

ƒ_ƒTƒ`ƒjƒu•s‘Ï—e‚Å‚ ‚Á‚½‚ªAƒCƒ}ƒ`ƒjƒu‚É‚æ‚莾Š³ƒRƒ“ƒgƒ[ƒ‹‚µ“¾‚½‚—îƒtƒBƒ‰ƒfƒ‹
‰ªŽR—T‰îi‘åã•{϶‰ï’†’Õa‰@jA‚ŒK‹PlA‰³ŠÛˆê•½A–x“à”ü—ßAŽO‰YWŽqAr–Ø@‘ñA“¡’J—m‘¾˜NAŽR‘º—º‰î

µ¿u‰‰
–«œ‘«”’ŒŒ•aŽ¡—ÂÌÅVî•ñEÅ‘Oü
’†‘O”Ž‹v

 

‘æ224‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@6ŒŽ1“ú

ä`‘ÑŒŒˆÚAŒãA‚q‚rƒEƒCƒ‹ƒX”x‰Š‚ɑ΂µ‚ăŠƒoƒrƒŠƒ““Š—^‚ðs‚¤‚à’vŽ€“I‚È“]‹A‚ð’H‚Á‚½ with MRC‚Ì1—á
‰ªŽR—T‰îAN@G’jC‰ª‘º_ŽjC“ì–ì@’qC’†“ˆN”ŽA’†ªF•FA’†‘O”Ž‹vC“ú–ì‰ë”V

 

“ú–{—AŒŒ×–EŽ¡—Êw‰ï
ŒF–{@5ŒŽ23“ú-25“ú

“–‰@‚Ì—AŒŒ•”‚Æ‘¢ŒŒ×–EˆÚAƒR[ƒfƒBƒl[ƒ^[i‚g‚b‚s‚bj‚ÅŽæ‚è‘g‚ÞˆÚAŠÖ˜A‹Æ–±
˜@—Ö—º‰îA‰®“c—´ÆA¼–{—F‹IA“¡–ìŒbŽOA”~–{—R—¢A“cŽçº”ŽA‰Í“c‘¥•¶A“ú–ì‰ë”V

 

“ú–{ˆãŠwŒŸ¸Šw‰ï
ŽRŒû@5ŒŽ18“ú-19“ú

“–‰@‚É‚¨‚¯‚錌¬”—AŒŒ•s‰žÇ—á‚ÌŒã•ûŽw“EŒŸ“¢
ŠC]“cˆÇ“ÞA•ŸŽR@’qŽqAûüŒK@‹PlA‹v“ç@–¾ä»A’†‘º@PmA[“c@Œb—˜“Þ AŽR‘º@—º‰î

 

‘æ41‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åã@3ŒŽ7“úE9“ú
O4-2
”ñŠ°‰ðŠúAML‚̈ÚA‘O––½ŒŒWT1mRNAƒŒƒxƒ‹‚É”ä—Ⴕ“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ÌŽ€–SƒŠƒXƒN‚ª‘‰Á‚·‚é

ˆäŒËŒ’‘¾˜YA’†‘O”ü‰ÀAN@G’jA‰ª‘º_ŽjA“ì–ì@’qA¼–{ŒõFA‹´–{—R“¿A•‰ªNMAœA£’©¶A’†“ˆN”ŽA’†ªF•FA“ú–ì‰ë”VA’†‘O”Ž‹v

O16-1
HLAˆê’vŒŒ‰–”‚Í”ñŒŒ‰ƒhƒi[‚©‚ç‚Ì“¯ŽíˆÚA‚É‚¨‚¯‚éPTC‚™‹y‚ÑTac‚ð—p‚¢‚½GVHD—\–h-—Õ°‘æ2‘ŠŽŽŒ±’†ŠÔ‰ðÍ-

’†ªF•FA’†‘O”Ž‹vA“ì–ì@’qA‰ª‘º_ŽjA¼–{ŒõFA–‹“à—z‰îA’·è÷ŽœA“cŠ_“à—D”üA—Ñ@“NÆAŒ´“c®Œ›AˆäŒËŒ’‘¾˜YAŽð“¿ˆêŠóA’JàV@’¼A‰ªŽR—T‰îAXŒû@TAœA£’©¶A’†‘O”ü‰ÀA’†“ˆN”ŽAN@G’jA•‰ªNMA“ú–ì‰ë”V

O19-4
SOSf’f‚É‚¨‚¯‚éŒo’¼’°–å–¬ƒVƒ“ƒ`ƒOƒ‰ƒtƒB[‚ƃVƒAƒgƒ‹Šî€‚Ì”äŠrŒŸ“¢
‰ª‘º_ŽjAN@G’jA‚ŒK‹PlAˆäŒËŒ’‘¾˜YA–‹“à—z‰îAˆäªÈ“ñA“ì–ì@’qA’†“ˆN”ŽA’†ªF•FAéŒã“ÄŽuAŽR–{@WA‰HŽº‰ë•vA‹g“c~ŽjA¬’JW•½A‰Íç²÷Ž¡A“ŒŽRŽ –¾A‰–Œ©@iA‘åàV­•FA“ú–ì‰ë”VA’†‘O”Ž‹v
O25-3
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãStenotrophomonas maltophiliaŠ´õÇ‚Ì“Á’¥‚¨‚æ‚Ñ”­ÇŠÖ˜AˆöŽq‚ÌŒŸ“¢
œA£’©¶AN@G’jA’†‘O”ü‰ÀA’†ªF•FA’†“ˆN”ŽA•‰ªNMAŽR“cNˆêAŠ|‰®@OA“ú–ì‰ë”VA’†‘O”Ž‹v

O31-5
HCTC‚Ì‹Æ–±‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg‚ð’Ê‚¶‚½’nˆæ‚ÌŒ»ó‚Ì”cˆ¬‚Ɖۑè‚ÌŒŸ“¢
”~–{—R—¢A“c’†—¢•cA•Ÿ“c—²_A“ú–ì‰ë”V

O36-5
“–‰@‚É‚¨‚¯‚鑽”­«œ‘Žî‚ɑ΂·‚鎩‰Æ‘¢ŒŒŠ²×–EˆÚA‚ÌŽ¡—ìÑ

–Ø‘º—F”üA‚ŒK‹PlAr–Ø@‘ñA‰³ŠÛˆê•½AŽO‰YWŽqA“¡’J —m‘¾˜NA‘¾“cŒ’‰îAŽR‘º—º‰î
O37-3
“¯Ží‘¢ŒŒŠ²×–EˆÚA‘O‚ÌŒŒ´beta-2 microgloburin‚Í‘S¶‘¶—¦‚Ì—\Œã—\‘ªƒ}[ƒJ[‚ƂȂ蓾‚é
Œ´“c®Œ›A’†ªF•FA’†‘O”ü‰ÀA“cŠ_“à—D”üA—Ñ@“NÆAˆäŒËŒ’‘¾˜YA–‹“à—z‰îA‰ª‘º_ŽjA“ì–ì@’qA¼–{ŒõFA•‰ªNMAœA£’©¶A’†“ˆN”ŽAN@G’jA“ú–ì‰ë”VA’†‘O”Ž‹v
P3-5
“¯Ží‘¢ŒŒ×–EˆÚAŒã“«ƒEƒCƒ‹ƒXŠ´õǂɑ΂·‚é–ƉuƒOƒƒuƒŠƒ“‘å—ʗÖ@‚Ì—LŒø«EˆÀ‘S«‚ÌŒŸ“¢

ˆäŒËŒ’‘¾˜YA’†ªF•FA‰ª‘º_ŽjA“ì–ì@’qA¼–{ŒõFAœA£’©¶A’†‘O”ü‰ÀA’†“ˆN”ŽAN@G’jA“ú–ì‰ë”VA’†‘O”Ž‹v
P12-2
ŠO‰È“IØœ‚ÆŽ©‰È‘¢ŒŒŠ²×–EˆÚA‚É‚æ‚芰‰ð‚ÉŽŠ‚Á‚½Langerhans×–E“÷Žî
’†”ö—²•¶A•š‰®”¿—I—¢A’ç@”üØŽqA’†ŽÉ—m•ãA–x“à”ü—ßA‹g“c‘SGA‹g‘º‘ì˜NA—Ñ@—ÇŽ÷AŽRªF‹v
P37-2
œ‘ƒoƒ“ƒNÌŽæŽó‚¯“ü‚ê‰Â”Û“ü—̓VƒXƒeƒ€‚Ì“ü—Í󋵂ơŒã‚̉ۑè

“c’†—¢•cA”~–{—R—¢Aœ‘ƒoƒ“ƒN‹ß‹EŽ––±‹ÇA•Ÿ“c—²_A“ú–ì‰ë”V
ŠÅP7-5
ƒNƒŠ[ƒ“ƒ‹[ƒ€–ʉ琉ÀŠÉ˜a‚ªŠ³ŽÒ‚ÌS—ó‹µ‚É‚à‚½‚ç‚·Œø‰Ê

ª—ˆ^•àA‹g’JŽÀ‰ÄA”¼“c‚³‚â‚©A“¡“c“Þ•äA“cŒ´³ŒbAŽs‘º—R‹I”TA‰L’rƒŽqA’ß“c—Œb
ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
–{‘Ô«ŒŒ¬”ÂŒŒÇ‚É‚¨‚¯‚é×–EŒ¸­—Ö@‚̈ʒu‚¯
’†‘O”Ž‹v

ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
‘¢ŒŒŠ²×–EˆÚAƒhƒi[‚̈À‘S«‚ɂ‚¢‚Ä`œ‘‹y‚ÑG-CSF‚ð—p‚¢‚½––½ŒŒŠ²×–EÌŽæ‚ɂ‚¢‚Ä`
“ú–ì‰ë”V

 

‘æ223‰ñ“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‹ž“s@3ŒŽ2“ú
ƒŠƒ“ƒpß•a•Ï‚ð”F‚ß‚¸‘½”­œ•a•Ï‚Åf’f‚³‚ꂽRichiterÇŒóŒQ‚Ì1—á
’JàV@’¼A•‰ªNMAŒ´“c®Œ›A‰ª‘º_ŽjA“ì–ì@’qA’†“ˆN”ŽAN@G’jA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V

Á‰»ŠÇúE‚É‚æ‚èf’f‚ÉŽŠ‚Á‚½ŒÊ”­«œ‘“÷Žî
ˆ°“c‹½–²i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†”ö—²•¶A’ç@”üØŽqA’†ŽÉ—m•ãA•š‰®”¿—I—¢A–x“à”ü—ßA‹g“c‘SGA‹g‘º‘ì˜NA—Ñ@—ÇŽ÷AŽRªF‹v

 

‘æ33‰ñ“ú–{‚ª‚ñŠÅŒìŠw‰ï
•Ÿ‰ª@2ŒŽ24“ú

ƒ‰ƒ“ƒ`ƒIƒ“ƒZƒ~ƒi[
–«œ‘«”’ŒŒ•a`ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚Ä`
“ú–ì‰ë”V

•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚Ì‚½‚ß‚Ì–òÜŽt‚ÌŽæ‚è‘g‚Ý
‚‹´Ž”V

Š³ŽÒŽ©g‚ª•a‚¢‚ÆŽ¡—ÂɌü‚«‡‚¢‘±‚¯‚邽‚ß‚ÌŠÅŒìŽt‚ÌŽæ‚è‘g‚Ý
’ß“c—Œb

 

2018

‘æ222‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@12ŒŽ15“ú
¶ŠU‹³ˆçu‰‰‰ï
‘¢ŒŒŠ²×–EˆÚA‚Æ’nˆæ˜AŒg
“ú–ì‰ë”V

äNã÷“àŽîᎂɂæ‚é”A˜H•Âǂ𶂶‚½‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–E«ƒŠƒ“ƒpŽî
•Ä–{–¢—ˆC•‰ªNMC‰ª‘º_ŽjC“ì–ì@’qC’†‘O”Ž‹vC“ú–ì‰ë”V

 

60th ASH (American Society of Hematology)
Atlanta@12ŒŽ9“úE12“ú
2087
Noninvasive diagnostic approach by per rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation
Okamura H, Koh H, Ido K, Makuuchi Y, Takakuwa T, Ine S, Nanno S, Nakashima Y, Nakane T, Jogo A, Yamamoto A, Hamuro M, Yoshida A, Kotani K, Higashiyama S, Kawabe J, Shiomi S, Ohsawa M, Hino M, Nakamae H
4664
Pre-transplant Serum Beta-2 Microglobulin Level is**a Potential Novel Prognostic Marker for **Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation
Harada H, Nakane T, Nakamae M, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H
4665
The Proportional Association between WT1 mRNA level in Peripheral Blood before Allogeneic Hematopoietic Cell Transplantation and Risk of Mortality in Acute Myeloid Leukemia Not in Remission
Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Hashimoto Y, Takeoka Y, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

3
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Kiladjian JJ, Zachée P, Hino M, Pane F
, Masszi T, Harrison CN, Mesa RA, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S

 

‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï

“Œ‹ž@11ŒŽ15“ú-18“ú
Ž©ŒÈ–ƉuÇó‚ð’æ‚·‚錌‰tŽ¾Š³‚É‚¨‚¯‚éB×–E«–ƉuˆÙí‚ÌŒŸ“¢
•“cáÁˆêA’†‘O”ü‰ÀAœA£’©¶A’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V
–«œ‘«”’ŒŒ•aŠ³ŽÒ‚ÌSŒŒŠÇŒn‡•¹Ç‚ɑ΂·‚éABI/CAVIAèò•”ƒGƒR[ŒŸ¸‚̈Ӌ`‚ÉŠÖ‚·‚é•ïŠ‡“IŒŸ“¢
’†‘O”ü‰ÀA’†‘O”Ž‹vA‹´–{[A‹gì~ˆêA“¡‰ªˆê–çA“ú–ì‰ë”V

 

‘æ110‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
“Þ—Ç@11ŒŽ10“ú
‹CŠÇH“¹á‘‡•¹‚Ì–¢•ª‰»‘å×–EƒŠƒ“ƒpŽî‚ɑ΂µAŽ©‰Æ‘¢ŒŒŠ²×–EˆÚAŒã‚ÉŠO‰È“IÄŒšp‚ðŽ{s‚µ‚½ˆê—á
—Ñ@“NÆA“ì–ì@’qA’†“ˆN”ŽA’†‘O”Ž‹vA“ú–ì‰ë”VA’†@—ºŽqA“¡Œ´—LŽjAŒY•”@Œ›A—›@žÄ’ŒA‰ª–{K”ü
RichterÇŒóŒQ‚ɑ΂µIbrutinib“à•ž‚ðŽ{s‚µ‚½2Ç—á‚ÌŒŸ“¢
’ç@«–çi¶’·‰ï•{’†•a‰@jAŽsŒ´O‘PAˆäªÈƒjAŠìàV—S‰îAN@Žj˜NA’†ˆä‹vŽÀ‘ãAêm’JˆÀ’ÃŽq
SƒAƒ~ƒƒCƒh[ƒVƒX‡•¹‚ª‹^‚í‚ꂽ‘½”­«œ‘Žî‚̈ê—á
’†ˆä‹vŽÀ‘ãi¶’·‰ï•{’†•a‰@jAN@Žj˜NAŠìàV—S‰îAŽsŒ´O‘PAˆäªÈƒjAêm’JˆÀ’ÃŽq
Ž•“÷‚É”’ŒŒ•a“÷Žî‚ðŒ`¬‚µ‚½‹}«‘Oœ‘‹…«”’ŒŒ•a‚̈ê—á
’ç@”üØŽqi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g“c‘SGA’†ŽÉ—m•ãA•šŒ©”¿—I—¢A‹g‘º‘ì˜NA—Ñ@—ÇŽ÷A’†”ö—²•¶AŽRªF‹v
HTLV-1ŠÖ˜AÒ‘ÇiHAMj‚ɇ•¹‚µ‚½Hodgkin-like Adult T-cell lymphoma‚̈ê—á
’†ŽÉ—m•ãi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g“c‘SGA’ç@”üØŽqA•šŒ©”¿—I—¢A–x“à”ü—ßA‹g‘º‘ì˜NA—Ñ@—ÇŽ÷A’†”ö—²•¶AŽRªF‹v
‰»Šw—Ö@‚É—\–h“I‘o“à’ŽË‚ð•¹—p‚µ‚½äSŒ´”­‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–EƒŠƒ“ƒpŽî‚̈êÇ—á
’F@®Žqi‹ž“s‘æ2Ô\Žš•a‰@jA‰ª–{–¾–çA¬X—F‹IŽqA’ç@N•FA²X–Ø“ÞXA‹›“ˆL•F

 

‘æ80‰ñ“ú–{ŒŒ‰tŠw‰ï@

‘åã@10ŒŽ12“ú-14“ú
OS1-10D-5
“–‰@‚É‚¨‚¯‚鑽”­«œ‘ŽîŠ³ŽÒ‚ɑ΂·‚éƒ_ƒ‰ƒcƒ€ƒ}ƒu‚ÌŽg—pŒoŒ±

‚ŒK‹Pli‘åã•{϶‰ï’†’Õa‰@jAr–Ø‘ñA‰³ŠÛˆê•½A¼‰Yˆ»”TAŽO‰YWŽqA“¡’J—m‘¾˜NAŽR‘º—º‰îA‘¾“cŒ’‰î
OS1-14D-4
‘¢ŒŒŠíŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚éƒvƒƒoƒCƒIƒeƒBƒNƒX‚̉e‹¿‚ÉŠÖ‚·‚鎟¢‘ãƒV[ƒNƒGƒ“ƒT[‰ðÍ
“¡’J@—m‘¾˜Ni‘åã•{϶‰ï’†’Õa‰@jCˆêŠÛ@’q”üCˆî‘º@^—R”üCŒÃàV@‘•cCŒ´“c@ŠxC‰½@•ûC‚ŒK@‹PlCr–Ø@‘ñCŽO‰Y@WŽqCŽR‘º@—º‰îC‘¾“c@Œ’‰î
OS1-5A-5
Å–¢•ª‰»Œ^‹}«œ‘«”’ŒŒ•a‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA‚ÉŠÖ‚·‚錟“¢
ŽRè@‘A–Ø@~AX@rˆêAŒ´“c‰î“lAàV@³ŽjA“à“c’¼”VA‘å‹´ˆê‹@A•Ÿ“c—²_AN@Žj˜NA‹àX•½˜aA¬ìŒ[‹±A‰œ‘ºœA˜aAˆêŒË’C•vA_“c‘PLA“c’†~ŽiA”M“c—RŽqA–ö“c³ŒõA–î–ìTŒá
OS1-‚WA-3
æ“V«—nŒŒ«•nŒŒf’f‚É‚¨‚¯‚é–Ô—…“Iˆâ“`ŽqŒŸ¸‚Ì—L—p«

‘„àV‘åŽ÷A–؋MŽqA¬‘q_”üA‰ª–{D—YAìã‚OAŽRªF‹vAŽR–{rŽŠA›–ì@m
OS1-10A-5
nj󫜑Žî1414—á‚ÌŒã•ûŽ‹“I‰ðÍFŠÖ¼œ‘ŽîƒtƒH[ƒ‰ƒ€‚©‚ç‚ÌÅV•ñ
“c’†G˜aA‹ÚàVŒ›‘¾˜YA’†’J@ˆ»A‹àŽqmbA‘¾“cŒ’‰îA¬™@’qA”ª–ØG’jA‰Ô–{@mA•£“c^ˆêAŽu‘º—EŽiAŽÄŽR_•FA¬Œ´®ŒbA’†’J‰pmAæ|“c~–çA‹›“ˆL•FA˜a“cŸ–çA‰G–ì—²”ŽA¼ˆä—˜[A“àŽRl“ñA¼“cŒõOA‘«—§—zŽqA‚ÜWŽjA•“cƒ–çA’J˜e‰ëŽjA“‡èçqA“ú–ì‰ë”VA¡“c˜a“TA–쑺¹ìA‹à‘q@÷A¼‘º@“ž
OS1-10B-‚U
RRMMŠ³ŽÒ‚ɑ΂·‚éKRD—Ö@‚¨‚æ‚ÑKD—Ö@‚ÌŒã•ûŽ‹“I‰ðÍiŠÖ¼œ‘ŽîƒtƒH[ƒ‰ƒ€j
‰¶“c‰ÀKAæ|“c~–çA‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiA‘¾“cŒ’‰îA“c’†G˜aA•£“c^ˆêA’†’J@ˆ»A‹›“ˆL•FA¬™@’qA¼“cŒõOA‘«—§—zŽqA”ª–ØG’jA“àŽRl“ñAV“°^‹IA¡“c˜a“TA“ú–ì‰ë”VA–쑺¹ìA“‡èçqA•“cƒ–çA‹à‘q@÷A‚ÜWŽjA¼‘º@“ž

OS1-‚TD-‚U
ƒTƒŠƒhƒ}ƒCƒh’P“ÆŽ¡—ÂðŽ{s‚µ‚½ÇŒó«œ‘Žî230—á‚ÌŒã•ûŽ‹“I‰ðÍiŠÖ¼œ‘ŽîƒtƒH[ƒ‰ƒ€j
‹àŽqmbAŽÄŽR_•FA”ª–ØG’jAæ|“c~–çA’†’J@ˆ»A¬™@’qA–Ø“c@‹œA“c’†G˜aAŽu‘º—EŽiA•£“c^ˆêA‘«—§—zŽqA˜a“cŸ–çA´“cŽÀŠóA‹›“ˆL•FA‘¾“cŒ’‰îA¬Œ´®ŒbAà_“cí‹`A¬—ѳsA“àŽRl“ñA‰G–ì—²”ŽA•“cƒ–çA¡“c˜a“TA‚ÜWŽjA“‡èçqA‹à‘q@÷A“ú–ì‰ë”VA–쑺¹ìA¼‘º@“ž

PS1-3-3
‚U”ÔõF‘̂̃gƒŠƒ\ƒ~[‚𔺂Á‚½‹}«’P‹…«”’ŒŒ•a
ŠÔ•”Œ«Š°i‘åã“S“¹•a‰@jAó“c—æŽqA”‹Œ´—SŽŠA•S£@‘åA›–ìˆÀŠìAáÁè@•A‚@‹N—Ç
PS1-6-2
–{‘Ô«ŒŒ¬”ÂŒŒÇŠ³ŽÒ‚̃ŠƒXƒN‘w•Ê
‹´–{—R“¿i’¹ŽæŒ§—§’†‰›•a‰@jA’†‘O”Ž‹vA“c’†FKA¬‘º—T”üA–x“à”ü—ßA‹g‘º‘ì˜NA‚ŒK‹PlA”ž’JˆÀ’ÃŽqAœA£’©¶A’†‘O”ü‰ÀAN@G’jA“ú–ì‰ë”V
PS1-13-4
‘ÌŠOŽ®–ŒŒ^lH”xiECMOjŽg—p‰º‚ɉ»Šw—Ö@‚ðs‚¢A‹~–½‚µ“¾‚½HIVŠÖ˜AS‘ŸŒ´”­ˆ««ƒŠƒ“ƒpŽî‚̈ê—á
•š‰®”¿—I—¢i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g‘º‘ì˜NA’ç@”üØŽqA’†ŽÉ—m•ãA–x“à”ü—ßA‹g“c‘SGA—Ñ@—ÇŽ÷A’†”ö—²•¶AŽRªF‹v
PS1-15-5
ƒXƒeƒƒCƒh“Š—^Œã‚ÉäB”j—ô‚ð‚«‚½‚µA“®–¬Çðp‚É‚æ‚è‹~–½‚µ‚¦‚½ŒŒŠÇ“àˆ««ƒŠƒ“ƒpŽîiAITLj Š³ŽÒ‚̈ê—á
¼‰Yˆ»”Ti‘åã•{϶‰ï’†’Õa‰@jA‚ŒK‹PlA‰³ŠÛˆê•½AŽO‰YWŽqAr–Ø‘ñA“¡’J—m‘¾˜NAŽR‘º—º‰îA¼“c“TŽjA‘¾“cŒ’‰î
PS1-17-1
Œ`Ž¿×–EŽî‚ÌŒã•ûŽ‹“I‘½Ž{Ý‹¤“¯Œ¤‹†iŠÖ¼œ‘ŽîƒtƒH[ƒ‰ƒ€j
’†’J@ˆ»A“c’†G˜aA”ª–ØG’jA‘¾“cŒ’‰îAŽÄŽR_•FAæ|“c~–çAV“°^‹IAŽu‘º—EŽiA¬™@’qA–Ø“c@‹œA‹àŽqmbA¡“c˜a“TA‰G–ì—²”ŽA¼“cŒõOA”Ñ“c³lA‘«—§—zŽqA•£“c^ˆêA‹›“ˆL•FA“àŽRl“ñA‚‹´—LjêA¼ˆä—˜[A˜a“cŸ–çA´“cŽÀŠóA“‡èçqA“ú–ì‰ë”VA•“cƒ–çA‹à‘q@÷A‚ÜWŽjA–쑺¹ìA¼‘º@“ž
OS2-8B-6
Ķ•s—Ç«•nŒŒ‚ɑ΂·‚éƒtƒ‹ƒ_ƒ‰ƒrƒ“Aƒƒ‹ƒtƒ@ƒ‰ƒ“ATBI ‚SGy‘Oˆ’u‚É‚æ‚éä`‘ÑŒŒˆÚA
N@G’jA‹g‘º‘ì˜NA“cŠ_“à—D”üA—Ñ@“NÆAŒ´“c®Œ›A‰ª‘º_ŽjA“ì–ì@’qAœA£’©¶A’†‘O”ü‰ÀA’†“ˆN”ŽA’†ªF•FA“ú–ì‰ë”VA’†‘O”Ž‹v

OS2-11C-2
Ä”­E“ALLŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚ɃCƒmƒcƒYƒ}ƒuƒIƒ]ƒKƒ}ƒCƒVƒ“‚ð“Š—^‚µ‚½‘æ‚R‘ŠŽŽŒ±‚É‚¨‚¯‚éƒAƒWƒAl‚ÌŒ‹‰Ê
“ú–ì‰ë”VA“à“crŽ÷A‘å¼@NAChul Won JungAYeow Tee GohA²“¡@Œ‰AMing Chung Wang
A¬–ì’mânA¼‰i@“sAM.Luisa PaccagnellaABarbara SleightAErik VandendriesA“¡ˆä—z‰îA“¡“‡’¼m

PS2-19-4
¸‘ƒŒ´”­PTCL, NOS‚̈ê—á
“cŠ_“à—D”üA’†“ˆN”ŽA‰ª‘º_ŽjA“ì–ì@’qAN@G’jA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V
PS2-25-1
ƒJƒ‹ƒtƒBƒ‹ƒ]ƒ~ƒu“Š—^Œã‚É‹}«S•s‘S‚ÉŽŠ‚Á‚½IgAŒ^‘½”­«œ‘Ží‚̈ê—á
‰³ŠÛˆê•½i‘åã•{϶‰ï’†’Õa‰@jA‚ŒK‹PlA¼‰Yˆ»”TAŽO‰YWŽqAr–Ø‘ñA“¡’J—m‘¾˜NAŽR‘º—º‰îA‘¾“cŒ’‰î
PS2-25-3
KMF‚É“o˜^‚³‚ꂽƒ{ƒ‹ƒeƒ]ƒ~ƒu‚ÆIMiDs—¼Ü‚É’ïR«‚ÌÄ”­œ‘Žî‚Ì—\Œã‰ðÍ
“¡Œ´—º‰îA“c’†G˜aA‹ÚàVŒ›‘¾˜YA‹àŽqmbAŽu‘º—EŽiA‘¾“cŒ’‰îA•£“c^ˆêA’†’J@ˆ»Aæ|“c~–çA”ª–ØG’jA˜a“cŸ–çA¬™@’qA‹›“ˆL•FAŽÄŽR_•FA¬Œ´®ŒbA’†’J‰pmA“àŽRl“ñA‘«—§—zŽqA”Ñ“c³lAà_“cí‹`A¼“cŒõOA‚ÜWŽjA–쑺¹ìA“‡èçqA“ú–ì‰ë”VA•“cƒ–çA’J˜e‰ëŽjA¡“c˜a“TA‹à‘q@÷A¼‘º@“ž
PS2-26-2
‰ß”SâfÇŒóŒQ‚𔺂¤Žá”N”­Ç‚ÌIgMŒ^‘½”­«œ‘Žî
‹g‘º‘ì˜Ni‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA—Ñ@—ÇŽ÷A’ç@”üØŽqA’†ŽÉ—m•ãA•š‰®”¿—I—¢A‹g“c‘SGA’†”ö—²•¶AŽRªF‹v

PS2-33-5
“–ŒŒ‰t“à‰È‚É‚¨‚¯‚éÝ‘îˆã—Ë@ŠÖ‚Ö‚ÌЉî
ŽsŒ´O‘Pi¶’·‰ï•{’†•a‰@jAˆäªÈ“ñAŠìàV—C‰îAN@Žj˜NA‘¾“c’‰MAŒÃì‰À‰›A’†ˆä‹vŽÀ‘ãAÂŽR‘×FA”ž’JˆÀ’ÃŽq

OS3-8A-6
ƒ‚ƒKƒ€ƒŠƒYƒ}ƒu•¹—p‰»Šw—Ö@‚É‚ÄŠ®‘SŠ°‰ð“ž’BŒã‚ÉŒŒŠÇ“à‘å×–EŒ^B×–EƒŠƒ“ƒpŽî‚ð”­Ç‚µ‚½ATL‚Ì1Ç—á
•S£@‘åi‘åã“S“¹•a‰@jAŠÔ•”Œ«Š°A›–ìˆÀŠìA‚@‹N—Ç
OS3-8B-3
“–Ž{Ý‚Å‚Ì ‚—îŽÒ–¢Ž¡—ÃATL‚ɑ΂·‚郂ƒKƒ€ƒŠƒYƒ}ƒu•¹—pCHOP—Ö@‚ÌŒã•ûŽ‹“IŒŸ“¢

‚@‹N—Çi‘åã“S“¹•a‰@jA•S£@‘åAŠÔ•”Œ«Š°A›–ìˆÀŠìA“ú–ì‰ë”V
OS3-13B-1
œ‘ƒoƒ“ƒN‚ð‰î‚µ‚½ƒR[ƒfƒBƒl[ƒgŠúŠÔ’Zk‚ÉŒü‚¯‚½ŠJŽnƒhƒi[l”‘‰Ái‚Tl->‚P‚Oljƒgƒ‰ƒCƒAƒ‹

•½ìŒoWA’A”nŒ¦ŽqA‘å‹´ˆêŽ÷A–L“ˆâM“¿A‘å¼@NA¬àVK‘×A‰Á“¡„“ñA“ú–ì‰ë”VA‘O“c‰ÃMA“ˆ“c@–¾A‹{–{•q_A”’“yŠî–¾AŽRŒûŒö•½A•Ÿ“c—²_
PS3-5-3
­—Ê’ZŠúŠÔ‚̃AƒŒƒ€ƒcƒYƒ}ƒu‚ª‘tŒ÷‚µ‚½AT×–E‘åè÷—±ƒŠƒ“ƒp«”’ŒŒ•a‚É”º‚¤Ô‰è‹…á”

•‰ªNMAN@G’jAŽð“¿ˆêŠóA“¡’J —m‘¾˜NA–î–쑸Œ[A–ö‘òFŽŸA“ú–ì‰ë”V
PS3-8-2
œ‘ˆÙŒ`¬ÇŒóŒQ‚©‚ç‚Ìi“W‚Æl‚¦‚ç‚ꂽAÒ‘d–ŒŠO‚ÉŽîᎌ`¬
‚µ‚½Ô‰è‹…“÷Žî
’†ŽÉ—m•ãi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA—Ñ@—ÇŽ÷AŽRãp@“OA’ç@”üØŽqAA•š‰®”¿—I—¢A–x“à”ü—ßA‹g‘º‘ì˜NA’†”ö—²•¶Aˆäã@Œ’AŽRªF‹v
PS3-19-1
f’f‚©‚玡—Â܂ł̊úŠÔ‚ª’Z‚¢‚Ù‚Ç‚—îDLBCLŠ³ŽÒ‚Ì—\Œã‚Í•s—Ç‚Å‚ ‚é

‹g“c‘SGi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†ŽÉ—m•ãA’ç@”üØŽqAA•š‰®”¿—I—¢A–x“à”ü—ßA‹g‘º‘ì˜NA—Ñ@—ÇŽ÷A’†”ö—²•¶AŽRªF‹v
PS3-24-8
“–‰@‚É‚¨‚¯‚éŽÀ—Õ°‚ł̃CƒLƒTƒ]ƒ~ƒu‚̈À‘S«‚Æ—LŒø«
‚ŒK‹Pli‘åã•{϶‰ï’†’Õa‰@jA‰³ŠÛˆê•½A¼‰Yˆ»”TAŽO‰YWŽqAr–Ø‘ñA“¡’J—m‘¾˜NA•‰ªNMAŽR‘º—º‰îA‘¾“cŒ’‰î
 

 

‘æ221‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@9ŒŽ22“ú

Œ‹Šj«• –Œ‰Š‚Ìf’f‚É“ïa‚µ‚½• …‚𔺂¤–«œ‘«”’ŒŒ•a‚Ì1—á
XŒû@TC—Ñ@“NÆC‰ª‘º_ŽjC“ì–ì@’qCN@G’jC’†ªF•FC’†‘O”Ž‹vCŽR“cNˆê, Š|‰®@O,“ú–ì‰ë”V

 

‘æ58‰ñ@“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï
–¼ŒÃ‰®@8ŒŽ24“ú-26“ú

‚Š´“xHBsRŒ´‘ª’è‚É‚¨‚¯‚éƒRƒ“ƒ^ƒ~ƒl[ƒVƒ‡ƒ“ƒŠƒXƒN‚ÌŒŸ“¢
•‘º˜aÆ, 쌴GŒb, ã–ìM–í, ‘ê‘òŒb’ÃŽq, ’†‘O”ü‰À, “¡‰ªˆê–ç, “ú–ì‰ë”V

 

‘æ19‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
é‹Ê@7ŒŽ21“ú-22“ú

‹³ˆçu‰‰
ˆãŠwŒ¤‹†EŠwpŠˆ“®‚É‚¨‚¯‚éŒÂlî•ñ‚̈µ‚¢•û

’†‘O”ü‰À

 

‘æ220‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@6ŒŽ16“ú
’á—p—ʃGƒgƒ|ƒVƒh‹y‚уXƒeƒƒCƒh“à•ž—Ö@‚ª—LŒø‚Å‚ ‚Á‚½‰è‹…Œ`Ž¿×–E—lŽ÷ó×–EŽîá‡iBPDCNj‚Ì1—á
‰³ŠÛˆê•½Ar–Ø@‘ñA‚ŒK‹PlAŽO‰YWŽqA“¡’J —m‘¾˜N‚AŽR‘º—º‰îA‘¾“cŒ’‰î
‘½‘ŸŠí‚É‚¨‚¯‚é’vŽ€“I‚ȉŠÇ‚𔺂Á‚½œ‘ˆÙŒ`¬ÇŒóŒQ‚Ì1—á
–Ø‘º—F”üA–‹“à—z‰îA•‰ªNMA“ì–ì@’qA’†“ˆN”ŽA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VAŒK]—DŽqA‘åàV­•F

 

‘æ109‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
_ŒË@6ŒŽ9“ú
Œo‹CŠÇŽx”x–E¶ŒŸ‚É‚æ‚é•a—Šw“If’f‚É‚æ‚莡—µ“¾‚½”xZ‚𔺂¤‹}«’P‹…«”’ŒŒ•a
Œ´“c®Œ›A’†ªF•FA‰ª‘º_ŽjA“ì–ì@’qA’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”V

 

‘æ219‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@3ŒŽ3“ú
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɶ‚¶‚½Aspergillus felis‚É‚æ‚éNP«”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì1—á
ˆäŒËŒ’‘¾˜YA‰ª‘º_ŽjA“ì–ì@’qA’†“ˆN”ŽA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VAŽR“ü˜aŽuAŽR“cNˆêAŠ|‰®@O

 

‘æ40‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
ŽD–y@2ŒŽ1“úE3“ú
O2-9-2(4)
“¯ŽíˆÚAŒã‚Ì[Ý«^‹ÛÇ‚Ì”­Ç—\‘ªƒ}[ƒJ[‚Æ‚µ‚Ẵgƒ‰ƒ“ƒXƒtƒFƒŠƒ“–O˜a

“ì–ì@’q
O2-3-2(2)
ˆÚAŒã‘å—ʃVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‚Í“¯ŽíˆÚA‚̃}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¢‚ÄGVHD‚ð—}§‚µAGVLŒø‰Ê‚ðŒ¸Žã‚³‚¹‚é
–‹“à—z‰î
O2-7-1(2)
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãŠ³ŽÒ‚ÌIgGƒTƒuƒNƒ‰ƒX‚Æ–«ŠúŠ´õÇ‚ÌŠÖ˜A«‚̉ðÍ
N@Žj˜N
P2-8(4)
‘ŠúŠm’èf’f‚Énested PCR–@‚ª—L—p‚Å‚ ‚Á‚½AHLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɶ‚¶‚½ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚̈ê—á
ûüŒK‹Pl

2017

59th ASH (American Society of Hematology)
Atlanta@12ŒŽ9“úE12“ú
1963
Pre-Transplant Transferrin Saturation Levels As a Predictive Marker for Invasive Fungal Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Nanno S, Koh H, Nishimoto M, Nakane T, Nakashima Y, Takeoka Y, Nakamae M, Hirose A, Hino M, Nakamae H
4448
Post-Transplant Cyclophosphamide Contributes to Impaired Graft-Versus-Leukemia Effects and Regulates Graft-Versus-Host Disease in the Murine Stem Cell Transplant Model
Makuuchi Y, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M
322
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
Kiladjian J-J, Verstovsek S, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Varela AI, Miller CB,  Rumi E, Rosti V, Blau IW, Mesa RA, Dong T, Francillard N, Laughlin M, Vannucchi AM

 

‘æ218‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
_ŒË@12ŒŽ2“ú

“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãAMicroascus spp.‚É‚æ‚é”x‰Š‚𗈂µ‚½1—á
—Ñ@“NÆA¼–{ŒõFA“ì–ì@’qA’†“ˆN”ŽA’†ªF•FA“ú–ì‰ë”VA’†‘O”Ž‹vA“¡–{Š°Ž÷AŽR“cNˆêA
Š|‰®@O

‹}«œ‘«”’ŒŒ•a‚ɑ΂·‚é’nŒÅ‚ߗÖ@’†‚ɇ•¹‚µ‚½Citrobacter braakii”sŒŒÇ
£”ö‰pLi‘åã“S“¹•a‰@jAŠÔ•”Œ«Š°A•S£@‘åA›–ìˆÀŠìA‚@‹N—ÇA•û—DA“à“c‘ì–í

 

‘æ108‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‘åã@11ŒŽ18“ú
’°ŠÔ–ŒŽîᎂŔ­Ç‚µ‚½ŒÀ‹ÇŠúߊO«NK/T×–EƒŠƒ“ƒpŽîA•@Œ^iENKLj‚Ì‚P—á
ì“Y–ƒˆßiˆãŠw•”6”N¶jA“cŠ_“à—D”üA“ì–ì@’qA¼–{ŒõFA•‰ªNMA’†“ˆN”ŽA’†ªF•FAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”V

 

‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‹ß‹EŽx•”‘‰ï
‹ž“s@10ŒŽ28“ú
ƒAƒNƒZƒX@ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXR‘ÌŽŽ–ò‚É‚©‚ñ‚·‚éŠî‘b“IŒŸ“¢
Šâ–{^Œ‹ŽqA¡ˆäd—ÇA쌴GŒbA‘å‰Yˆ»ŽqA“¡‰ªˆê–çA“ú–ì‰ë”V

 

‘æ79‰ñ“ú–{ŒŒ‰tŠw‰ï

“Œ‹ž@10ŒŽ20“ú-22“ú
OS1-4C-1
^«‘½ŒŒÇ‚¨‚æ‚Ñ–{‘Ô«ŒŒ¬”ÂŒŒÇ‚É‚¨‚¯‚éƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹‚Ì•ªÍ
‚ŒK‹PlA’†‘O”ü‰ÀA“ì–ì@’qA¼–{ŒõFA’†“ˆN”ŽAN@G’jA’†ªF•FA•‰ªNMA“ú–ì‰ë”VA’†‘O”ü‰À
OS2-9B-4
”­ì«–éŠÔŒŒF‘f”AÇŠ³ŽÒ‚É‚¨‚¯‚銈«Ž_‘f‚ÆŒŒðÇ.
N@Žj˜NAN@G’jA“y‰®³•FA•ÐŽR‹MŽqA¼–{ŒõFA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAÂŽR‘×FA•½ˆä@ŠwA”ž’JˆÀ’ÃŽqA’†‘O”Ž‹vA“ú–ì‰ë”V
PS2-44-2
ƒNƒ‰ƒhƒŠƒrƒ“‚ª‘tŒø‚µ‚½Hairy cell leukemia-Japanese variant‚̈ê—á
’†ªF•FA‰ª‘º_ŽjAâˆä“c‹IŽqA“¡ˆäˆê‹MA’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA‘åàV­•FA“ú–ì‰ë”V
PS2-25-1
“–Ž{Ý‚É‚¨‚¯‚é¬lT×–E”’ŒŒ•a/ƒŠƒ“ƒpŽî17—á‚ɑ΂·‚郂ƒKƒ€ƒŠƒYƒ}ƒu‚ÌŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢
‚@‹N—Çi‘åã“S“¹•a‰@jAŠâ‰i³ŽqA•S£@‘åAŠÔ•”Œ«Š°A›–ìˆÀŠìA“ú–ì‰ë”V
PS2-2-3
S?‰t’™—¯4”NŒã‚Éf’f‚³‚ꂽS‘ŸŒ´”­ˆ««ƒŠƒ“ƒpŽî
–x“à”ü—ßi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†”ö—²•¶A’ç@”üØŽqA’†ŽÉ—m•ãA•š‰®”¿—I—¢A‹g‘º‘ì˜NA—Ñ@—ÇŽ÷A‹à“‡@LA”‹Œ´Œ‰’ÊA•Ÿ“‡—TŽqAˆäã@Œ’AŽRªF‹v
OS3-10A-1
“ú–{lDLBCLŠ³ŽÒ‚É‚¨‚¯‚éƒIƒrƒkƒcƒYƒ}ƒu‚Ì—LŒø«‚¨‚æ‚шÀ‘S«FGOYAŽŽŒ±•”•ªW’c‰ðÍ
—Š@W–çA’†‘O”Ž‹vA“à“crŽ÷A–L“ˆâM“¿A’†¢ŒÃ’mºAˆÉ“¤’ÃG“ñA”©@´•FA–k–ìrsAÔŽi_ˆêA’ߌ©@ŽõA‹à‘q@÷A’†“‡G–¾Aã“c‹±“TA’·“¡GŽiA‘å—ä@ŒªA”ò“àŒ«³A—é‹{~ŽiAΓc—zŽ¡A’£@‚–¾A“c‘ºGlAÎì—²”VAã“c‰p“TA‹v—Í@—mA’C–¤—zˆê
OS3-10A-5
“ú–{lÄ”­E“«––½«T×–EƒŠƒ“ƒpŽîŠ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½ƒvƒ‰ƒ‰ƒgƒŒƒLƒT[ƒg‚Ì‘æ1/2‘Š—Õ°ŽŽŒ±
“¿‰i—²”VA”ò“àŒ«³A‰iˆäG˜aA‘O“c‰ÃMA’†ªF•FA‰ºŽR@’BA’‡—¢’©ŽüAŽðˆäƒŠƒJAÎì—²”VAˆÉ“¤’ÃG“ñAã“c—´ŽO
OS2-4B-5
ŠÖ¼ƒ~ƒGƒ[ƒ}ƒtƒH[ƒ‰ƒ€‚É“o˜^‚³‚ꂽ‘½”­«œ‘ŽîŠ³ŽÒ‚ɑ΂·‚éKRD—Ö@‚ÌŽ¡—ÃŒø‰Ê‚ÌŒã•ûŽ‹“I‰ðÍ
‰¶“c‰ÀKAæ|“c~–çA‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiA‘¾“cŒ’‰îA“c’†G˜aA•£“c^ˆêA¼“cŒõOA’†’J@ˆ»A“àŽRlmA‹›“ˆL•FA¬™@’qA¡“c˜a“TA“ú–ì‰ë”VA–쑺¹ìA“‡èçqA•“cƒ–çA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA¼‘º@“ž
OS3-‚P‚TA-1
KMF‚É“o˜^‚³‚ꂽ‘½”­«œ‘ŽîŠ³ŽÒ‚É‚¨‚¯‚銲זEÌŽæ•s—Ç‚ÌŒã•ûŽ‹“I‰ðÍ
•£“c^ˆêA‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiA‘¾“cŒ’‰îA’†’J@ˆ»A¬™@’qAAæ|“c~–çA”ª–ØG’jA“c’†G˜aA“àŽRlmAã’Ò—R—¢A‰G–ìF”ŽAV“°^‹IA‘«—§—zŽqA‰Í“c‰p—¢A¼“cŒõOA‹›“ˆL•FAÎì@~A¡“c˜a“TA‹à‘q@÷A•“cƒ–çA“ú–ì‰ë”VA–쑺¹ìA‚Üi‹ß“¡jjWŽjA“‡èçqA¼‘º@“ž

OS3-‚P‚TA-5
nj󫑽”­«œ‘Žî‚ɑ΂·‚鎩‰Æ––½ŒŒŠ²×–EˆÚAŒã‚Ì’nŒÅ‚ߗÖ@‚¨‚æ‚шێ—Ö@‚Ì—L—p«
’†’J@ˆ»A‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiAæ|“c~–çAV“°^‹IA‘¾“cŒ’‰îA¬™@’qA•£“c^ˆêA”ª–ØG’jA“c’†G˜aAã’Ò—R—¢A‰G–ìF”ŽA‹›“ˆL•FA‰Í“c‰p—¢A‘«—§—zŽqA“àŽRlmA¼ˆä—˜ŒõA¼“cŒõOAÎì@~Aà_“cí‹`A‚‹´—LjêA¡“c˜a“TA“‡èçqA“ú–ì‰ë”VA•“cƒ–çA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA–쑺¹ìA¼‘º@“ž

OS3-‚P‚TB-3
ƒvƒ‰ƒg[‚ÍŠùŽ¡—ѽ”­«œ‘Žî‚ɑ΂·‚郌ƒiƒŠƒhƒ~ƒhŽ¡—Â̗\ŒãˆöŽq‚Å‚ ‚é
‘¾“cŒ’‰îAr–Ø@‘ñA’†’J@ˆ»A‹àŽqmbA•£“c^ˆêAŽu‘º—EŽiA”ª–ØG’jAŽÄŽR_•FAæ|“c~–çA“àŽRlmA¬™@’qA“c’†G˜aA‰Í“c‰p—¢A‹›“ˆL•FAÎì@~A¬Œ´®ŒbA‰G–ìF”ŽAV“°^‹IA‚‹´—²KA´…‹`•¶A’†’J‰pmA¡“c˜a“TA‹à‘q@÷A•“cƒ–çA“ú–ì‰ë”VA–쑺¹ìA‚Üi‹ß“¡jjWŽjA“‡èçqA¼‘º@“ž
OS3-‚P‚TB-5
’´‚—î(80ΈÈãjnj󫑽”­«œ‘Žî‚ɑ΂·‚鎡—ìÑFKMF‚É‚¨‚¯‚éŒã•ûŽ‹“I‰ðÍ
Žu‘º—EŽiA‹àŽqmbA’†’J@ˆ»A¬™@’qA•£“c^ˆêA“c’†G˜aA‘¾“cŒ’‰îAŽÄŽR_•FA‹›“ˆL•FAæ|“c~–çA”ª–ØG’jA¼ˆä—˜ŒõAã’Ò—R—¢A¼“cŒõOA‘«—§—zŽqA‰G–ìF”ŽA‰Í“c‰p—¢A“àŽRlmAìã@ŠwA¬Œ´®ŒbA¡“c˜a“TA“‡èçqA“ú–ì‰ë”VA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA–쑺¹ìA•“cƒ–çA¼‘º@“ž

 

‘æ49‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï
‰¡•l@9ŒŽ21“ú-23“ú
”Ä—pŽ©“®•ªÍ‘•’u—p‘ª’莎–òuƒiƒmƒsƒAIL-2Rv‚ÌŠî‘b“IŒŸ“¢
ìŒûç”T, ã–ìM–í, ‘å‰Yˆ»Žq, ‰œˆä–õŽq, “¡‰ªˆê–ç, ’†‘O”ü‰À, “ú–ì‰ë”V

 

‘æ217‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@9ŒŽ16“ú
’°ƒŠƒ“ƒpŠÇŠg’£Ç‚ÌŒo‰ß’†‚É”­Ç‚µ‚½‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–E«ƒŠƒ“ƒpŽî
’†ˆä‹vŽÀ‘ãA•‰ªNMA’†ªF•FA“ì–ì@’qA¼–{ŒõFA“ú–ì‰ë”VAŽR㔎ˆê

 

‘æ18‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
ŽD–y@7ŒŽ22-23“ú
ŽY‰ÈDICŠÖ˜A2Ç—á‚É‚¨‚¯‚é‹ÃŒÅEü—n•ªŽqƒ}[ƒJ[‚Æ2ŽÐFDPED-ƒ_ƒCƒ}[‚Ì„ˆÚ
“¡ˆäˆê‹M, ¡ˆäd—Ç, ‹v•Û“c _, “¡‰ªˆê–ç, ã“cD, ¬‹{ŽR –L, “à“cŒ[Žq,ŽO™‘ì–ç, ’†‘O”ü‰À, “ú–ì‰ë”V
œ‘“h–••W–{‚ւ̖ƉuõF‚ÌŽŽ‚Ý
ˆÀ”ö«K, ŽsŒ´O‘P, ‹Tˆä¹–ë, ŒI–{—íŽq, ‹g‰ªŒ«“ñ, ¬”¨ —Á, ’Jì ’, êm’JˆÀ’ÃŽq

 

‘æ107‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“s@6ŒŽ17“ú
ˆÚA‘OƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXIgG‰A«‚ð’悵‚½ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXö•šŠ´õƒŒƒVƒsƒGƒ“ƒg
ˆäŒËŒ’‘¾˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘×FA”ž’JˆÀ’ÃŽqA’†‘O”Ž‹vA“ú–ì‰ë”VA’J@Œc•F

 

‘æ39‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
¼]@3ŒŽ2“úE4“ú
P6-3
ƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–òŽž‘ã‚̃tƒBƒ‰ƒfƒ‹ƒtƒBƒAõF‘Ì—z«‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA‚Ì—LŒø«
ˆäŒËŒ’‘¾˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘×FA”ž’JˆÀ’ÃŽq
P14-2
¬l“¯Ží‘¢ŒŒŠ²×–EˆÚAŠ³ŽÒ‚̃AƒfƒmƒEƒCƒ‹ƒXoŒŒ«äNã÷‰Š‚ɑ΂·‚éƒVƒhƒtƒHƒrƒ‹Ž¡—Â̌ã•ûŽ‹“IŒ¤‹†
‹g‘º‘ì˜NA¼–{ŒõFA’†ªF•FAN@G’jA’†“ˆN”ŽA•‰ªNMA’†‘O”ü‰ÀAœA£’©¶A“ú–ì‰ë”VA’†‘O”Ž‹v
P16-4
‘ŠúŠm’èf’f‚Énested PCR–@‚ª—L—p‚Å‚ ‚Á‚½AHLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɶ‚¶‚½ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚̈ê—á
–‹“à—z‰îA¼–{ŒõFA—Ñ@—ÇŽ÷A‹v–ì‰ë’qA•F⌚Ž™A²“¡“N¶AŽR“cNˆêA’†“ˆN”ŽAN@G’jA’†ªF•FA–ì˜C£ˆê”üA‹àŽqKOAŠ|‰®@OA“ú–ì‰ë”VA’†‘O”Ž‹v
P12-6
‘ŠúŠm’èf’f‚Énested PCR–@‚ª—L—p‚Å‚ ‚Á‚½AHLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɶ‚¶‚½ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚̈ê—á
–x“à”ü—ßi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA—Ñ@—ÇŽ÷A’ç@”üØŽqA•š‰®”¿—I—¢A”‹Œ´Œ‰’ÊA‹à“‡@LA’†”ö—²•¶Aˆäã@Œ’AŽRªF‹v
P4-6
‚킪‘‚É‚¨‚¯‚錌‰ŽÒŠÔ––½ŒŒŠ²×–E“€Œ‹‚ÌŽÀ‘Ô‚Ì”cˆ¬‚Ì‚½‚߂̃Aƒ“ƒP[ƒg’²¸
¬—Ñ@•A‘å‹´ˆê‹PAŒ´Œû‹žŽqA‰œŽR”üŽ÷A“ú–ì‰ë”VA“c’†~ŽiAã“c‹±“TA¼“c“O–çA”M“c—RŽqA‚—œ”ü”TŽqA”Ñ“c”ü“ÞŽqAŽºˆäˆê’jA–î•”W³A‹{‘ºkˆê

 

BMT tandem meeting 2017
Orlando@2ŒŽ22“úE26“ú
P
Cidofovir treatment for adenovirus-associated hemorrhagic cystitis in adult recipients of allogeneic hematopoietic stem cell transplantation: a retrospective comparative study
Yoshimura T, Nishimono M, Nakane T, Koh H, Nakashima Y, Takeoka Y, Nakamae M, Hirose A, Hino M, Nakamae H

 

5rd International Symposium of Training Plan for Oncology Professionals

‘åãA3ŒŽ12“ú
Immunoprofile changes during dasatinib treatment in patients with chronic myeloid leukemia: a prospective observational study.
Kuno M

“ú—Õ‹Z‹ß‹EŽx•”ŒŒ‰tŒ¤C‰ï
‘åã@2ŒŽ4“ú-5“ú
“¯ŒŒ‰tŽ¾Š³(‘¢ŒŒŠ²×–EˆÚA‚ðŠÜ‚Þ)‚̃f[ƒ^‚ÌŒ©•ûEl‚¦•û
’†‘O@”ü‰À

2016

58th ASH (American Society of Hematology)

San Diego, Dec 3-6, 2016

Combination of Frailty Status and Comorbidity Score Improves the Prediction of Survival in Patients with Myelodysplastic Syndrome Due to Good Predictive Capability for Infection-Related Mortality
Sakatoku K, Takeoka Y, Araki T, Yamamura R, Nakane T, Nakamae H, Hino M, Ohta K

Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)
Shibayama H, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, Ishikawa J, Kamimura T, Fukushima K, Imamura Y, Eto T, Sunami K, Shimokawa M, Akashi K, Kanakura Y

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial
Kadowaki N, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, Ishikawa J, Nagafuji K, Imamura Y, Yamazaki H, Shimokawa M, Akashi K, Kanakura Y

 

‘æ214‰ñ“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@12ŒŽ3“ú
52
ˆê‰ß«‚ÌŽ©‘RŠ°‰ð‚ð”F‚ß‚½ŒŒŠÇ“à‘å×–EƒŠƒ“ƒpŽî
ŠìàV—S‰îA’·è÷ŽœA¼–{ŒõFA“ì–ì@’qAN@G’jA’†“ˆN”ŽA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V

 

“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘æ61‰ñ‹ß‹EŽx•”—á‰ï
‘åã@11ŒŽ12“ú
‹³ˆçu‰‰
“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŠî‘b‚Æ—Õ°ŒŸ¸‚ÌŠÖ‚í‚è

’†‘O”ü‰À
ƒVƒ“ƒ|ƒWƒEƒ€
‘¢ŒŒŠ²×–EˆÚA‚É‚¨‚¯‚é—Õ°ŒŸ¸‚Ì–ðŠ„@ŒÄ‹z‹@”\ŒŸ¸
’†ªF•FEŽR‰º^—Žq
ƒVƒ“ƒ|ƒWƒEƒ€
‘¢ŒŒŠ²×–EˆÚA‚É‚¨‚¯‚é—Õ°ŒŸ¸‚Ì–ðŠ„@SƒGƒR[ŒŸ¸
¼–{ŒõFE‹gì~ˆê

 

‘æ106‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‘åã@10ŒŽ29“ú
33
õF‘Ì11qŒ‡Ž¸‚𔺂¤–«ƒŠƒ“ƒp«”’ŒŒ•a‚ɃCƒuƒ‹ƒ`ƒjƒu‚ª‘tŒø‚µ‚½1—á
•S£@‘åiJR‘åã“S“¹•a‰@jAŠÔ•”Œ«Š°A›–ìˆÀŠìA‚@‹N—Ç
41
AIH‚Æ”ñŠ´õ«”x‰Š‚𔺂¤MDS‚É“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½1—á
‰YãŽÀ‹GA‰ª‘º_ŽjA¼–{ŒõFA“ì–ì@’qA•‰ªNMA’†“ˆN”ŽAN@G’jA’†ªF•FA’†‘O”Ž‹vB“ú–ì‰ë”V

 

‘æ78‰ñ“ú–{ŒŒ‰tŠw‰ï

‰¡•l@10ŒŽ13“ú-15“ú
OS-1-133
Comparison between presepsin and other biomarkers for diagnosing hematological diseases

Koh H, Nanno S, Katayama T, Hirose A, Nakamae M, Hino M, Nakamae H
PS-2-235
Case report: Paraneoplastic immune thrombocytopenic purpura concurrent with colon cancer.

Koh S, Nakane T, Koga Y, Nishimoto M, Hayashi Y, Tauchi Y, Nagahara H, Koh H, Nakashima Y, Nakamae H, Hirakawa K, Hino M
PS-2-85
Dose escalation of dasatinib for the treatment of two cases of CML with severe arrhythmia

Makuuchi Y, Nishimoto M, Kuno M, Nagasaki J, Hayashi Y, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M
PS-1-172
Follicular lymphoma harboring recurrent but rare t(3;9)(q27;p13): a case report

Manabe MiJR‘åã“S“¹•a‰@j, Kito
K, Momosa D, Sugano Y, Ishida E, Koh KR
PS-1-227
­—ʂ̃{ƒ‹ƒeƒ]ƒ~ƒu¥ƒfƒLƒTƒƒTƒ]ƒ“‚ð—p‚¢‚½ˆÛŽ—Ö@‚ÌŒã•ûŽ‹“IŒ¤‹†

r–Ø@‘ñi‘åã•{϶‰ï’†’Õa‰@jAŽR‘º—º‰îAŽð“¿ˆêŠóA“¡’J —m‘¾˜NA•‰ªNMA“ú–ì‰ë”VA‘¾“cŒ’‰î
PS-2-179
Mogamulizumab-combinated chemotherapy in untreated elderly ATLL: report of 3 cases in our institution.

Koh KRiJR‘åã“S“¹•a‰@j,
Momosa D, Manabe M, Sugano Y, Hino M
PS-2-247
Acquired factor V inhibitor with bleeding symptoms documented after the start of prasgrel.

Sakatoku Ki‘åã•{϶‰ï’†’Õa‰@j, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Ohta K
PS-2-67
Mediastinal germ cell tumor associated with myelodysplastic syndrome

Kanashima Hi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Tsutsumi M, Fuseya H, Horiuchi M, Hayashi Y, Hagihara K, Nakao T, Akiyoshi K, Inoue T, Yamane T

PL-3
Crinical features and prognosis of unselected patients with AML and RAEB-2: JALSG CS07 study
Miyazaki Y, Sakura T, Yanada M, Takase K, Imai K, Dobashi N, Aoyama Y, Sawa M, Itonaga H, Usuki K,Honda S, Ohtake S, Kiyoi H, Ohnishi K, Kobayashi Y, Naoe T

OS-2-30
Identification of multiple myeloma-specific antigens asa immunotherapeutic target
s
Hosen N, Hasegawa K, Aoyama Y, Ichihara H, Mugitani A, Nakao T, Yamane T, Manabe M, Tsuboi A, Nakata J, Nishida S, Oka Y, Oji Y, Hino M, Kumanogoh A, Sugiyama H
PS-2-47
Clinical impact of body-mass index on the outcome of Japanese patients with acute myeloid leukemia.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohshima K, Naoe T, Ohno R, Ohashi K
OS-3-71
Kansai Myeloma Forum‚É“o˜^‚³‚ꂽMGUS‚Æ–³ÇŒó«œ‘Žî644—á‚Ì—Õ°Œo‰ß‚̉ðÍ.

‘¾“cŒ’‰îAŽR‘º—º‰îA“c’†G˜aAŽÄŽR_•FA¬Œ´®ŒbA’†’J@ˆ»A¬™@’qA–Ø“c@‹œAà_“c^ˆêAV“°^‹IA¬—ѳsA•“cƒ–çA‹àŽqmbA‹›“ˆL•FAã’Ò—R—¢A¼“cŒõOA‚‹´—²KAà_“cí‹`A’†’J‰pmA¡“c˜a“TA“‡èçqA’J˜e‰ëŽjA–쑺¹ìA“ú–ì‰ë”VA¼‘º@“žA‹à‘q@÷A‚Üi‹ß“¡jWŽj
OS-3-72
Retrospective analysis of 1200 symptomatic multiple myeloma cases registered in Kansai Myeloma Forum.

Kobayashi M, Kanda J, Shindo M, Kaneko H, Imada K, Tanaka H, Kosugi S, Kida T, Ohta K, Kuroda J, Shibayama H, Kohara T, Nakaya A, Fuchida S, Kamitsuji Y, Uoshima N, Yagi H, Adachi Y, Kawata E, Uchiyama H, Hamada T, Takahashi T, Matsuda M, Iida M, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A
OS-3-80
Retrospective multicenter study of primary plasma cell leukemia.

Nakaya A, Tanaka H, Kaneko H, Kosugi S, Kida T, Ohta K, Kamitsuji Y, Shibayama H, Kohara T, Kobayashi H, Shindo M, Fuchida S, Takahashi R, Kanda J, Uoshima N, Yagi H, Adachi Y, Kawata E, Uchiyama H, Hamada T, Takahashi T, Matsuda M, Iida M, Imada K, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A

 

‘æ48‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï
‰¡•l@9ŒŽ22“ú-24“ú
ŒŸ‘Ì”À‘—ƒVƒXƒeƒ€\’z‹y‚ÑŒŸ¸‹@ŠíXV‚É‚æ‚é‰ü‘P‚Æ‚»‚ÌŒø‰Ê
¼‹g G, “ú–ì‰ë”V, ’†‘O”ü‰À, “¡‰ªˆê–ç, ŽR‰º ˜j, ¡ˆäd—Ç, 쌴Gœ¨
ƒVƒNƒƒXƒ|ƒŠƒ“‘ª’è‚É‚¨‚¯‚錋‰Ê‚̘¨—£‚ɂ‚¢‚Ä
쌴Gœ¨A‘å‰Yˆ»ŽqA¼‹g@GAŠâ–{^Œ‹ŽqA¡ˆäd—ÇAŽR‰º@˜jA“¡‰ªˆê–çA•E–ì‘×”ŽA’†‘O”ü‰ÀA“ú–ì‰ë”V

 

‘æ65‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï
_ŒË@9ŒŽ1“ú-4“ú
ƒA[ƒLƒeƒNƒgi2000SR‚É‚æ‚éPIVKA-II‘ª’莎–ò‚ÌŠî‘b“IŒŸ“¢
‘å‰Yˆ»ŽqA¡ˆäd—ÇA쌴Gœ¨A•E–ì‘×”ŽA“ú–ì‰ë”VA’†‘O”ü‰À
2-45
Ž©ŒÈ–ƉuÇó‚ð’æ‚·‚錌‰tŽ¾Š³‚É‚¨‚¯‚éB×–E«–ƉuˆÙí‚ÌŒŸØ‚Ì‚½‚ß‚ÌŠî‘b“IŒŸ“¢
•“c^ˆêC’†‘O”ü‰ÀA’†‘O”Ž‹vC“ú–ì‰ë”V
6-8
CD6‚ð—p‚¢‚½Treg‰ð̓pƒlƒ‹‚Ì—L—p«‚ɂ‚¢‚Ä
“¡Œ´–qŽqA“¡ˆäˆê‹MA’r–{@ÊA¡ˆäd—ÇA颖ì‘×”ŽA’†‘O”ü‰ÀA’†‘O”Ž‹vC“ú–ì‰ë”V

 

‘æ17‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
•Ÿ‰ª@8ŒŽ6“ú-7“ú
148
×–E“œ‰ÙÜPerFix-ncˆ—‚É‚æ‚é×–E•\–ÊRŒ´‚ւ̉e‹¿
“¡ˆäˆê‹MC“¡Œ´–qŽqC’r–{@ÊA¡ˆäd—ÇA‹v•Û“c@_Aé™–ì‘×”ŽA’†‘O”ü‰ÀA’†‘O”Ž‹vC“ú–ì‰ë”V

 

21th Congress of EHA (European Hematology Association)
Copenhargen@6ŒŽ9“úE12“ú
ePoster
The alteration of immunoprofile during dasatinib treatment in a patients with chronic myeloid leukemia: a prospective observational study
Kuno M, Nakamae H, Katayama T, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Nakashima Y, Koh H, Nakane T, HIno M

 

‘æ212‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã@6ŒŽ25“ú
14
–{‘Ô«ƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‚ɃXƒeƒƒCƒh‚ƃŠƒcƒLƒVƒ}ƒu‚Ì•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½Ç—á
’F@®Žqi‰ŠúŒ¤CˆãjC‹g‘º‘ì˜NC’†‘O”Ž‹vC“ú–ì‰ë”VA—Ñ@‘å•ã, “c’†N”VAŽsì‰À—_

 

‘æ105‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‘åã@6ŒŽ18“ú
2
S‘Ÿƒy[ƒXƒ[ƒJ[‚ð—¯’u‚µ‰»Šw—Ö@‚ðŽ{s‚µ‚½S‘ŸŒ´”­DLBCL‚Ì1—á
–‹“à—z‰îA¼–{ŒõFA‹v–ì‰ë’qA—Ñ@—ÇŽ÷A’†‘O”Ž‹vA“ú–ì‰ë”VA•â@ˆºAΈä@‰p
37
der(6)t(1;6)(q11;p21.3)‚𔺂¢œ‘üˆÛ‰»‚Ìis‚ð”F‚ß‚½MDS RARS-T
’·è÷Žœi¶’·‰ï•{’†•a‰@jAˆäŒËŒ’‘¾˜YAŽsŒ´O‘PAÂŽR‘×FA‘¾“c’‰MA”ž’JˆÀ’ÃŽq

 

‘æ38‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
–¼ŒÃ‰®@3ŒŽ3“úE5“ú
WS2-1
ˆÚAŒãƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‘å—ʗÖ@‚É”º‚¤“Å«‚Ì•]‰¿‚Æ‚»‚Ì‘Îô
¼–{ŒõF
O28-1
ˆÚA‘OŽ©—¥_Œo‹@”\’ቺ‚Í“¯Ží‘¢ŒŒ×–EˆÚA—\Œã‚ɑ΂·‚é‹­—Í‚È—\‘ªˆöŽq‚Å‚ ‚é
’†ªF•FA’†‘O”ü‰ÀAN@G’jA¼–{ŒõFA—Ñ@—ÇŽ÷A’†“ˆN”ŽA“ú–ì‰ë”VA’†‘O”Ž‹v
O18-3
Fludarabine/Busulfan‚ð—p‚¢‚½ˆ««ƒŠƒ“ƒpŽî‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA‘Oˆ’u
N@Žj˜NA¼–{ŒõFA‹v–ì‰ë’qA–‹“à—z‰îA‚ŒK‹PlA‰ª‘º_ŽjA‹g‘º‘ì˜NA“ì–ì@’qA—Ñ@—ÇŽ÷AN@G’jA’†“ˆN”ŽA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀA“ú–ì‰ë”VA’†‘O”Ž‹v
ŠÅP4-1
Š³ŽÒ¥‰Æ‘°—p‚Ì‘Þ‰@Žx‰‡ƒ}ƒbƒv‚ðŽg—p‚µ‚½Žæ‚è‘g‚Ý
‚–ØŠG—A‰L’rƒŽqA‰Í–ìŒjŽqA“cŒ´³ŒbA‹{è—œ¹AŒ´“c‰Ê•àA[]ŽìŠó
LS17
PostCY‘å—ʗÖ@‚ð—p‚¢‚½ƒnƒvƒˆÚA‚Ì¡Œã‚̉”\«`ˆÚAŒã“¯Ží–Ɖu”½‰žA–ƉuÄ\’z‚ÌlˆÄ‚ðŠÜ‚ß`
’†‘O”Ž‹v

 

BMT tandem meeting 2016
Hawaii@2ŒŽ18“úE22“ú
321
Prognostic Impact of the Subcutaneous Adipose Tissue Loss on Survival Outcome in Patients with Multiple Myeloma
Sakatoku K,Takeoka Y, Miura A, Yamamura R, Araki T, Seura H, Okamura T, Hino M, Ohta K
612
Potential Value of Low-Dose ATG Treatment for Steroid-Resistant Acute GVHD
Murata M, Ikegame K, Ogawa H, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Ichinohe T, Atsuta Y, Teshima T, Morishita Y

 

2015”N

57th ASH (American Society of Hematology)

Orland, Dec 11-14, 2015

Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation
Nakane T, NakamaeM, Koh H, Nishimoto M, Hayashi Y, Hirose A, Nakashima Y, Hino M, Nakamae H

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients
Hirai M, Inoue A, Hashimura M, Aimoto M, Sakamoto E

 

‘æ25‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï

‰¡•lA11ŒŽ21“ú|23“ú
“¯Ží‘¢ŒŒŠ²×–EˆÚA‚É‚¨‚¯‚éƒJƒXƒ|ƒtƒ@ƒ“ƒMƒ“‚ƃJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQÜ•¹—pŽž‚Ì–ò•¨‘ŠŒÝì—p‚¨‚æ‚шÀ‘S«‚ÉŠÖ‚·‚錟“¢
úº˜a–Ú“ÄŽjA¼–{ŒõFA‚‹´³–çA’†‘ºˆÀFANG’jA’†‘O”Ž‹vA¼ì•ŽiA“ú–ì‰ë”VA‰iŽRŸ–ç

 

‘æ104‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï

‹ž“sA11ŒŽ7“ú
DLBCL’·ŠúŠ°‰ðŒã‚É”­Ç‚µ‚½BCL2ABCL6AMYC“]À—z«‚ÌIntermediate BL/DLBCL
‹î‘qŒ[‘¾iM6Šw¶jA‚ŒK‹PlA¼–{ŒõFA‰ª‘º_ŽjA—Ñ@—ÇŽ÷A’†“ˆN”ŽAN@G’jA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VAŒK]—DŽqA‘åàV­•F
‹}«œ‘«”’ŒŒ•a‚ɑ΂·‚錌¬”—AŒŒ’†‚Ɍċz‹‡”—‚ð’悵‚ÄŽ€–S‚ÉŽŠ‚Á‚½‚PÇ—á
ˆäŒËŒ’‘¾˜Yi¶’·‰ï•{’†•a‰@jA’·èõŽœAŽsŒ´O‘PAÂŽR‘×FA”ž’JˆÀ’ÃŽq
‰Â‹t«‚ÌdasatinibŠÖ˜A”x“®–¬«‚ŒŒˆ³Ç‚ð”­Ç‚µ‚½–«œ‘«”’ŒŒ•a
’·èõŽœi¶’·‰ï•{’†•a‰@jAˆäŒËŒ’‘¾˜YAŽsŒ´O‘PAÂŽR‘×FA”ž’JˆÀ’ÃŽqA–ì–{—z‘¾AŽ†XŒö—Y

 

‘æ62‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï

’·—ÇìA11ŒŽ19“ú|22“ú
”A’¾ŸÔŒŸ¸‚É‚¨‚¢‚ătƒ@ƒuƒŠ[•a‚Æf’f‚µ“¾‚½‚PÇ—á
‘ê‘òŒb’ÃŽqA’†‘O”ü‰ÀA“ú–ì‰ë”VA•E–ì‘×”Ž

 

‘æ53‰ñ“ú–{ŠàŽ¡—Êw‰ï

‹ž“sA10ŒŽ29“ú|31“ú
ˆÝ‚ª‚ñ‚̃Qƒmƒ€‰ðÍ ˆÝŠà‚Ìi“W‚É‹y‚Ú‚·œ‘—R—ˆŠÔŽ¿×–E‚ÌŠÖ—^‚ÌŒŸ“¢
Š}“‡ —T–¾, ”ª‘ã ³˜a, ’†‘O ”Ž‹v, –kŽR ‹IB, ‘“c „, –؉º tl, ŸNˆä Žé, –Lì ‹MO, ‹v•Û ®Žm, “c’† _–¾, ˜ZŽÔ ˆêÆ, ‘啽 ‰ëˆê, ’†ª F•F, “ú–ì ‰ë”V, •½ì O¹

 

‘æ74‰ñ“ú–{ŠàŠw‰ï

–¼ŒÃ‰®A10ŒŽ8“ú|10“ú
Bone Marrow Derived Mesenchymal Stem Cells Are Attracted into the Gastric Cancer Microenvironment
Š}“‡ —T–¾, ”ª‘ã ³˜a, ‘“c „, –؉º tl, Xè ŽìŽÀ, •Ÿ‰ª ’B¬,, ’†ª F•F, ’†‘O ”Ž‹v, “ú–ì ‰ë”V, ‘啽 ‰ëˆê, •½ì O¹

 

‘æ47‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï
‰¡•lA10ŒŽ8“ú|10“ú

ˆÙ픽‰ž‚ð”F‚ß‚½‚ƒqƒAƒ‹ƒƒ“Ž_ŒŒÇ‚̈ê—á

ã–ì M–í, ‰œˆä –õŽq, ‹v•Û“c _, •E–ì ‘×”Ž, “ú–ì ‰ë”V

 

‘æ77‰ñ“ú–{ŒŒ‰tŠw‰ï
Î쌧—§‰¹Šy“°A‹à‘òA10ŒŽ16“ú|10ŒŽ18“ú
SY1-4
HLA haplo-identical allogeneic hematopoietic cell transplantation using reduced dose post-transplantation cyclophosphamide (PT/CY)

Nakamae H
OS-2-98
Comparison of presepsin and procalcitonin as biomarkers to detect infection in febrile neutropenia
Koh H, Aimoto M, Katayama T, Hirose A, Nakamae M, Hino M, Nakamae H
OS-1-172
Two cases of primary cardiac lymphoma in our institute

Hagihara Ki‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Nakao T, Yoshida M, Ueda H, Horiuchi M, Kanashima H, Yamane T
OS-2-11
Ruxolitinib is effective and safe in Japanese polycythenia vera (PV) patients with splenomegaly
Kirito KiŽ¡Œ±j, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, Dany H, Yamauchi K, Amagasaki T, Ito K, Masayuki H
OS-2-48
Dose early treatment improve the outcome of patients with transplant-ineligible symptomatic myeloma?.
Nakaya AiKMFj, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida S, Uoshima N, Kawata E, Kamitsuji Y, Iida M, Matsuda M, Takahashi T, Hamada T, Uchiyama H, Kuroda J, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, ShindoM, Tanaka H, Tsudo M, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A
OS-2-49
Retrospective analysis of MM patients with dual refractory to bortezomib and IMiDs in KMF registry
Kohara TiKMFj, Shibayama H, Nakatani E, Kaneko H, Fuchida S, Yagi H, Kuroda J, Kobayashi M, Shindo M, Ohta K, Kosugi S, Kida T, Tanaka H, Nakaya A, Adachi Y, Uchiyama H, Kawata E, Kamitsuji Y, Iida M, Matsuda M, Takahashi T, Hamada T, Nomura S, Shimazaki C, Tsudo M,, Hino M, Matsumura I, Taniwaki M, Kanakura Y, Takaori-Kondo A
OS-3-39
Second primary malignacies among patients with myeloma-related-diseases in KMF database
Kosugi SiKMFj, Shibayama H, Kida T, Nakatani E, Ohta K, Kaneko H, Yagi H, Tanaka H, Fuchida S, Nakaya A, Kobayashi M, Kuroda J, Kamitsuji Y, Uoshima N, Adachi Y, Tsudo M, Shimazaki C, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y, Takaori-Kondo A
PS-1-195
A rare case of nonleukemic myeloid sarcoma with expression of B-cell markers.
Takakuwa T, Nakane T, Kuwae Y, Nishimoto M, Hayashi Y, Nakashima Y, Koh H, Nakamae H, Ohsawa M, Hino M
PS-1-243
Prognostic significance of WT1 mRNA expression level at diagnosis in elderly MDS patients
Nagasaki Ji¶’·‰ï•{’†•a‰@j, Ido K, Okita J, Manabe M, aoyama Y, Mugitani A
PS-1-310
Encephalomyelitis associated with chronic GVHD after allogeneic bone marrow transplantation
Ueda Hi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Kanashima H, Horiuchi M, Hagihara K, Nakao T, Yamane T, Morihata H
PS-2-60
A rare chromosomal abnormality of t(3;8)(q25;q24) appeared during treatment for AML: a case report
Manabe Mi‘åã“S“¹•a‰@j, Wada K, Momose D, Sugano Y, Hino M, Yamane T, Ishida E, Koh KR
PS-2-306
Long-term treatment with lenalidomide for multiple myeloma in our institutey
Mugitani Ai¶’·‰ï•{’†•a‰@j, Ido K, Nagasaki J, Aoyama Y, Ohta T, Furukawa Y
PS-2-338
nj󫜑Žî969Ç—á‚É‚¨‚¯‚étáŠQ‚ÌŒã•ûŽ‹“I‰ðÍ
‹àŽqmbiKMFj, ”ª–ØG’j, ¬Œ´®“¾, ŽÄŽR_•F, “c’†G˜a, •£“c^ˆê, –Ø“c@‹œ, ¬™@’q, •“cƒ–ç, ‘¾“cŒ’‰î, V“°^‹I, ¬—ѳs, ã’Ò—R—¢, ’†’J@ˆ», ‘«—§—zŽq, ‰Í“c‰p—¢, “àŽRl“ñ, ‹›“ˆL•F, ‰Y£•¶–¾, ‚‹´—²K, ‚‹´—Ljê, ”Ñ“c³l, ¼‘º@“ž, “ú–ì‰ë”V, ‹à‘q@÷, “‡èçq, ’J˜e‰ëŽj, –쑺¹ì, ’Ê“°@–ž, ‚ÜWŽj@

 

‘æ13‰ñ“ú–{—Õ°Žîᇊw‰ï
ƒƒCƒgƒ“ŽD–yAŽD–yA7ŒŽ16“ú|18“ú

P1-2-15
IgG4ŠÖ˜AŽ¾Š³‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½IgG4—z«MALTƒŠƒ“ƒpŽî‚̈ê—á

‹v–ì‰ë’qA’†ªF•FA–{ŠÔŒ\ˆê˜YA˜a“c’¼Ž÷AN@Žj˜NA‹g‘º‘ì˜NA¼–{ŒõFA’†‘O”Ž‹vAXˆä‰pˆêA“ú–ì ‰ë”V

P3-8-15
Žá”N”­ÇPTCL-NOS‚ɑ΂µ‚ÄŽ©‰ÆˆÚAŒãupfront‚Å“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½Ç—á

‹g‘º‘ì˜NA’†ª F•FA–‹“à—z‰îA‹v–ì‰ë’qA‚ŒK‹PlA‰ª‘º_ŽjAN@Žj˜NA“ì–ì@’qA¼–{ŒõFA“ú–ì‰ë”V

P3-1-63
Neutrophil-to-lymphocyte ratio and treatment outcome in NSCLC patients received EGFR-TKI as first or second-line therapy

^ çéŽõAŒ´“c”Ž‰ëA‹{’n—•FA’|“à—é‰ÀAŽR‰ªV”ªA“ú–ì‰ë”V

 

‘æ16‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
–¼ŒÃ‰®‘Û‰ï‹cêA–¼ŒÃ‰®A7ŒŽ11“ú|12“ú

(ƒ‰ƒ“ƒ`ƒIƒ“ƒZƒ~ƒi[1j‘ۊɊî‚¢‚½ŒŸ¸‚Æ–«œ‘«”’ŒŒ•a‚ÌÅVŽ¡—Ãí—ª
“ú–ì‰ë”V

2Ží—Þ‚ÌŽŽ–ò‚Ì‘g‚݇‚킹‚É‚æ‚éFDP/D-ƒ_ƒCƒ}[”ä‚ƋÌťü—n•ªŽqƒ}[ƒJ[‚Æ‚ÌŠÖŒW
“¡ˆäˆê‹MA“¡Œ´–qŽqA’r–{@ÊAŽR‰º@˜jA‹v•Û“c@_A•E–ì‘×”ŽA“ú–ì‰ë”V

 

‘æ103‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï

‹ž“sA6ŒŽ20“ú
B×–E«ƒ}[ƒJ[—z«‚ðŽ¦‚µ‚½ŒÇ—§«è÷—±‹…“÷Žî
]è–ƒˆßŽqA‚ŒK‹PlA¼–{ŒõFA’†ªF•FA‰ª‘º_ŽjA—Ñ@—ÇŽ÷A’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”VAŒK]—DŽqA‘åàV­•F

 

20th Congress of EHA (European Hematology Association)

Vienna, June 11-14, 2015

E1389
Plasma levels of presepsin (soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome
Nanno S, Koh H, Katayama T, Hashiba M, Sato A, Makuuchi Y, Nagasaki J, Yoshimura T, Okamura H, Nishimoto M, Hirose A, Nakamae M, Nakane T, Hino M, Nakamae H

E1167
A comparison of oral levofloxacin and cefepime in patients with low-risk febrile neutropenia by the Japan febrile neutropenia study group
Yoshida I, Tamura K, Oze I, Takahashi T, Hino M, Hatanaka K, Nakao Y, Narumi H, Itoh T,Ohyashiki K, Tanimoto M, Urabe A, Kanamaru A, Masaoka T
PB1805
Diagnostic value of plasma levels of presepsin (soluble CD14-subtype) for febrile neutropenia in patients with hematologic malignancies
Koh H, Katayama T, Hashiba M, Sato A, Kuno M, Makuuchi Y, Takakuwa T, Okamura H, Hirose A, Nakamae M, Hino M, Nakamae H

 

‘æ64‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï
•Ÿ‰ªA5ŒŽ16“ú|17“ú

”’ŒŒ‹…”’á’lˆæ‚É‚¨‚¯‚éXN-1000‚̃ŠƒT[ƒ`€–Ú‚Ì—L—p«‚ɂ‚¢‚Ä

“¡Œ´ –qŽq, ’r–{ Ê, “¡ˆä ˆê‹M, ‹v•Û“c _, •E–ì ‘×”Ž, ’†‘O ”ü‰À, “ú–ì ‰ë”V

CLEIA–@‚É‚æ‚éƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXR‘Ì‘ª’莎–ò‚ÌŠî‘b“IŒŸ“¢

쌴 Gœ¨, ¡ˆä d—Ç, •E–ì ‘×”Ž, “ú–ì ‰ë”V

 

41th EBMT (European Society for Blood and Marrow Transplantation)

Istanbul, TurkeyAMarch 22-25
Drug interaction and safety profiles of concomitant use of caspofungin and tacrolimus in allogeneic hematopoietic stem cell transplant recipients.
Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Hayashi Y, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

 

ASCPT (American Society of Clinical Pharmacology and Therapeutics)

New Orleans, March 3-7
Panobinostat PK/PD in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma (RRMM)
Mu S, Tajima T, Corrado C, Sunami K, Suzuki K, Hino M, Kuroda Y, Shibayama H, Lin R, Waldron E, Binlich F

 

‘æ37‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
_ŒË@3ŒŽ6“úE8“ú
O13-1
“¯Ží‘¢ŒŒŠ²×–EˆÚA‘O‚Ì––½‹C“¹•Âǃ}[ƒJ[V50/V25’l‚ÍAˆÚAŒã‚̶‘¶—\‘ªˆöŽq‚Æ‚µ‚Ẳ¿’l‚ª‚‚¢Žw•W‚Å‚ ‚é
’†‘O”ü‰ÀAŽR‰º^—ŽqA’†‘O”Ž‹vA’†ªF•FAN@G’jA’†“ˆN”ŽAœA£’©¶A—Ñ@—ÇŽ÷A¼–{ŒõFA“ú–ì‰ë”V
O18-1
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚Ì׋ۊ´õ—\–h‚Æ‚µ‚Ä‚Ì”ñ‹zŽû«‚Æ‹zŽû«R‹Û–ò‚Ì”äŠr
N@Žj˜NA’†‘O”Ž‹vAŽR“cNˆêA¼–{ŒõFA—Ñ@—ÇŽ÷AN@G’jA’†“ˆN”ŽA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŠ|‰®@OA“ú–ì‰ë”V
O28-2
œ‘ƒoƒ“ƒNƒhƒi[‚Ì•¡”‰ñœ‘’ñ‹Ÿ‚ÉŠÖ‚·‚錟“¢Fƒhƒi[‚Ì•‰’S‚ƈÚAŠ³ŽÒ‚̶’…—¦‚ւ̉e‹¿
ÜŒ´Ÿ–¤AŒáû¸_ŒúA‰œŽR”üŽ÷A—Ž‡—ºˆêAàV@³ŽjA“c–ìè—²“ñA‹Êˆä‰ÀŽqA–L“ˆâM“¿A’†”öN•vA“ú–ì‰ë”VA‹{è‘׎iA_“c‘PLA‹àX•½˜a
O7-5
¬Ž™‚¨‚æ‚Ѭl‚É‚¨‚¯‚éˆÚAŒã”ñŠ´õ«pŒã”x‡•¹Ç‚ÉŠÖ‚·‚錤‹†|“ñŽŸ’²¸‰ðÍŒ‹‰Ê•ñi20-18FGVHDˆÈŠO‚̇•¹ÇWGj
‹S’Ë^mA¬ìŒ[‹±A•Ÿ“c—²_A“ú‚“¹OA‹àX•½˜aA‰ª“cŒbŽqAˆäã‰ë”üA‰Á“¡„“ñAX“‡‘×—YA⊪@šæA—é–Ø—¥˜NA”M“c—RŽqA“ú–ì‰ë”VA“¡ˆäLŽ¡A’‡@ªGŽ÷
P7-6
¶‘ÌtˆÚAŒã‚ÌMDS(RAEB-2)‚ɑ΂µA”ñŒŒ‰œ‘ˆÚA‚ðŽ{s‚µ‚½¢ŠE‰‚ÌÇ—á
’†“ˆN”ŽA’†ªF•FA‹g‘º‘ì˜NA‹v–ì‰ë’qA–‹“à—z‰îA‚ŒK‹PlA‰ª‘º_ŽjAN@Žj˜NA“ì–ì@’qA¼–{ŒõFA—Ñ@—ÇŽ÷AœA£’©¶A’†‘O”ü‰ÀAN@G’jA’†”ö‹gFA’†‘O”Ž‹vA“ú–ì‰ë”V
P10-6
ˆÚAŒã‘å—ʃVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‚ð—p‚¢‚½HLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã–«Šú‚ÉL”͂ȉ¡’f«Ò‘‰Š‚ð’悵‚½Ä”­«‹}«ŽUÝ«”]Ò‘‰Š‚̈ê—á
–‹“à—z‰îA¼–{ŒõFA’†‘O”Ž‹vA—Ñ@—ÇŽ÷AN@G’jA‹v–ì‰ë’qA’†“ˆN”ŽAŽR–{Œ\ˆêA‚‹´—˜KA’†ªF•FA“ú–ì‰ë”V
P20-1
‚—îŽÒ‚É‚¨‚¯‚邃ŠƒXƒNœ‘ˆÙŒ`¬ÇŒóŒQ‚¨‚æ‚Ñ‹}«œ‘«”’ŒŒ•a‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA‚Ì–ðŠ„
‘å–k~–çi¶’·‰ï•{’†•a‰@jA’·è÷ŽœAŒÃ‰ê—TŽ÷AŠÔ•”Œ«Š°AÂŽR‘×FA”ž’JˆÀ’ÃŽq
P33-6
œ‘ƒoƒ“ƒNƒhƒi[ÌŽæ‚ɑ΂·‚é‘¢ŒŒŠ²×–EˆÚAƒR[ƒfƒBƒl[ƒ^[‚Ì–ðŠ„
”~–{—R—¢A“ú–ì‰ë”VA’†ªF•FA’†“ˆN”ŽA¼–{ŒõFA’†‘O”ü‰ÀAœA£’©¶
ŠÅP6-7
‘¢ŒŒŠ²×–EˆÚA„i‹’“_•a‰@‚ÌŠˆ“®•ñ
ã–ì^—RŽqAŠâŒ©–¾ŽqAŽR–ì–õŽqA‹{–{’qŽqA‰L’rƒŽqA“ú–ì‰ë”V
ŠÅP7-1
‘Þ‰@Žx‰‡‚Ì•W€‰»`‘Þ‰@Žx‰‡ƒ}ƒbƒv‚ðŠˆ—p‚µ‚Ä`
¼‰Y—TŽqA쑺—R‰ÄA–ìâmŽÀA’J@~ŽqA‹{–{’qŽqA‰L’rƒŽq
ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
ƒhƒi[‚̈À‘S«
“ú–ì‰ë”V

 

3rd International Symposium of Training Plan for Oncology Professionals

‘åãA2ŒŽ7“ú
Diagnostic value of serum ferritin and risk factors for hemohpagositic syndrome following allogeneic hematopoietic stem cell transplantations
Nanno S

 

2014”N

56th American Society of Hematology
San FranciscoADec 6-9
1145
Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation

Koh S, Nakamae H, Yamada K, Nishimoto M, Hayashi Y, Koh H, Nakashima Y, Nakane T, Hirose A,  Nakamae M, Kakeya H, Hino M

1208
The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation

Nakamae M, Nakamae H, Yamashita M, Nishimoto M, Hayashi Y, Koh H, Nakane T, Nakashima Y, Hirose A, Hino M

3256
A Detailed Analysis of Myelodysplastic Syndrome Complicated By Autoimmune or Inflammatory Disorders: A Possible Efficacy of Low-Dose Lenalidomide

Takeoka Yi‘åã•{϶‰ï’†’Õa‰@j, Miura A, Nakamura K, Nakamura J, Yamamura R, Araki T, Nakamae H, Hino M, Ohta K

3260
Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Hirai MiŽl“V‰¤Ž›•a‰@j, Aimoto M, Inoue A, Hashimura M, Sakamoto E, Nakamae H, Hino M

4441
A Retrospective Study of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Clinical Significance of Treatment Intensity and Comprehensive Geriatric Assessment (CGA)

Yoshida Mi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Horiuchi M, Ueda H, Hagihara K, Kanashima H, Nakao T, Yamane T

1815[‹¤“¯Œ¤‹†]
Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Tanimoto M, Miyamura K, Miyamoto T, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H,  Yamamoto M, Kubo K, Tsukada J,  Kondo M, Aoki M, Okada H, Yanada M

805[‹¤“¯Œ¤‹†]
Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR

Matsumura I, Nakamae H, Yoshida C, Fletcher L, Branford S, Koga D, Sogabe T, Kanakura Y, Naoe T

2547[‹¤“¯Œ¤‹†]
Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Transformed from Ph-Negative Myeloproliferative Neoplasm: A Study from the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Tsudo M, Iwato K, Ichinohe T, Atsuta Y, Takami A

2580[‹¤“¯Œ¤‹†]
Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3)

Tanosaki R, Choi I, Shimokawa M, Utsunomiya A, Tokunaga M, Nakano N, Fukuda T, Nakamae H, Takemoto S, Kusumoto S, Tomoyose T, Sueoka E, Shiratsuchi M, Suehiro Y, Yamanaka T, Okamura J, Uike N

4541[‹¤“¯Œ¤‹†]
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd 

Larson AR, Kim D-W, Issaragrilsil S, le Coutre P, Llacer PDE, Etienne G, Clark ER, Flinn I, Nakamae H, Hochhaus A, Saglio G, Kantarjian MH, Donohue B, Deng W, Menssen DH, Hughes PT

 

‘æ206‰ñ“ú–{“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï

‹ž“sA12ŒŽ6“ú
cladribine‚ª‘tŒ÷‚µ‚½hairy cell leukemia‚Ì‚P—á
‘å–k~–çi¶’·‰ï•{’†•a‰@j,’·è÷ŽœCŒÃ‰ê—T‹KCŠÔ•”Œ«Š°CÂŽR‘×FCêm’JˆÀ’ÃŽq

 

‘æ61‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï

•Ÿ‰ª‘Û‰ï‹cêA11ŒŽ22“ú-25“ú
ƒOƒ‹ƒRƒwƒ‚ƒOƒƒrƒ“^ƒOƒ‹ƒR[ƒX•ªÍ‘•’uAH-8290‚ÌŠî‘b“IŒŸ“¢
¡ˆäd—ÇC쌴GŒbC•E–ì‘×”ŽC“ú–ì‰ë”V
Multi-color flow cytometry‚ð—p‚¢‚½Œ’íl‚Ì––½ŒŒ–Ɖu’S“–×–E”ä—¦
“¡ˆäˆê‹MC“¡Œ´–qŽqAŽR‰º@˜jC‹v•Û“c@_A•E–ì‘×”ŽC’†‘O”ü‰ÀA’†‘O”Ž‹vA“ú–ì‰ë”V
‘¢ŒŒŠ²×–EˆÚAŠ³ŽÒ‚É‚¨‚¯‚éŒÄ‹z‹@”\‚Ì„ˆÚ‚â—\Œã‚Æ‚ÌŠÖ˜A
ŽR‰º^—ŽqC–Ø‘ºMŒMA’†‘O”ü‰ÀC’†‘O”Ž‹vA•E–ì‘×”ŽA“ú–ì‰ë”V
ƒCƒ“ƒXƒŠƒ“»Ü‚ƃCƒ“ƒXƒŠƒ“‘ª’莎–ò‚̌𷔽‰ž«‚ÌŒŸ“¢
쌴GŒbC¡ˆäd—ÇA•E–ì‘×”ŽC’†‘O”ü‰ÀA“ú–ì‰ë”V

 

‘æ101‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A‘åãA11ŒŽ8“ú

HLA”¼‡’vˆÚAŒãÄ”­Žž‚ÉŠÌ’_“¹Œny‘f㸂ð’悵AƒfƒtƒFƒ‰ƒVƒƒNƒX‚ªDLST‚Å—z«‚Æ‚È‚Á‚½Ç—á
‹g‘º‘ì˜NA’†‘O”Ž‹vA‰ª‘º_ŽjAN@Žj˜NA¼–{ŒõFAN@G’jA“ú–ì‰ë”VA‚“c‚³‚ä‚èA”‹Œ´~Ži

ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒƒNƒ`ƒ“ÚŽíŒã‚ÉITP‚ð”­Ç‚µ‚½‚RÇ—á
’·è÷ŽœAŠÔ•”Œ«Š°A‘å–k~–çAŒÃ‰ê—T‹KAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq

 

‘æ76‰ñ“ú–{ŒŒ‰tŠw‰ï
‘åã‘Û‰ï‹cêA‘åãA10ŒŽ31“ú|11ŒŽ2“ú
OS-3-85
Promising outcomes from intra-arterial steroid infusion for severe gut- graft versus-host disease
Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M
OS-3-169
Usefulness of per rectal portal scintigraphy to diagnose the cause of liver dysfunction in all-HSCT
Okamura H, Koh H, Takakuwa T, Nanno S, Nishimoto M, Hayashi Y, Nakashima Y, Nakane T, Hirose A, Nakamae M, Nakamae H, Hino M
OS-1-108
Retrospective comparison of 3 BTZ-based therapies (BD, CBD, and MPB) and MP in elderly MM patients

Fuchida SiKMFj, Nakatani E, Kuroda J, Kaneko H, Tanaka H, Yagi H, Uoshima N, Kosugi S, Ohta K, Kohara T, Miyamoto K, Ishii K, Kida T, Shibayama H, Matsumura Y, Uchiyama H, Kawata E, Adachi Y, Iida M, Kamitsuji Y, Shindo M, Kobayashi M, Nomura S, Takaori-Kondo A, Matsumura I, Tsudo M, Hino M, Taniwaki M, Shimazaki C, Kanakura Y
OS-1-109
Novel agents for the elderly patients with multiple myeloma: Analysis in Kansai Myeloma Forum
Yagi HiKMFj, Hamamoto H, Tsubaki K, Fuchida S, Kosugi S, Kuroda J, Uoshima N, Kaneko H, Ohta K, Miyamoto K, Tanaka H, Ishii K, Adachi Y, Kohara T, Matsumura Y, Kida T, Shibayama H, Nakagawa M, Iida M, Kawata E, Takahashi T, Uchiyama H, Nomura S, Matsumura I, Hino M, Tsudo M, Shimazaki C, Taniwaki M, Takaori-Kondo A, Kanakura Y
OS-1-110
The effects of consolidation and maintenance therapies for symptomtic MM patients after auto HSCT.
Shibatama HiKMFj, Nakatani E, Kuroda J, Fuchida S, Kaneko H, Ohta K, Kohara T, Kosugi S, Adachi Y, Yagi H, Kobayashi M, Miyamoto K, Tanaka H, Uoshima N, Kida T, Ishii K, Kamitsuji Y, Hamada T, Takahashi T, Uchiyama H, Kawata E, Matsuda M, Nomura S, Matsumura I, Hino M, Tsudo M, Shimazaki C, Taniwaki M, Takaori-Kondo A, Kanakura Y
OS-1-113
ISS is a predictive factor of SCT effect for symptomatic myeloma patients under age 65
Kaneko MiKMFj, Nakatani E, Shibatama H, Kohara T, Kobayashi M, Miyamoto K, Shindo M, Fuchida S, Tanaka H, Kuroda J, Yagi H, Kosugi S, N, Kida T, Uoshima N, Matsumura Y, Kamitsuji Y, Adachi Y, Ohta K, Ishii K, Uchiyama H, Takahashi T, Iida M, Takaori-Kondo A, Shimazaki C, Matsumura I, Taniwaki M, Nomura S, Hino M, Tsudo M, Kanakura Y
OS-2-33
Retrospective multicenter study of ocular adnexal mucosa-associated lymphoid tissue lymphoma
Saitoh NiOLSGj, Shibayama H, Kohara T, Hashida N, Nishida K, Maeda Y, Inoue N, Ueda S, Sohma T, Iwasaki Y, Sugahara H, Hashimoto K, Azenishi Y, Arima N, Terada Y, Morii E, Sugiyama H, Matsumura I, Nomura S, Ogawa H, Hino M, Kanakura Y
OS-2-130
Update of a phase 1/2 study of ponatinib in Japanese patients with Philadelphia positive leukemia
Tojo AiŽ¡Œ±j, Kyo T, Yamamoto K, Takahashi N, Nakamae H, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Iwasaki H, Hatake K, Matsumura I, Usui N, Yanase K, Hu S, Tuner C, Naoe T, Ohyashiki K
PS-1-324
Adult case of anti-neutrophil antibody-positive agranulocytosis
Koh,S, Koh H, Kuroda M, Kubo Y, Inaba M, Kuno M, Makuuchi Y, Okamura H, Yoshimura T, Nanno S, Nishimoto M, Nakashima Y, Nakamae H, Ueda M, Hino M
PS-1-221
‰»Šw—Ö@‚ÆMogamulizumab‚ª‘tŒ÷‚µ‚½‰E‰ºŽˆ–ƒáƒ‚𔺂¤Œã• –ŒATL‚̈êÇ—á
‚@‹N—Çi‘åã“S“¹•a‰@jA•S£@‘åA›–ìˆÀŠìAš –{“Þ’ÃŽqA‘å–ì_ŽiAΓc‰p˜aA’†ªF•FA˜a“cŸ–çA¼‰ª‰ë—YA“ú–ì‰ë”V
PS-1-222
Mogamulizumab treatment for Adult T-cell leukemia/ lymphoma: Report of 6 cases in our institution
Koh KRi‘åã“S“¹•a‰@j, Momose D, Sugano Y, Wada K, Hino M
PS-1-257
B-cell acute lymphoblastic leukemia developed after chemotherapy without alkylating agents for MM
Ueda Hi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Horiuchi M, Yoshida M, , Hagihara K, Kanashima H, Nakao T, Yamane T
PS-1-257
ŽèŽwæ’[‚̉󎀂ɂĔ­Ç‚µ‚½‚PŒ^iƒ‚ƒmƒNƒ[ƒiƒ‹jƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ
r–Ø@‘ñi‘åã•{϶‰ï’†’Õa‰@jA•‰ªNMAŽR‘º—º‰îAŽO‰YWŽqA“¡’J —m‘¾˜NA’†‘ºƒŽqA’†‘ºPm
PS-2-96
A case of chronic myelomonocytic leukemia concomitant with monoclonal gammopathy
Harada Ni•{’†•a‰@j, Okita J, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-133
Double hit lymphoma treated by up-front autologous stem cell transplantation: A case report
Nagasaki Ji•{’†•a‰@j, Okita J, Harada N, Koga Y, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-166
Results of Devic therapy in six patients with central nervous system lymphoma in a single institute
Yoshida Mi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Horiuchi M, Ueda H, Hagihara K, Kanashima H, Nakao T, Yamane T
PS-2-178
A case of angioimmunoblastic T cell lymphoma presenting with IgM monoclonal gammopathy
Okita Ji•{’†•a‰@j, Nagasaki J, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-204
Bilateral hearing loss after bortezomib therapy in a multiole myeloma patient
Mugitani Ai•{’†•a‰@j, Okita J, Nagasaki J, Manabe M, Aoyama Y, Ohta T, Furukawa Y
PS-2-205
‘½”­«œ‘Žî‚ɑ΂·‚éBortezomib+lenalidomideŽ¡—Ì㎞‰¿––½ŒŒŠ²×–EˆÚA‚ÌŒã•ûŽ‹“IŒŸ“¢
¬‘q˜aŠOA•‰ªNMA²“¡@ŒªA’†”ö—²•¶A¬—Ñ^ˆêAŽRªF‹vA–Ø‘º•¶•FA‘¾“cŒ’‰îA’r“c‰FŽŸ
PS-2-295
Acute colonic pseudo-obstruction following allogeneic stem cell transplantation: A case report
Aoyama Yi•{’†•a‰@j, Manabe M, Nagasaki J, Ohkita J, Koga Y, Kumura T, Ohta T, Furukawa Y, Mugitani A
ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€
ŒŒ‰tŽ¾Š³Ž¡—ÂÌÅ‘Oü
“ú–ì‰ë”V

 

‘æ15‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
å‘ä‘ÛƒZƒ“ƒ^[Aå‘äA7ŒŽ20“ú|21“ú

(‹³ˆçu‰‰4jAPL‚Ì—Õ°‚ÆÅVŽ¡—Ã
“ú–ì‰ë”V

ATLL‚©‚玡—Ê֘A”’ŒŒ•aiM4)‚ð”­Ç‚µ‚½Ç—á
“¡Œ´–qŽqA“¡ˆäˆê‹MA’r–{@ÊA¡ˆäd—ÇAŽR‰º@˜jA‹v•Û“c@_A•E–ì‘×”ŽA’†‘O”ü‰ÀA“ú–ì‰ë”V

 

‘æ24‰ñ“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ï
ŠÖ¼ˆã‰È‘åŠwA–‡•ûA6ŒŽ28“ú|29“ú

10ƒJƒ‰[ƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚É‚æ‚é³íœ‘×–E‚Ì•\–ÊRŒ´‰ðÍ
“¡Œ´ –qŽq, “¡ˆä ˆê‹M, ’r–{ Ê, ŽR‰º ˜j, ‹v•Û“c _, •E–ì ‘×”Ž, ’†‘O ”ü‰À, ’†‘O ”Ž‹v, “ú–ì ‰ë”V

 

‘æ68‰ñ“ú–{Œð’ʈãŠw‰ï
JR”Ž‘½ƒVƒeƒBA”Ž‘½A6ŒŽ7“ú|8“ú

“«ALK‰A«–¢•ª‰»‘å×–EŒ^ƒŠƒ“ƒpŽî‚ÉABVd‚ª’˜Œø‚µ‚½ˆê—á
›–ì ˆÀŠì(JR‘åã“S“¹•a‰@), Γc ‰p˜a, ˜a“c Ÿ–ç, ‚ ‹N—Ç, •S£ ‘å, “ú–ì ‰ë”V

 

‘æ63‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï
Žé˜hƒƒbƒZAVŠƒA5ŒŽ17“ú-18“ú

ƒGƒNƒ‹[ƒVƒXŽŽ–òƒ^ƒNƒƒŠƒ€ƒX‚ÌŠî‘b“IŒŸ“¢
¡ˆä d—ÇA쌴 Gœ¨, ‰Fm ˜a«, •E–ì ‘×”Ž, “ú–ì ‰ë”V

ŒŒ’†ƒVƒNƒƒXƒ|ƒŠƒ“‘ª’è‚Ì3–@‚É‚æ‚錟“¢
쌴 Gœ¨, ¡ˆä d—Ç, ‰Fm ˜a«, •E–ì ‘×”Ž, “ú–ì ‰ë”V
uƒA[ƒLƒeƒNƒgEhigh sensitiveƒgƒƒ|ƒjƒ“I STv‚ÌŠî‘b“IŒŸ“¢
‰Fm ˜a«, ¡ˆä d—Ç, 쌴 Gœ¨, •E–ì ‘×”Ž, “ú–ì ‰ë”V

 

‘æ134”N‰ï“ú–{–òŠw‰ï
ƒzƒeƒ‹“úqŒF–{AŒF–{A3ŒŽ27“ú|30“ú

’ŽË—pƒuƒXƒ‹ƒtƒ@ƒ““Š—^Žž‚Ìáz¹”­ì—\–h‚ɑ΂·‚éƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€‚Ì—LŒø«‚¨‚æ‚шÀ‘S«‚ÉŠÖ‚·‚錟“¢
“¿˜a–Ú “ÄŽj, ‚‹´ ³–ç, Œõì NŽq, N G’j, ’†‘O ”Ž‹v, ¼ì •Ži, “ú–ì ‰ë”V, ‰iŽR Ÿ–ç

 

‘æ12‰ñ“ú–{—Õ°Žîᇊw‰ï
•Ÿ‰ª‘Û‰ï‹cêA•Ÿ‰ªA7ŒŽ17“ú|19“ú

Empirical voriconazole therapy for febrile neutropenia in Japanese patients: The 5th Febrile Neutropenia Study

N G’jA“ú–ì ‰ë”VA‘¾“c Œ’‰îA‹g“c –«A’J–{ Œõ‰¹A‘剮•~ ˆê”nA‰Y•” »•vA“c‘º ˜a•vA‹àŠÛ º‹vA³‰ª “O

Cefozopran, meropenem, or imipenem-cilastatin versus cefepime as empirical therapy in high-risk febrile neutropenia

’†ª F•FA“c‘º ˜a•vA‹Ê’u rŽ¡A‹g“c Œ÷A•Ÿ“‡ r—mA’J–{ Œõ‰¹A‘剮•~ ˆê”nA‰Y•” »•vA³‰ª “OA‹àŠÛ º‹v

MGUSA–³ÇŒó«œ‘Žî‚Ì—Õ°Œo‰ß:KMF‚É“o˜^‚³‚ꂽ206—á‚ÌŒã•ûŽ‹‰ðÍ

‘¾“c Œ’‰îA¬™ ’qA¬—Ñ ³sA•“c ƒ–çA“c’† G˜aA•£“c ^ˆêAŽÄŽR _•FA‹›“ˆ L•FA’†’J ‰pmA‹à‘q ÷

The effectiveness of salvage chemotherapy with S-1 for pretreated NSCLC patients: single center retrospective study
^ çéŽõi϶‰ï–ì]•a‰@jA‹{’n —•FAŽR‰ª V”ªA“°‘O ®eA“ú–ì ‰ë”V

Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With AML or High risk MDS
ÂŽR ‘×Fi¶’·‰ï•{’†•a‰@jAŠÔ•” Œ«Š°A‹v‘º Šx‰›AŒ´“c ®Œ›A’·è ÷ŽœA‘å–k ~–çA”ž’J ˆÀ’ÃŽq

Diffuse large B-cell lymphoma during azathioprine therapy for autoimmune hepatitis: a case repor‚”

ŠÔ•” Œ«Š°i¶’·‰ï•{’†•a‰@jA“y×H —˜•vA‘å–k ~–çA’·è ÷ŽœAŒ´“c ®Œ›AÂŽR ‘×FA‹v‘º Šx‰›A‘¾“c ’‰MAŒÃì ‰À‰›A ”ž’J ˆÀ’ÃŽq

ŠÖ¼œ‘ŽîƒtƒH[ƒ‰ƒ€‚É“o˜^‚³‚ꂽ577—á‚Ìnj󫜑ŽîÇ—á‚Ì—Õ°“I‰ðÍ

ŽÄŽR _•FA‹àŽq mbA¬™ ’qA‘¾“c Œ’‰îA“c’† G˜aA•£“c ^ˆêA•“c ƒ–çA”ª–Ø G’jA’†’J ‰pmA‹à‘q ÷

FN ‘æ4ŽŸŒ¤‹† Low Risk ; CFPM vs LVFX

‹g“c Œ÷A”ö£ Œ÷A‚‹´ •×A“ú–ì ‰ë”VA”¨’† ˆê¶A’†”ö ‹gFA¬Œ© OA‘剮•~ ˆê”nAˆÉ“¡ ‘ô¶A“c‘º ˜a•v

Carbapenems are as useful as cefepime for the treatment of febrile neutropenia associated with hematological disorders
’†ì –õÍA—é–Ø Œ›ŽjA‘¾“c Œ’‰îA“ú–ì ‰ë”VA‘剮•~ ˆê”nA‹àŠÛ º‹vA“c‘º ˜a•vA‰Y•” »•vA³‰ª “O

 

‘æ101‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A‘åãA6ŒŽ28“ú

ƒgƒŠƒ\ƒ~[‚W‚𔺂¤MDS(RCMD)‚ɇ•¹‚µ‚½DŽ_‹…«Ž‹_Œo‰Š
’·è÷ŽœA¼–{ŒõFA’†ªF•FAN@G’jA–‹“à—z‰îAN@Žj˜NA’†‘O”Ž‹vA“ú–ì‰ë”V

 

40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Milan, Italy@3ŒŽ20“úE4ŒŽ2“ú

PH-P373
Promising outcomes from intra-arterial steroid infusions in patients with treatment-resistant acute gastrointestinal graft-versus-host disease.

Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Hamamoto S, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M

PH-AB083
Diagnostic value of serum ferritin and risk factors for hemophagocytic sydrome following allogeneic hematopoietic cell transplantation .

Nanno M, Koh H, Nakashima Y, Katayama T, Kuno M, Makuuchi Y, Nagasaki J, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Nakamae M, Hirose A, Nakane T, Nakao Y, Nakamae H, Hino M

 

2014 BMT tandem meeting

Dallas, Texas@2ŒŽ26“úE3ŒŽ2“ú

3593
Voriconazole vs. itraconazole for antifungal prophylaxis in patients with GVHD:A prospective randomized trial

Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kono A, Moriuchi Y, Ago H, Yamashita T, Takata T, Yoshida M, Hino M, Yamaguchi T, Fukuda T

 

‘æ36‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‰«“ê@3ŒŽ7“úE9“ú
O13-5
—\Œã•s—ÇAŽ¡—Ã’ïR«‹}«
”’ŒŒ•aAMDS‚ɑ΂·‚éˆÚAŒãCY‘å—ʗÖ@‚É‚æ‚éHLA”¼‡’v––½ŒŒŠ²×–EˆÚA‚Ì’PŽ{Ý‘OŒü‚«pilotŒ¤‹†
’†‘O”Ž‹vAN@G’jA¼–{ŒõFA’†“ˆN”ŽA“ì–ì@’qA‹g‘º‘ì˜NAN@Žj˜NA‰ª‘º_ŽjA–‹“à—z‰îA‹v–ì‰ë’qA’†ªF•FA’†‘O”ü‰ÀAœA£’©¶A“ú–ì‰ë”V
O12-1
Š³ŽÒ
‚ƃhƒi[‚ÌKIRˆâ“`ŽqŒ^‚ªˆÚAŒãCY‘å—ʗÖ@‚ð—p‚¢‚½ƒnƒvƒˆÚAŒã‚ÌÄ”­‚É‹y‚Ú‚·‰e‹¿
N@G’jA’†‘O”Ž‹vA–‹“à—z‰îA‹v–ì‰ë’qA’·è÷ŽœAN@Žj˜NA‰ª‘º_ŽjA‹g‘º‘ì˜NA“ì–ì@’qA¼–{ŒõFAˆäã—LŠóŽqAœA£’©¶A’†‘O”ü‰ÀA’†“ˆN”ŽA”‹Œ´Œ‰’ÊAŽ›“c–FŽ÷A’†ªF•FA“ú–ì‰ë”V
O12-2
ˆÚAŒã
CY‘å—ʗÖ@‚ð—p‚¢‚½ŒŒ‰ŽÒŠÔHLA”¼‡’v––½ŒŒŠ²×–EˆÚA‚É‚¨‚¢‚ÄAƒhƒi[HLA“ÁˆÙ“IR‘Ì‚ª‰A«‰»‚µ¶’…‚ɬŒ÷‚µ‚½‚Q—á
’†“ˆN”ŽA’·è÷ŽœA¼–{ŒõFAN@G’jAœA£’©¶A’†‘O”ü‰ÀA’†‘O”Ž‹vA“ú–ì‰ë”V
O24-4
¬lĶ•s—Ç«•nŒŒ‚̶’…•s‘S‚ɑ΂·‚é‚Q‰ñ–Ú“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŒŸ“¢[“ú–{‘¢ŒŒŠ²×–EˆÚAŠw‰ï@¬lĶ•s—Ç«•nŒŒWorking group.
‘å¼@NA‰êŒÃ^ˆêAN@G’jAX@‹B•FA’†”öáÁ“ñA“à“c’¼”VA‘å‹´ˆê‹PA⊪@šæAX“‡‘×—YA‰Á“¡„“ñA—é–Ø—¥˜NAŽRèGl
O29-1
HLAˆê’vŒŒ‰‚Ü‚½‚Í7-8/8HLAˆê’v”ñŒŒ‰ƒhƒi[‚©‚ç‚Ì“¯Ží‘¢ŒŒŠ²×–EˆÚA‚É‚¨‚¯‚éMMF‚¨‚æ‚уJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQÜ‚ð—p‚¢‚½GVHD—\–h‚Ì—L—p«F‘½Ž{Ý‹¤“¯‘æ2‘Š—Õ°ŽŽŒ±
’†ªF•FA’†‘O”Ž‹vA•àVÊŽqA‰ª‘º“Ä•vA“ú‚“¹OAŽR‰º‘ì–çA‰Í–첕vAÄ“¡@Œ’AÂŽR‘×FA”¨’†ˆê¶A•ÐŽR‹`—YA–òŽt_Œö˜aA¼ˆä—˜[A‚Œ©º—ÇAŽRŒû‘ñ—mA“ú–ì‰ë”VA•Ÿ“c—²_
P-B1-7
Šˆ“®«ãŠ{“´‰Š‚ð‡•¹‚µ‚½‰»Šw—Ö@—ð‚Ì‚È‚¢’áŒ`¬«MDS‚ɑ΂µASeattleŒ^ƒ~ƒjˆÚA‚ðŽ{s‚µ‚½‚P—á.
’†“ˆN”ŽAdâ@ŽÀA’†ªF•FA¼–{ŒõFAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”V
P-C1-5
ä`‘ÑŒŒˆÚAŒãˆêŽŸ¶’…•s‘S‚ɑ΂µ‚ĈÚAŒãCY‘å—ʗÖ@‚É‚æ‚錌‰ŽÒŠÔHLA”¼‡’vˆÚA‚Ŷ’…‚𓾂½Bechet•a‚ÆMDS‚Ì•¹”­—á
‹g‘º‘ì˜NA’·è÷ŽœAˆî—tWŽqA‹v–ì‰ë’qA¼–{ŒõFAN@G’jAœA£’©¶A’†‘O”ü‰ÀA”‹Œ´Œ‰’ÊA’†“ˆN”ŽAŽ›“c–FŽ÷A’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V
P-T1-1
ˆÚAŒãCY‘å—ʗÖ@‚É‚æ‚éHLA”¼‡’vˆÚAŒã‚Ì”’ŒŒ•a•ªŽqÄ”­‚ɑ΂µ‚ÄDLI‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á
N@Žj˜NA’†‘O”Ž‹vA–‹“à—z‰îA‹v–ì‰ë’qAâ•”^“Þ”üA’·è÷ŽœA‰ª‘º_ŽjA“ì–ì@’qA‹g‘º‘ì˜NA¼–{ŒõFA’†“ˆN”ŽA”‹Œ´Œ‰’ÊAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷AN@G’jA’†ªF•FA’†”ö‹gFA“ú–ì‰ë”V
P-Z1-3
‘¢ŒŒŠ²×–EˆÚAŠ³ŽÒ‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰î“üŒø‰Ê‚Æ“]“|‚ɂ‚¢‚Ä
ŽR‰º[ái•{’†•a‰@jAŽµ–삳‚â‚©A•ŸˆäË“ñAŽè’ËN‹MA”ž’JˆÀ’ÃŽqAÂŽR‘×F
P-G2-5
APL‚ɑ΂µ‚ÄŽ©‰Æ‘¢ŒŒŠ²×–EˆÚAŒã‚É‚P‚R”N‚Ì’·Šú‚ÌŒo‰ß‚ðŒo‚ÄŽ¡—Ê֘A”’ŒŒ•a‚ð”­Ç‚µA“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½ˆê—á
Œ´“c®“¿i•{’†•a‰@jA‘å–k~–çA‚ŒK‹PlAŠÔ•”Œ«Š°AÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq
P-J‚Q-‚P
HLA•s“K‡ŒŒ‰ŽÒŠÔ‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½Œ`Ž¿×–E”’ŒŒ•a‚Ì‚P—á
‚ŒK‹Pli•{’†•a‰@jA‘å–k~–çAŒ´“c®“¿AŠÔ•”Œ«Š°AÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq
O7-4
‹}«”’ŒŒ•aŽ¡—ÃŒã‚̶Šˆ‚ÌŽ¿iQOLj‚ÉŠÖ‚·‚鉡’f“IŒ¤‹†FˆÚA‚Ɖ»Šw—Ö@‚Ì”äŠr
•àVÊŽqAŽRŒû‘ñ—mAX@‹B•FA‹àX•½˜aA“¡àV@MA‘å¼@NAŒb”üé•FA‰Í–첕vA“ú–ì‰ë”VA’†¢ŒÃ’mºA–¼˜a—Rˆê˜YAÄ“¡•¶ŒìA‹ß“¡’‰ˆêA‹´–{–¾ŽqA•Ÿ“cûé_
O24-3
Ķ•s—Ç«•nŒŒ‚É‚¨‚¯‚鎾Š³Š´Žó«HLAƒAƒŠƒ‹‚ƶ’…•s‘S‚Æ‚ÌŠÖŒW
ŽRèGlAX@‹B•FAN@G’jA‘å¼@NA‰êŒÃ^ˆêA‹{‘ºkˆêA¬àVK‘×A“à“c’¼ ”VA‘å‹´ˆê‹PA²”ö@_A⊪@šæAX“‡‘×—YA‰Á“¡„“ñA—é–Ø—¥˜NA’†”öáÁ“ñ
ŠÅO2-‚S
‘¢ŒŒŠ²×–EˆÚAƒTƒ|[ƒgƒ`[ƒ€‚ª•ø‚¦‚Ä‚¢‚é—Ï—“I–â‘è‚ƑΈ
’ß“c—ŒbAŽRèm”üAˆ¢•””ü²ŽqA‹{–{’qŽqA‰L’rƒŽq
P-ŠÅB1-3
‘¢ŒŒ×–EˆÚA•a“‚É‚¨‚¯‚éƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÌŒ»ó‚Ɖۑè.
ŽRèm”üA“cŒ´³ŒbA’ß“c—ŒbA‹{–{’qŽqA‰L’rƒŽqA“ú–ì‰ë”V
P-ŠÅF1-3
‰»Šw—Ö@‚¨‚æ‚Ñ‘¢ŒŒŠ²×–EˆÚAŒã‚ÌHŽ–ƒpƒ“ƒtƒŒƒbƒg‚Ì“dŽq‰»
£ŒË—F”üA“¡“c“Þ•äA‹{è—œ¹AŽRè—zŽqA‹{–{’qŽqA‰L’rƒŽqA‰ÔŽR‰ÀŽqA¼–{ŒõFA“ú–ì‰ë”V
P-ŠÅF2-3
ŒŒ‰t“à‰ÈŠO—ˆŠ³ŽÒ‚ÌHŽ–ÛŽæó‹µ”cˆ¬‚Ɖh—{ŠÇ—‰î“ü‚̈Ӌ`‚ÉŠÖ‚·‚é’²¸
‰ÔŽR‰ÀŽqA“¡–{_’A¼‰Y”üKA’†ªF•FA“ú–ì‰ë”V

 

‘æ203‰ñ“ú–{“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï

‘åãA3ŒŽ1“ú
‘å‹…«•nŒŒ‚ɉÁ‚¦‚ÄLDã¸CŒŒ¬”ÂŒ¸­CƒnƒvƒgƒOƒƒrƒ“’ቺ‚ð’悵‚½ƒrƒ^ƒ~ƒ“B12Œ‡–RÇ
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j,‘å–k~–çC’·è÷ŽœCŒ´“c®Œ›CÂŽR‘×FC‹v‘ºŠx‰›C‘¾“c’‰MCŒÃì‰À‰›Cêm’JˆÀ’ÃŽq
Rituximab‚ª‘tŒø‚µ‚½“«ŒŒð«ŒŒ¬”ÂŒ¸­«Ž‡”Á•a‚Ì‚P—á
•“c^ˆßŽq, ’†“ˆN”Ž, ’†ªF•F, ¼–{ŒõF, N@G’j, ’†‘O”Ž‹v, “ú–ì‰ë”V

 

2013”N

‘æ202‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã‘ی𗬃Zƒ“ƒ^[A‘åãA12ŒŽ14“ú

”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂·‚鉻Šw—Ö@Œã‚É”­Ç‚µ‚½AõF‘̈Ùít811;16)(q23;p13)‚𔺂¤Ž¡—Ê֘A‹}«œ‘«”’ŒŒ•a
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@jA‘å–k~–çA’·èõŽœAŒ´“c®Œ›AÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A”ž’JˆÀ’ÃŽq

 

55th American Society of Hematology
New OrleansADec 7-10
3404
HLA Haplo-Identical Peripheral Blood Stem Cell Transplantation Using High-Dose Cyclophosphamide Post-Transplantation For Poor Prognosis Or Refractory Acute Leukemia and Myelodysplastic Syndrome: A Prospective Pilot Study At a Single Center

Nakamae H, Koh H, Nishimoto M, Nakashima Y, Nanno S, Yoshimura T, Koh S, Okamura H, Nagasaki J, Nakane T, Nakamae M, Hirose A, Hino M

1536
A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Hirai MiŽl“V‰¤Ž›•a‰@j, Nakane T, Inoue A, Hashimura M, Aimoto M, Sakamoto E, Nakamae H, Hino M

4586[‹¤“¯Œ¤‹†]
Gvhd Prophylaxis With Mycophenolate Mofetil and Calcineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matched Siblings Or 7–8/8 HLA-Matched Unrelated Volunteer Donors: A Japanese, Multicenter, Phase II Trial

Nakane T, Nakamae H, Kurosawa S, Okamura A, Hidaka M, Yamashita T, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Takami A, Yamaguchi T, Hino M, FukudaT

2729[‹¤“¯Œ¤‹†]
Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Miyamura K, Miyamoto T, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, 0Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo m, Amagasaki T, Kawahara E, Yanada M

3385[‹¤“¯Œ¤‹†]
Retrospective Analysis Of The Recent Treatment Strategies For The Patients With Myeloma-Related Diseases Registered In Kansai Myeloma Forum

Tanaka H, Kosugi S, Kida T, Ohta K, Yamamura R, Shibayama H, Kohara T, Kaneko H, Fuchida S, Kobayashi M, Miyamoto K, Shindo M, Kuroda J, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Boku S, Ishii K, Matsuda M, Takahashi T, Hamada T, Adachi Y, Nakatani E, Nomura S, Taniwaki M, Takaori A, Shimazaki C, Tsudo M, Hino M, Matsumura I, Kanakura Y

4270[‹¤“¯Œ¤‹†]
Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)

Kato H, Chihara D, Kato K, Kim S-W, Mori T, Sawa M, Ohno Y, Hashimoto H, Hino M, Iwato K, Chou T, Sakamaki H, Suzuki R, Suzumiya J

3998[‹¤“¯Œ¤‹†]
Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Tanaka H, Imagawa J, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Morita S, Sakamoto J, Kimura S

Online-Only-201
Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders

Koh H, Nakamae H, Aimoto M, Katayama T, Hirose A, Nakamae M, Hino M

 

‘æ100‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒRƒ“ƒOƒŒƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^[A11ŒŽ30“ú
ˆ««ƒŠƒ“ƒpŽî`clinical question‚ÆOLSG‚Ì–ðŠ„
“ú–ì‰ë”V
ä`‘ÑŒŒˆÚAŒãCoprinopsis Cinerea (Hormgraphiella Aspergillataj‚É‚æ‚é”dŽí«Š´õÇ‚ð”­Ç‚µ‚½‚P—á
“ì–ì@’qA’†ªF•FA‰ª‘º_ŽjA¼–{ŒõFA
N@G’jA’†‘O”Ž‹vA“ú–ì‰ë”VA‘åàV­•FA‘º’·•ÛŒ›A‹TˆäŽ•F
BRAF•ÏˆÙ‰A«ACD5ECD33‰A«ACD103‰A«‚Ì•\–ÊŒ`Ž¿‚ð’悵‚½Hairy cell leukemia
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@jA‘å–k~–çA‚ŒK‹PlAŒ´“c®Œ›AÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A”ž’JˆÀ’ÃŽq

 

‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï
_ŒË‘Û‰ï‹cêA_ŒËA10ŒŽ31“ú-11ŒŽ1“ú
‘Û•W€’l‚Ö‚Ì•ÏŠ·‰Â”\‚ÈBCR-ABL1 mRNA‘ª’èƒLƒbƒg‚Ì‘½Ž{Ý—Õ°«”\ŽŽŒ±
’†’J@’†A‹{‘ºkˆêA‰ª–{^ˆê˜YA”–ˆä‹IŽqAÔŽi_ˆêA“ú–ì ‰ë”VA’†¢ŒÃ’mºA‚‹´’¼lA’rK@½A“o@•×A’¼]˜aŽ÷
œ‘•W–{‚É‚æ‚éITP”»’èŠî€‚ɂ‚¢‚Ä‚ÌŒŸ“¢
“¡Œ´–qŽqA’r–{@ÊA“¡ˆäˆê‹MA¡ˆäd—ÇA‹v•Û“c@_A•E–ì‘×”ŽA’†‘O”Ž‹vA“ú–ì‰ë”V

 

‘æ51‰ñ “ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï
‹ž“sA10ŒŽ24“ú-25“ú
Ž©‰Æ––½ŒŒŠ²×–EˆÚAŒã‚Éneutropenic enterocolitis‚ð‡•¹‚µ‚½ ”ñHodgkinƒŠƒ“ƒpŽî
¼‰ª‘å•ãi¶’·‰ï•{’†•a‰@j, ŠÔ•”Œ«Š°, ‘å–k~–ç, ûüŒK‹Pl, Œ´“c®Œ›, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ŒÃì‰À‰›, êm’JˆÀ’ÃŽq
Azacitidine“Š—^‚ª‘tŒø‚µ‚½, õF‘̈Ùídel(20q)‚ð—L‚·‚é –«œ‘’P‹…«”’ŒŒ•a
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j, ‘å–k~–ç, ‚ŒK‹Pl, Œ´“c®Œ›, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ŒÃì‰À‰›, êm’JˆÀ’ÃŽq

 

‘æ75‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
ƒƒCƒgƒ“ŽD–yAŽD–yA10ŒŽ11“úE13“ú

OS-1-24
Risk factor hor hemophagositic syndrome following allogeneic hematopoietic cell transplamtaion
Nanno S, Koh H, Sakabe M, Nagasaki J, Okamura H, Koh S, Yoshimura T, Inaba A, Aimoto M, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Hagihara K, Nakao Y, Nakane T, Terada Y, Nakamae H, Hino M

OS-1-134
dasatinb“à•ž‚É‚æ‚èCMLƒNƒ[ƒ“‚É‚æ‚é‚Æl‚¦‚ç‚ê‚éd“x‚Ìœ‘—}§‚ð’E‚µ‚½Ç—á
’†“ˆN”ŽA’†‘O”Ž‹vAâ•”^“Þ”üA¼–{ŒõFAN@G’jA“ú–ì‰ë”V
OS-2-33i‹¤“¯Œ¤‹†j
MP therapy for Multiple myeloma in the era of new agents in Kansai Myeloma Forum
Shimura Y, Kuroda J, Ohta K, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Tsudo M, Shimazaki C, Takaori A, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y
OS-2-140i‹¤“¯Œ¤‹†j
Prognostic analysis of angioimmunoblastic T cell lymphoma (AITL) cases from OLSG registry
Mitsui H, Kamae T, Kuyama J, Nakatani E, Fujii N, Sugahara H, Shibano M, Azenishi Y, Shimizu Y, Uoshima N, Shibayama H, Hattori H, Maeda Y, Nakagawa M, Kim EH, Harada H, Wada Y, Miyoshi T, Tominaga N, Fushimi H, Take H, Arima N, Hashimoto K, Okada M, Kourogi T, Terada Y, Yamauchi A, Ueda S, Morii E, Hino M
OS-2-165i‹¤“¯Œ¤‹†j
SIL2R at the diagnosis is an independent prognostic factor for FL (OLSG cohort analysis)
Kohara T, Shibayama H, nakatani E, Take H, Tsukaguchi M, Tokumine Y, Uoshima N, Soma T, Hattori H, Azenishi Y, Sugahara H, Maeda M, Tamaki T, Ueda S, Fujii S, Kubota T, Arima N, Mitsui H, Yoshida H, Tabata R, Okamoto T, Urase F, Morii E, Kanakura Y, Hino M
OS-3-4i‹¤“¯Œ¤‹†j
uRIST with low-dose ATG-F multicenter phase II trial
Fuji S, Kim SW, Yano S, Hagiwara S, Nakamae H, Hidaka M, Ito T, Ohashi K, Hatanaka K, Takami A, Kurosawa S, Yamashita T, Yamaguchi T, Fukuda T
OS-3-32i‹¤“¯Œ¤‹†j
Retrospective analysis of clinical course of 123 MGUS and 54 SMM patients registered in KMF
Ohta K, Yamamura R, Takeoka Y, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Mathumura Y, Yoshii Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
OS-3-43i‹¤“¯Œ¤‹†j
Nirotinib vs imatinib for newly-diagnosed CML-CP: ENESTnd 48 month update in Japanese patients
Fukuda T, Nakamae H, Shibayama H, Kurokawa M, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Matsumura I, Matsuda A, Amagasaki T, Ito K
OS-3-44i‹¤“¯Œ¤‹†j
Nirotinib in CML-CP patients with suboptimal response (SoR) to imatinib (IM): SENSOR 12-month data
Miyamura K, Miyamoto T, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Naoe T, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Amagasaki T, Kondo M, Kawabata E, Yanada M
OS-3-49i‹¤“¯Œ¤‹†j
Phase I/II trial of imatinib dose reduction study for CML-CP patients: The JALSG CML-DR1 study
Ishikawa M, Ohnishi K, Miyamura K, Aoyama Y, Uoshima N, Naoe T
OS-3-50i‹¤“¯Œ¤‹†j
Clinical performance study of a BCR-ABL1 kit which reports BCR-ABL1 mRNAon an international scale
Hino M, Miyamura K, Okamoto S, Usui N, Akashi K, Nakaseko C, Takahashi N, Nakatani N, Nobori T, Naoe T
OS-3-73i‹¤“¯Œ¤‹†j
Lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in Kansai Myeloma Forum
Kobayashi T, Kuroda J, Ohta K, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Tsudo M, Shimazaki C, Takaori A, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y
OS-3-92i‹¤“¯Œ¤‹†j
Voriconazole vs itraconazole for antifungal prophylaxis in patients with GVHD: A randomized trial
Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kohno A, Moriuchi Y, Ago H, Yamashita T, Hino M, Yamaguchi T, Fukuda T
OS-3-156i‹¤“¯Œ¤‹†j
HDT with auto-PBSCT for myeloma in the new-agent era: A retrospective analysis of KMF registry
Kosugi S, Ohta K, Tanaka H, Shibayama H, Kohara T, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
OS-3-163i‹¤“¯Œ¤‹†j
Retrospective analysis of 434 symptomatic myeloma cases registered in Kansai Myeloma Forum
Shibayama H, Ohta K, Tanaka H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Matsumura Y, Boku S, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
PS-1-85
ƒAƒUƒVƒ`ƒWƒ“Ž¡—Ã’†‚É‹}«”’ŒŒ•a‰»‚µ‚½‚Q—á
•½ˆä@ŠwiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ÞA‹´‘ºŒõ°Aˆäã“ÖŽiA‘Š–{Ž÷AŽsŒ´O‘PA’†‘O”Ž‹vA“ú–ì‰ë”V
PS-1-100
"myeloid neoplasm with PDGFA rearrangement" with rare chromosomal abnormarity t(14;12)(q12;p13)
Yoshida Mi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Kanashima H, Nakao T, Ueda H, Manabe M, Murakami A, Tamagawa N, Yorifuji T, Yamane T
PS-1-149
Bendamustine‚É‚æ‚è•nŒŒ‚̉ü‘P‚ª‚Ý‚ç‚ꂽŠ¦—â‹ÃW‘fLJ•¹¬ƒŠƒ“ƒp‹…«ƒŠƒ“ƒpŽî‚Ì‚P—á
‹v–ì‰ë’qi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†”ö—²•¶A‹T“c—˜–¾A‹g“c‘SGA‹à“‡@LAŽRªF‹v

PS-1-217
“–‰@‚É‚¨‚¯‚éÄ”­–”‚͓«‚Ì‚—îŽÒˆ««ƒŠƒ“ƒpŽî‚ɑ΂·‚égemcitabine‚ÌŽg—pŒoŒ±
ˆäã“ÖŽiiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ÞAŽsŒ´O‘PA‘Š–{Ž÷A‹´‘ºŒõ°A“ú–ì‰ë”VA•½ˆä@Šw

PS-1-225
Angioimmunoblastic T cell lymphoma complicated by endocapillary glomerulonephritis
Nanno S, Nakamae H, Kuwamura Y, Ishimura E, Sakabe M, Inaba A, Koh S, Yoshimura T, Nishimoto M, Hayashi Y, Terada Y, Nakane T, Ohsawa M, Hino M

PS-2-161
Multiple thrombosis with chromosomal abnormalities of t(8;22) in a patient with Burkitt leukemia
Takakuwa Ti¶’·‰ï•{’†•a‰@j, Ohkita J, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-172
New encouraging treatment strategy: Short cycles BR followed by RT for limited stage transformed FL
Terada Y, Inaba A, Yoshida A, Kuwae Y, Koh H, Nakane T, Nakamae H, Hosono M, Ohsawa M, Shiomi S, Hino M
PS-2-182
T cell rich B cell lymphoma: An unusual case with both T- and B-cell genotypes
Ohta Ti¶’·‰ï•{’†•a‰@j, Sugaya Y, Furukawa Y, Mugitani A, Hino M
PS-2-221
Successful treatment for peripheral ATL cells with Mogamulizumab and for lymphnodes with radiation
Harada Ni¶’·‰ï•{’†•a‰@j, Ohkita J, Takakuwa T, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-233
A case of anaplastic large cell lymphoma relapsed after breast reconstitution with silicone implants
Nakao Ti‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[j, Yoshida M, Kanashima H, Fukushima H, Sugiyama H, Inoue T, Yamane T
PS-2-344
Guillain Barre like syndrome following allogeneic cord blood transplantation in a patient with BPDCN
Nakano Hi¶’·‰ï•{’†•a‰@j, Takakuwa T, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A

PS-1-61i‹¤“¯Œ¤‹†j
Preliminary report of a phase 1/2 study of ponatinib in Japanese patients with Ph+ leukemia
Tauchi T, Tojo A, Nakamae H, Kobayashi Y, Okamoto S, Miyamura K, Kyo T, Iwasaki H, Hatake K, Usui N, Narasimhan NI, Hu S, Yanase K, Zhang J, Naoe T, Ohyashiki K

 

‘æ199‰ñ“à‰ÈŠw‰ï‹ß‹E’n•û‰ï

‹ž“sA9ŒŽ7“ú
‰E㎈‹Ø—͒ቺ‚Å”­Ç‚µ‚½_ŒoƒŠƒ“ƒpŽî‚Ì‚P—á
‹T“c˜a–¾i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†”ö—²•¶, A“c‰p–ç, ‹g“c‘SGA‹à“‡@LAŽRªF‹v
ˆ««ƒŠƒ“ƒpŽî‚ª‹^‚í‚ꂽˆÝŠà”dŽí«œ‘ŠàŽîÇ‚Ì‚P—á
‘å–k~–çi¶’·‰ï•{’†•a‰@jA‚ŒK‹PlAŒ´“c®Œ›AŠÔ•”Œ«Š°AÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽqA‘¾“c’‰M
von Willebrand•a‚ɇ•¹‚µ‚½—‘‘ƒoŒŒ‚Ì‚P—á
‹v‘ºŠx‰›i¶’·‰ï•{’†•a‰@jAÂŽR‘×FAŠÔ•”Œ«Š°A‚ŒK‹PlAŒ´“c®Œ›A‘å–k~–çA”ž’JˆÀ’ÃŽq

 

IDWeek 2013

San FranciscoA10ŒŽ2“ú-6“ú
Diagnostic usefulness of a new in situ hybridization method for detection of global bacterial DNA in febrile neutropenia
Aimoto M, Koh, H, Matsuhisa A, Inoue S, Katayama T, Nagasaki J, Sakabe M, Okamura H, Yoshimura T, Inaba A, Koh S, Nanno S, Nishimoto M, Nakashima Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakane T, Nakamae H, Hino M

 

‘æ14‰ñ “ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï

“Œ‹žA7ŒŽ27“ú
‘S˜r“]À der(5;17)(p10;q10)‚𔺂Á‚½‘¢ŒŒŠíŽîᇠ3—á‚̉ðÍ
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j, ‘å–k~–ç, ‚ŒK‹Pl, Œ´“c®Œ›, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ŒÃì‰À‰›, êm’JˆÀ’ÃŽq

 

‘æ45‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï

ç—tA7ŒŽ26“ú-27“ú
ˆãŠw‰È‚T”N¶‚Ö‚Ì’†SÖ¬úŽh‘}“üƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ŽÀK‚ÌŽŽ‚Ý
’†ªF•FA‰œ@KŽqA‰ª“c–¾ŽqAŽñ“¡‘¾ˆêA“ú–ì‰ë”VAœA‹´ˆê—T

 

‘æ11‰ñ“ú–{—Õ°Žîᇊw‰ï
å‘ä‘ÛƒZƒ“ƒ^[Aå‘äA‚WŒŽ29“ú-31“ú
G•½ã”çŠà‚𜂭isAÄ”­”ñ¬×–E”xŠà‚ɑ΂·‚éBevacizumab•¹—p‰»Šw—Ö@ ‚ÌŒã•ûŽ‹“IŒŸ“¢
^ çéŽõi‘åã•{϶‰ï–ì]•a‰@jA“¡’J —m‘¾˜NAŽR‰ª V”ªA“ú–ì ‰ë”V
ˆêŽ{Ý‚É‚¨‚¯‚é¬×–E”xŠà‚ɑ΂·‚鉻Šw—Ö@‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢ .
“¡’J —m‘¾˜Ni‘åã•{϶‰ï’†’Õa‰@jA^ çéŽõ
Reciprocal t(7;11)(p15;p15): A rare but recurrent translocation in acute myeloid leukemia. Report of 3 cases.
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j,‘å–k~–ç, Œ´“c®Œ›, ‚ŒK‹Pl, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ŒÃì‰À‰›, êm’JˆÀ’ÃŽq

 

‘æ99‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A6ŒŽ22“ú

––½ŒŒ‚ÅCD25‰A«AƒŠƒ“ƒpß‚ÅCD25—z«‚ðŽ¦‚µ‚½¬lT×–E”’ŒŒ•a^ƒŠƒ“ƒpŽî
‹g“c‘SGi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹T“c˜a–¾A‹à“‡@LA’†”ö—²•¶AŽRªF‹vA‚@‹N—Ç
A“c粇ŽqA¼‰ª‰ë—Y

EvansÇŒóŒQ”­ÇŒã20”N‚ÌŒo‰ß‚ðŒo‚ăN[ƒ€ƒX‰A«—nŒŒ«•nŒŒ‚𔺂¤DLBCL‚ð‡•¹‚µ‚½‚P—á
‹g‘º‘ì˜NA’†ªF•FAˆî—tWŽq
AN@G’jA’†”ö‹gFA’†‘O”Ž‹vA“ú–ì‰ë”VA“¡–ìŒbŽOAŒüˆä@ŒåA‹Tè–LŽÀ

“–‰@‚É‚¨‚¯‚éƒ{ƒ‹ƒeƒ]ƒ~ƒu”牺“Š—^‚ÌŽg—pŒoŒ±.
‚ŒK‹Pli¶’·‰ï•{’†•a‰@jA‘å–k~–çAŒ´“c®Œ›
AŠÔ•”Œ«Š°AÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq

 

‘æ18‰ñ “ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï

_ŒËA6ŒŽ8“ú
‘¢ŒŒŠíŽîᇂɑ΂·‚éI––Šúf—Â̎À‘Ô’²¸ (’PŽ{ÝŒã•ûŽ‹“IŒ¤‹†)
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j, ‘å–k~–ç,‚ŒK‹Pl,Œ´“c®Œ›,ÂŽR‘×F,‹v‘ºŠx‰›, ‘¾“c’‰M,ŒÃì‰À‰›,¼‰i^ŽÀ,êm’JˆÀ’ÃŽq

 

‘æ200‰ñ“ú–{“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï

_ŒËA6ŒŽ8“ú
Azacitidine“Š—^‚É‚æ‚è, ‡•¹‚µ‚½äXŠà‚ÌŽîᇃ}[ƒJ[‚ªˆêŽž“I ‚ɒቺ‚µ‚½Ž¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@j, ‘å–k~–ç, ‚ŒK‹Pl, Œ´“c®Œ›, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ŒÃì‰À‰›, êm’JˆÀ’ÃŽq

 

1st International Symposium of Training Plan for Oncology Professionals

‘åãA3ŒŽ16“ú
Prognostic value for survival of serum ferritin levels before and after allogeneic hematopoietic cell trasnplantation (HCT)
Koh S

 

‘æ35‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
Î쌧—§‰¹Šy“°A‹à‘òA3ŒŽ7“úE9“ú
SY2-5u‘ã‘ÖˆÚAƒ\[ƒX‚Ì‘I‘ðFHLA“K‡ŒŒ‰ƒhƒi[‚ª‚¢‚È‚¢‚Æ‚«‰½‚ð‘I‚ÔHv
ˆÚAŒã‚Ì‘å—ʃVƒNƒƒzƒXƒtƒ@ƒ~ƒhiCY)‚𕹗p‚µ‚½ŒŒ‰ŽÒŠÔHLAƒnƒvƒˆê’vˆÚA
’†‘O”Ž‹v
WS4-2
“¯Ží‘¢ŒŒ×–EˆÚAŒãŒŒ‹…æÃHÇŒóŒQ‚Ìf’f
.
N@G’j
P1-130
“Œ‘åˆã‰ÈŒ¤•ûŽ®“±“üŒã‚ÌAraC/CY/TBI‚ð‘Oˆ’u‚É—p‚¢‚½”ñŒŒ‰ä`‘ÑŒŒˆÚA¬Ñ‚̕ω».
¼–{ŒõFA’†‘O”Ž‹vAœA£’©¶A
”~–{—R—¢A’†‘O”ü‰ÀAN@G’jA’†ªF•FA“ú–ì‰ë”V
P2-208
“–‰@‚É‚¨‚¯‚éƒXƒeƒƒCƒh’ïR«EˆË‘¶«‹}«GVHD‚ɑ΂·‚魗ʃTƒCƒ‚ƒOƒƒuƒŠƒ“iATGjŽ¡—ìÑ
¼–{ŒõFA’†‘O”Ž‹vAœA£’©¶A
”~–{—R—¢A’†‘O”ü‰ÀAN@G’jA’†ªF•FA“ú–ì‰ë”V

P2-311
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ÌŒŒ´ƒtƒFƒŠƒ`ƒ“’l‚Ì„ˆÚ‚Æ—\Œã—\‘ª‚É‚¨‚¯‚éd—v«.
’†‘O”ü‰ÀA’†‘O”Ž‹vAN@G’jA
’†ªF•FA’†“ˆN”ŽAœA£’©¶AŽ›“c–FŽ÷A”‹Œ´Œ‰’ÊA¼–{ŒõF

P1-060
“–‰@‚É‚¨‚¯‚é‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–EƒŠƒ“ƒpŽî‚ɑ΂·‚鎩‰Æ––½ŒŒŠ²×–EˆÚA•¹—p‘å—ʉ»Šw—Ö@
‹à“‡@Li‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g“c‘SGA¬ì‹g•FA’†”ö—²•¶Aˆäã@Œ’AŽRªF‹v
P1-027
“¯ŽíˆÚAŒãÄ”­‚ɑ΂·‚éĈÚA‚ÌŒoŒ±.
ŠÔ•”Œ«Š°i¶’·‰ï•{’†•a‰@jAÂŽR‘×FA”¨’†ˆê¶A‹›“ˆM•FAã’Ò—R—¢A‹gˆä—R”üA‹Ê’urŽ¡

OS-2
HLA6RŒ´“K‡ŒŒ‰AHLA1RŒ´•s“K‡ŒŒ‰AHLA8/8ƒAƒŠƒ‹“K‡”ñŒŒ‰ŽÒŠÔˆÚA‚Ì’PŽ{Ý‚É‚¨‚¯‚éˆÚA¬Ñ‚Ì”äŠrŒŸ“¢
—Ñ@—ÇŽ÷i‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@jA“¡@d•vA“c“‡Œ¦ŽqAˆÉ“¡@•àAˆäã–¾ˆÐA‚–ì‹vmŽqA‹´–{®‰ÀAã“c—º‰îA—³–ì^—YA^‰Æhˆê˜YA‰«’†Œh“ñA•àVÊŽqA‹à@¬Œ³A“c–ìè—²“ñA•½‰Æ—E“ñAŽR‰º‘ì–çA•Ÿ“c—²_

ŠÅP1-42
ƒŠƒnƒrƒŠƒpƒ“ƒtƒŒƒbƒg쬂ɂæ‚éŠÅŒìŽt‚̈ӎ¯‚̕ω».
‘ºã˜a‘ãAX씪ç‘ãAV‘î”ü‰ÀA‹{–{’qŽqAˆîè…“ÞŽq

2012”N

54th American Society of Hematology
AtlantaADec 8-11
1187
Tolerated, Low-Dose Deferasirox : Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Hirai MiŽl“V‰¤Ž›•a‰@j, Yamamura R, Nakamae H, Terada Y, Inoue A, Hashimura M, Ichihara H, Sakamoto E, Hino M

1628[‹¤“¯Œ¤‹†]
Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL : The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis

Terada Y, Take H, Shibayama H, Hashimoto K, Kuwayama M, Fujii N, Azenishi Y, Maeda Y, Yamagami T, Uoshima N, Tsukaguchi M, Semba O, Misui H, Ueda S, Soma T, Nakagawa M, Matuda M, Urase F, Kiyoi T, Yoshida H, Sugahara H, Yamashita K, Tominaga N, Kubota T, Arima N, Mori S, Tamaki T, Okamoto T, Anzai N, Akasaka H, Tabata R, Ikeda J, Wada N, Aozasa K, Hino M

1037[‹¤“¯Œ¤‹†]
Cefozoplan, Meropenem, or Imipenem-Cilastatin Versus Cefepime As an Empirical Therapy in High Risk Febrile Neutropenic Adult Patients: A Multicenter Prospective Randomized Trial

Nakane T, Tamaki T, Tamura K, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A

3095[‹¤“¯Œ¤‹†]
Older Age Increases Non-Relapse Mortality in Patients with Grade II–IV Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the Japanese Trump Database

Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Morishima Y, Nagamura T, Sakamaki H, Atsuta Y, Murata M

3046[‹¤“¯Œ¤‹†]
Clinical Factors Predicting the Response of Acute Graft-Versus-Host Disease to Corticosteroid Therapy

Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Taniguchi S, Mori T, Eto T, Morishima Y, Nagamura-Inoue T, Yabe H, Atsuta Y, Sakamaki H, Suzuki R

3027[‹¤“¯Œ¤‹†]
Reduced-Intensity Versus Myeloablative Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 45 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Nakamae H, Katayama Y, Morishima Y, Suzuki R, Kato K, Sakamaki H, Nishimoto N, Masauzi N

 

‘æ199‰ñ“à‰ÈŠw‰ï‹ß‹E’n•û‰ï

‘åãA12ŒŽ8“ú
ƒ‚ƒKƒ€ƒŠƒYƒ}ƒu»Üiƒ|ƒeƒŠƒWƒIj‚Ì“–‰@‚Å‚ÌŽg—pó‹µ
Œ´“c®Œ›i•{’†•a‰@jA’†–ì—TŽj, ‚ŒK‹Pl, ‰ª–{Gˆê˜Y, ŠÔ•”Œ«Š°AÂŽR‘×F, ‹v‘ºŠx‰›, êm’JˆÀ’ÃŽq

 

‘æ98‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“sƒeƒ‹ƒTA12ŒŽ1“ú

Œ¸—ÊR-Bendamustine‚É‚ÄŠ°‰ð‚ª“¾‚ç‚ꂽ‰‰ÄŽ¡—Ã’ïR«‚¨‚æ‚ÑÄ”­mantle cell lymphoma.
•S£@‘åiJR‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—Ç
A˜a“cŸ–ç

ƒ{ƒ‹ƒeƒ]ƒ~ƒu‚ð”牺“Š—^‚µ‚½IgDŒ^‘½”­«œ‘Žî‚Ì‚PÇ—á.
‚ŒK‹PlAŒ´“c®Œ›A’†–ì—TŽjA‰ª–{Gˆê˜YAŠÔ•”Œ«Š°A‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq
’†••a•Ï‚É”º‚¤”A•öÇ‚ð‡•¹‚µ‚½3q21q26‚¨‚æ‚Ñ7õF‘̈Ùí‚ð—L‚·‚éAML‚̈ê—á
“ì–ì@’qA”‹Œ´Œ‰’ÊAâ•”^“Þ”üAˆî—tWŽqA¼–{ŒõFAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”VA‰i“c—F‹MA‰º–쑾˜Y

‹H‚ÈõF‘̈Ùít(4;12)(q12;p13)‚ð—L‚·‚霑ˆÙŒ`¬ÇŒóŒQ‚Ì‚P—á
‹g“c‘SGA¬ì‹g•FA‹à“‡@LA’†”ö—²•¶AŽRªF‹vAŠÔ•”Œ«Š°

 

‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï
‹ž“s‘—§‘Û‰ïŠÙA11ŒŽ29“ú-12ŒŽ2“ú

O-001
ŒŒ’†ƒCƒ“ƒXƒŠƒ“‘ª’è‚É‚¨‚¯‚é25“ƒ|ƒŠƒGƒ`ƒŒƒ“ƒOƒŠƒR[ƒ‹’¾“a–@‚ÌŒŸ“¢.
쌴GŒbA•E–ì‘×”ŽA‹v•Û“c@_A’†‘O”ü‰ÀA“ú–ì‰ë”V

O-180
“¯Ží‘¢ŒŒŠ²×–EˆÚA‘O‚¨‚æ‚ÑAˆÚAŒã‚ÌŒŒ´ƒtƒFƒŠƒ`ƒ“’l‚ª—\Œã‚É—^‚¦‚é‰e‹¿‚̕“IŒŸ“¢.
’†‘O”ü‰ÀA’†‘O”Ž‹vAN@G’jA’†ªF•FAœA£’©¶A’†“ˆN”ŽA“ú–ì‰ë”V
O-200
ƒGƒ‰ƒXƒgƒOƒ‰ƒtƒB[(Fibroscan502)‚ð—p‚¢‚½–«ŠÌŽ¾Š³‚Ìi“W“x•]‰¿‚ÌŒŸ“¢
ŽR‰º^—ŽqA‹´–{‚ ‚ä‚ÝA•“cߎqA•“c@³A“¡ˆä‰pŽ÷AXì_ˆÀA’†‘O”ü‰ÀA•E–ì‘×”ŽA“ú–ì‰ë”V

O-361
ÌŒŒŽx‰‡ƒVƒXƒeƒ€ForYou‚ð—p‚¢‚½ÌŒŒŽžƒgƒ‰ƒuƒ‹‰ñ”ð‚Ö‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä
“¡Œ´–qŽqA…Œ´—SŽŸA¡ˆäd—ÇA•E–ì‘×”ŽA’†‘O”ü‰ÀA“ú–ì‰ë”V

 

‘æ50‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï
‰¡•lA10ŒŽ25“ú
H“¹Šà‚ɑ΂·‚épŒã‰»Šw—Ö@Œã‚É”­Ç‚µ‚½Ž¡—Ê֘A‹}«œ‘«”’ŒŒ•a.
ŠÔ•”Œ«Š°i•{’†•a‰@jA¬â‹ÑŽi, Œ´“c®Œ›, ’†–ì—TŽj, ‚ŒK‹Pl, ‰ª–{Gˆê˜Y, ÂŽR‘×F, ‹v‘ºŠx‰›, êm’JˆÀ’ÃŽq

 

‘æ74‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“s‘Û‰ïŠÙA‹ž“sA10ŒŽ19“úE21“ú

OS-1-50i‹¤“¯Œ¤‹†j
Ä”­ƒnƒCƒŠƒXƒN“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãŠ³ŽÒ‚ɑ΂·‚éWT1ƒyƒvƒ`ƒhƒƒNƒ`ƒ“‘æ‚P‘Š—Õ°ŽŽŒ±
•Ûå’¼‹Bi‘åã‘åŠwjA‘O“c“N¶A•Ÿ“‡Œ’‘¾˜YAX–{‘n¢ŽqA’†“c@A’†]‹gŠóA¼“cƒKA’؈五ŽA‹ß“¡’‰ˆêA–å˜e‘¥ŒõA“ú–ì‰ë”VA”ö˜H—S‰îA‰ª@–FOAŒFƒm‹½@~A‹à‘q@÷A™ŽRŽ¡•v

OS-1-74
‘½”­«œ‘Žî‚Ì•aŠúf’f‚É‚¨‚¯‚éFDG-PET/CT‚Ì—L—p«.
ŽR‘º—º‰îi϶‰ï’†’Õa‰@jA£‰YGâMAr–Ø@‘ñA“¡’J—m‘¾˜NA•‰ªNMA
^@çéŽõA¬â‚³‚¨‚èA‰ª‘ºŒõ‰pA‘¾“cŒ’‰î

OS-1-135i‹¤“¯Œ¤‹†j
Cord blood transplantation for adult T-cell leukemia/lymphoma: The JSHCT WG study.
Kato Ki‹ãB‘åŠwj, Cho I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Hino M, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A

OS-1-146i‹¤“¯Œ¤‹†j
DLI for 1st hematologic relapse of AML: A retrospective nationwide analysis by JSHCT Adult AML WG.
Takami Ai‹à‘ò‘åŠwj, Fukuda T, Miyazaki Y, Hino M, 1kanamori H, Morishima Y, Tanaka J, Atsuta Y, Kanda Y, Yamaguchi T, Nakao S, Kuwatsuka Y, Yano S, Yokoyama H
OS-1-169(‹¤“¯Œ¤‹†)
Randomized controlled study of the efficacy of 3 antibiotics for the empiric therapy of FN patients.
Hatanaka Ki˜a‰ÌŽRˆã‰È‘åŠwj, Nakane T, Hino M, Tamaki T, Takada T, Yoshida I, Fukushima T, Tatsumi Y, Tanimoto M, Urabe A, Masaoka T, Kanamaru A, Tamura K
PS-1-67
AML (M7) from 5q-syndrome with JAK2 mutation achieved complete remission by standard chemotherapy.
Okamoto Si•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Manabe M, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A
PS-1-77
­—ʃVƒ^ƒ‰ƒrƒ“+ƒAƒNƒ‰ƒ‹ƒrƒVƒ“+ƒAƒUƒVƒ`ƒWƒ“—Ö@‚Å—ÇD‚ÈŒo‰ß‚ÉŽŠ‚Á‚½–«œ‘’P‹…«”’ŒŒ•a‚Ì2—á.
‹´‘ºŒõ°iŽl“V‰¤Ž›•a‰@jAˆäã“ÖŽiAŽsŒ´O‘PAâ–{Œb—˜“ÞA•½ˆä@ŠwA“ú–ì‰ë”V

PS-1-81
FISH of blood and buccal mucosa is useful to identify constitutional trisomy 8 mosaicism in +8 MDS.
Takeoka Yi϶‰ï’†’Õa‰@j, Yamamura R, Kosaka S, Fujitani Y, Araki T, Koh G, Ohta K

PS-1-84
Acute fibrinous and organizing pneumonia (AFOP) associated with MDS complicated by hemophagocytosis.
Nanno S, Koh H, Manabe M, Yoshida M, Okamura H, Bingo M, Koh S, Yoshimura T, Inaba A, Aimoto M, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Nakao Y, Nakane T, Tarada Y, Nakamae H, Ohsawa M, Hino M

PS-1-194
R-CHOP compared with R-CHOP plus RT for localized DLBCL: A retrospective OLSG study.
Terada Y, Take H, Shibayama H, Hashimoto K, Kuwayama M, FujiiN, Azenishi Y, Maeda Y, Yamagami T, Uoshima N, Tsukaguchi M, Semba O, Mitsui H, Ueda S, Soma T,
Matsuda M, Urase F, Kiyoi T, Yoshida H, Sugahara H, Yamashita K, Tominaga N, Kubota T, Arima N, Mori S, Tamaki T, Okamoto T, Wada N, Aozasa K, Hino M

PS-1-300
Chronic GVHD-related polymyositis and hepatitis that occurred subsequent to a bruise of the thigh.
Koh S
Akoh H, Sakabe M, Yoshida M, Okamura H, Inaba A, Bingo M, Yoshimura T, Nanno S, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Nakane T, Terada Y, Nakamae H, Ohsawa M, Hino M

PS-1-326i‹¤“¯Œ¤‹†j
A survey of vaccination after allogeneic hematopoietic stem cell transplantation in Hanwa Area.
Yakushijin Ki_ŒË‘åŠwj, Fuji S, Aoyama Y,
Uoshima N, Kamitsuji Y, Tamaki H, Nakane T, Hatanaka K, Mathui K, Yonetani N, Matsuoka H
PS-1-339
Trends in the antibiotic-susceptibility of pathogens of bacteria in the hematology department.
Fujitani Yi϶‰ï’†’Õa‰@j, Takahashi M, Araki T, Takeoka Y, Koh G, Kosaka S, Yamamura R, Ohta K
OS-2-134i‹¤“¯Œ¤‹†j
Nilotinib in CML patients with suboptimal response to imatinib: Early results from the SENSOR study.
Miyamoto Mi‹ãB‘åŠwj, Miyamura K, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Naoe T, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Amagasaki T, Kawahara E, Yanada M

OS-2-137i‹¤“¯Œ¤‹†j
Nilotinib vs imatinib for newly-diagnosed CML-CP:36-month update with PK analysis in Japanese pts.
Kanda Yié‹Êˆã‰È‘åŠwj, Nakamae H, Shibayama H, Kurokawa M, Nakaseko C, Fukuda T, Nagai T, Ohnishi K, Mathumura I, Mathuda A, Amagasaki T, Kojo N, Kawahara E

PS-2-64
ƒAƒUƒVƒ`ƒWƒ“Ž¡—Âðs‚Á‚½24Ç—á.
•½ˆä@ŠwiŽl“V‰¤Ž›•a‰@jA•S£@‘åA‹´‘ºŒõ°Aˆäã“ÖŽiAŽsŒ´O‘PAâ–{Œb—˜“ÞA–p@‹ÎAA‚@‹N—ÇA’†”ö‹gFA”‹Œ´Œ‰’ÊA’†ªF•FAŽRªF‹vA’†‘O”Ž‹vA“ú–ì‰ë”V
PS-2-104
A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: A case presentation.
Mabane Mi•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Okamoto S, Aoyama Y, Kumura T, Ohta K, Furukawa Y, Mugitani A
PS-2-142
EBV-associated T/NK cell lymphoma after radioimmunotherapy and Rituximab for follicularlymphoma.
Mugitani Ai•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Okamoto S, Manabe M, Aoyama Y, Kumura T, Ohta K, Furukawa Y, Hanai J, Inoue T
PS-2-279
A case of chronic pulumonary hypertension caused by pulmonary microembolism in patient of ET.
Koh Gi϶‰ï’†’Õa‰@j, Fujitani Y, Takeoka Y, Kosaka S, Yamanura R, Ohta K
OS-3-34
Older age is an influencing factor in increased NRM after aGVHD: A retrospective analysis from TRUMP
Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Morishima Y, Nagamura T, Sakamaki H, Atsuta Y, Murata M

SH-45
Azacitidine‚Æ‘¼‚ÌRŠàÜ‚Æ‚Ì•¹—p‚ª‘tŒ÷‚µ‚½MDS overt AML‚Ì1Ç—á
ˆäã“ÖŽiiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ÞAŽsŒ´O‘PA‹´‘ºŒõ°A•½ˆä@ŠwA“ú–ì‰ë”V

 

‘æ17‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï
_ŒËA6ŒŽ23“ú
Šç–Ê‚ÌŽîᎌ`¬«•a•Ï‚ɑ΂µ‚ÄMohs“îp‚ðŽg—p‚·‚邱‚Æ‚É‚æ‚è, ‰»Šw—Ö@ŠúŠÔ’†‚ÌÇóŠÉ˜a‚ª‰Â”\‚Å‚ ‚Á‚½ˆ««ƒŠƒ“ƒpŽîÇ—á.
ŠÔ•”Œ«Š°i•{’†•a‰@jA,㌴TŽi, •½“‡ÊŽq, ‹g‰ªŒ[Žq, ‰ª–{Gˆê˜Y, ÂŽR‘×F, ‹v‘ºŠx‰›, ‘¾“c’‰M, ¼‰i^ŽÀ, êm’JˆÀ’ÃŽq

 

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy


San FranciscoASep 9-12

D-1402
Usefulness of Procalcitonin and C-Reactive Protein as Diagnostic Markers of Bacterial Infection in Febrile Neutropenia

Aimoto M, Koh H, Bingo M, Yoshida M, Okamura H, Yoshimura T, Inaba A, Koh S, Nanno S, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakane T, Nakamae H, Hino M

 

‘æ198‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‹ž“sƒeƒ‹‚³A‹ž“sA9ŒŽ8“ú
‹¹‘BMALTƒŠƒ“ƒpŽî‚Ì1—á.
’†”ö—²•¶i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g“c‘SGA¬ì‹g•FA‹à“‡@LAŽRªF‹vA•Ÿ“‡—TŽqAˆäã@Œ’

 

16th International Congress of Dietetics


SydneyASep 5-8

Practical Approach Conducted by NST to Standardize Diet Guidelines for Immunosuppressed Patients

Hanayama Y, Fujimoto H, Tamehira A, Takaki S, Nishimoto M

 

‘æ13‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
‚’ÎŒ»‘㌀êA‘åãA7ŒŽ28“úE29“ú
õF‘̈Ùíder(5;19)(p10;q10)‚𔺂Á‚½AML2—á‚ÌŒŸ“¢
ŠÔ•”Œ«Š°i•{’†•a‰@jA‚ŒK‹PlA’†–ì—TŽjAŒ´“c®Œ›A‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A”ž’JˆÀ’ÃŽq

 

‘æ10‰ñ“ú–{—Õ°Žîᇊw‰ï
‘åã‘Û‰ï‹cêA‘åãA7ŒŽ26“úE28“ú

ŠÖ߃ŠƒEƒ}ƒ`‚ÌŽ¡—Ã’†‚ÉŒz•”ƒŠƒ“ƒpߎ‚Å”­Ç‚µŽ¡—Â̒†Ž~‚É‚æ‚Á‚Ĉꎞ“I‚ÉŽîᇂ̎©‘R‘Þk‚ªŠÏŽ@‚³‚ꂽŒ´”­•s–¾‘BŠà.
“¡’J—m‘¾˜Ni϶‰ï’†’Õa‰@jA^@çéŽõAŽR‘º—º‰îA•‰ªNMA¬â‚³‚¨‚è
Ar–Ø@‘ñA‘¾“cŒ’‰îA“ú–ì‰ë”V

Žq‹{èòŠàŽ¡—Ã10”NŒã‚É”­¶‚µ‰»Šw—Ö@‚ª—LŒø‚Å‚ ‚Á‚½‰“Šu“]ˆÚ‚𔺂¤ãè–åŠà‚ÌÇ—á.
^@çéŽõi϶‰ï’†’Õa‰@jA“¡’J —m‘¾˜NAŽR‘º —º‰îA•‰ª NMA¬ã ‚³‚¨‚èAr–Ø ‘ñA‘å“c Œ’ ‰îA“ú–ì ‰ë”V

’¼’°Šà‚ɑ΂·‚éS-‚P—Ö@Œã‚É”­Ç‚µ‚½–«œ‘«”’ŒŒ•a.
ŠÔ•”Œ«Š°i•{’†•a‰@jA¼‹F•¶AŒ´“c®Œ›A’†–ì—TŽjA‚ŒK‹PlA‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq

 

‘æ97‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A6ŒŽ23“ú

20
Žîᇕö‰óÇŒóŒQDIC‚ɑ΂µ‚ÄŠ£‘‡lƒtƒBƒuƒŠƒmƒQƒ“»Ü‚ªPhALL.
ÂŽR‘×Fi•{’†•a‰@jA‰ª–{Gˆê˜YAŠÔ•”Œ«Š°A‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽq

31
SMILE—Ö@‚ÅCR‚𓾂é‚à‚»‚ÌŒãƒAƒOƒŒƒbƒVƒuNK×–E”’ŒŒ•a—l‚Ì•a‘Ô‚ð’悵‚½ãŠ{Ž•“÷Œ´”­NK/T×–EƒŠƒ“ƒpŽî‚Ì‚P—á.
•S£@‘åi‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—ÇA˜a“cŸ–çAΓc‰p˜a
38
ˆÚAŒã”ÄŒŒ‹…Œ¸­‚𗈂µ‚½œ‘ƒpƒ‹ƒ{ƒEƒCƒ‹ƒXŠ´õÇ‚Ì‚P—á
‹g‘º‘ì˜NA’†ªF•FA‰ª‘º_ŽjAˆî—tWŽqAN@Žj˜NA“ì–ì@’qA¼–{ŒõFAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”V

‹³ˆçu‰‰
CMLf—Âɂ¨‚¯‚éÅV‚̘b‘è
’†‘O”Ž‹v

 

‘æ197‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
_ŒË‘Û‰ï‹cêA_ŒËA6ŒŽ9“ú
34
Morganella MorganiiŒŒ—¬Š´õ‚æ‚èSŠO–Œ‰Š‚ð”­Ç‚µSƒ^ƒ“ƒ|ƒi[ƒf‚ð’悵‚½‘½”­«œ‘Žî‚Ì‚P—á.
¬ì‹g•Fi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹à“‡@LA’†”ö—²•¶AŽRªF‹v
138
“¯Ží‘¢ŒŒŠ²×–EˆÚAiallo-HSCTjŒã‚ÌŠˆàCIPS(calcineurin-inhibitor induced pain syndrome)‚Ì2—á.
’†”ö‹gFA‰ª‘º_ŽjA¼–{ŒõFA—Ñ@—ÇŽ÷AN@G’jA’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V

146
“û–[‚É•a•Ï‚ª‚Ý‚ç‚ꂽALK‰A«–¢•ª‰»‘å×–EŒ^ƒŠƒ“ƒpŽî
ŠÔ•”Œ«Š°i•{’†•a‰@jA‚ŒK‹PlA’†–ì—TŽjAŒ´“c®Œ›A‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A”ž’JˆÀ’ÃŽq

 

‘æ59‰ñ“ú–{—AŒŒE×–E—Ö@Šw‰ï
‹ž‰¤ƒvƒ‰ƒUA“Œ‹žA4ŒŽ14“úE16“ú
—⎮Ž©ŒÈR‘Ì‚Æ“¯ŽíR‘̂𕹂¹Ž‚‚½‚ß“K‡ŒŒ‚Ì‘I‘ð‚É‹ê—¶‚µ‚½1Ç—á.
•“c^ˆêi—AŒŒ•”jA¼–{—L‹IA”ö“ˆ¬ŽqA“¡–ìŒhŽOA“cŽçº”ŽA‰Í“c‘¥•¶A‰ª‘º_ŽjA“ú–ì‰ë”V

 

‘æ109‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ï
‚݂₱‚ß‚Á‚¹A‹ž“sA4ŒŽ13“úE15“ú
643
”­ì«–éŠÔŒŒF‘f”AÇŠ³ŽÒ‚ɑ΂·‚é“–‰@‚¨‚æ‚ÑŠÖ˜AŽ{݂ł̃GƒNƒŠƒYƒ}ƒu“Š—^ŒoŒ±.
N@Žj˜NA’†ªF•FAÂŽR‘×FAŽR‘º—º‰îA‘¾“cŒ’‰îA‹à“‡@LAˆäã“ÖŽiA“ú–ì‰ë”V

 

‘æ27‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ï
_ŒË‘Û‰ï‹cêA_ŒËA2ŒŽ23“úE24“ú
643
ä`‘ÑŒŒˆÚAŠ³ŽÒ‚ɑ΂µ‚ăOƒ‹ƒ^ƒ~ƒ“»Ü‚Ì•ž—p‚ª—LŒø‚Å‚ ‚Á‚½1—á.
ˆä㮎qAˆ×•½ˆºŽqA¡ˆä—ÁAŠâŒ©–¾ŽqAˆîè…“ÞŽqA‰ÔŽR‰ÀŽqA“¡–{_’A¼–{ŒõFA’†ªF•FA“ú–ì‰ë”V

 

‘æ34‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åã‘Û‰ï‹cêA‘åãA2ŒŽ24“úE25“ú
YS1-6iÅ—DGŒû‰‰Üj
ƒCƒ“ƒtƒ‹ƒGƒ“ƒUBŒ^RŒ´—z«‚ªŽ‘±‚µ‚½ó‘Ô‚Å”ñŒŒ‰“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½AML with MRC‚Ì‚P—á.
â•”^“Þ”üA‰ª‘º_ŽjA‹g“c‘SGAN@G’jA”õŒã^“oAˆî—tWŽqA“ì–ì@’qA‘Š–{Ž÷A¼–{ŒõFA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°A’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A”‹Œ´Œ‰’ÊA’†”ö‹gFA’†‘O”Ž‹vA“ú–ì‰ë”V
OS1-077
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã–«Šú‚É‚¨‚¯‚éS‹@”\áŠQƒŠƒXƒNˆöŽq‚Ì•]‰¿.
¼–{ŒõFA’†‘O”Ž‹vA’†ªF•FA
N@G’jA—Ñ@—ÇŽ÷A’†‘O”ü‰ÀA‹g“c‘SGA”õŒã^“oA‰ª‘º_ŽjA‘Š–{Ž÷AŠÔ•”Œ«Š°A‹g‘º‘ì˜NAˆî—tWŽqA“ì–ì@’qAœA£’©¶A”‹Œ´Œ‰’ÊA’†”ö‹gFAŽ›“c–FŽ÷A“ú–ì‰ë”V
OS1-083
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãDŽ_‹…‘‘½‚¨‚æ‚Ñ‚»‚Ì’ö“x‚ªˆÚA—\Œã‚Ö—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
’†ªF•FA’†‘O”Ž‹vAœA£’©¶A
N@G’jA’†‘O”ü‰ÀA—Ñ@—ÇŽ÷A¼–{ŒõFA‹g“c‘SGA”õŒã^“oA‰ª‘º_ŽjA”~–{—R—¢Aˆî—tWŽqA‹g‘º‘ì˜NAŽsŒ´O‘PA“ì–ì@’qA”‹Œ´Œ‰’ÊAŽ›“c–FŽ÷A“ú–ì‰ë”V

OS2-050
”ñŒŒ‰ŽÒ––½ŒŒŠ²×–EÌŽæ‚É‚¨‚¯‚éŽ{Ý“àCTC‚ƃoƒ“ƒNƒR[ƒfƒBƒl[ƒ^[‚Ì‹¦“­‚ÌŽŽ‚Ý.
”~–{—R—¢A’†‘O”ü‰ÀAœA£’©¶
A”óŒû’qŽqA•ÐŽR‹MŽqA’Óc@òA’†ªF•FA“ú–ì‰ë”V

PS-A-048
‘¢ŒŒ×–EˆÚAŒã‚Ì–«GVHD‚É‚æ‚éŠp–ŒúEE’×ᇂɑ΂µ‚Ä•\‘wŠp–ŒˆÚA‚ÆŽ©ŒÈŒŒ´“_Šá‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á.
‹g“c‘SGAN@G’jA‰ª‘º_ŽjA”õŒã^“oAˆî—tWŽqA“ì–ì@’qA‘Š–{Ž÷A¼–{ŒõFA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°A’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A”‹Œ´Œ‰’ÊA’†”ö‹gFA’†‘O”Ž‹vA•Ä“c@åA”’–Ø–M•FA“ú–ì‰ë”V
PS-B-071
POEMSÇŒóŒQ‚ÉŽ©‰Æ––½ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½ˆê—á.
‹à“‡@Li‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA¬ì‹g•FAŒüˆä@ŒåA’†”ö—²•¶A’†–ì@’qAˆäã@Œ’AŽRªF‹v

ŠÅPS-A-060
‘¢ŒŒ×–EˆÚAŠ³ŽÒ‚ɑ΂·‚鎕‰È˜AŒgƒVƒXƒeƒ€‚Ì\’z.
™ŽRK—é
A¼–{“TŽqA¼‰Y—TŽqAŠâŒ©–¾ŽqAŽR–ì–õŽqA‹{–{’qŽqAˆîè…“ÞŽqA“ú–ì‰ë”V

 

2011”N

‘æ196‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‹ž“sƒeƒ‹ƒTA‹ž“sA12ŒŽ17“ú
‘Ζƒáƒ‚É‚Ä”­Ç‚µƒ‰ƒ“ƒ_ƒ€”畆¶ŒŸ‚É‚Äf’f‚µ“¾‚½ŒŒŠÇ“à‘å×–EŒ^BƒŠƒ“ƒpŽî‚Ì‚P—á.
•S£@‘åiJR‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—ÇA˜a“cŸ–çA–Ø‘ºÊA´–ì@ˆ¤AŽR–{F“¿AŠâ–{ˆêG
H. influenzae‚É‚æ‚é”x‰Š‚©‚çSƒ^ƒ“ƒ|ƒi[ƒf‚𗈂µ‚½ˆ««ƒŠƒ“ƒpŽî‚Ì‚P—á.
Œüˆä@Œåi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹à“‡@LA’†”ö—²•¶AŽRªF‹vA‹gˆä—R”üAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞAŽè“‡”Ž•¶

 

53th American Society of Hematology
San-DiegoADec 10-13
2000
Risk Factors Affecting Cardiac Left Ventricular Systolic and Diastolic Function and Hypertrophy in the Chronic Phase Post-Allogeneic Hematopietic Cell Transplantation

Nishimoto M, Nakamae H, Nakane T, Koh H, Hayashi Y, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hirose A, Hagihara K, Nakao Y, Terada Y, Hino M

3764
Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib

Hayashi Y, Nakamae H, Katayama T, Nakane T, Koh H, Nishimoto M, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hagihara K, Nakao Y, Terada Y, Hino M

3071[‹¤“¯Œ¤‹†]
Double-Unit Cord Blood Transplantation for Hematological Malignancies in Japan: Multicenter Phase II Study (C-SHOT 0507)

Wake A, Kai SR, Okada M, Kurata M, Atsuta Y, Ishikawa J, Hino M, Aotsuka N , Kasai M, Misawa M, Taniguchi S, Kato S

452[‹¤“¯Œ¤‹†](oral)
Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Saglio G, LeCoutre PD, Pasquini R, Jootar S, Nakamae H, Flinn IW, Hochhaus A, Hughes TP, Larson RA, Hoenekopp A, Gallagher NJ, Yu R, Blakesley RE, Kim DW, Kantarjian HM

1935[‹¤“¯Œ¤‹†]
Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation (RIST) for Patients Aged 50-70 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Kanamori H, Kako S, Kato H, Nishiwaki S, Furukawa T, Saito M, Taniguchi S, Nakamae H, Yujiri T, Naganuma-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka  J

 

‘æ96‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A‘åãA11ŒŽ12“ú
ä`‘ÑŒŒˆÚAŒã‚ÉSƒ^ƒ“ƒ|ƒi[ƒf‚ð”­Ç‚µS”X‰t‚©‚çHHV6 DNA‚ªŒŸo‚³‚ꂽˆê—á.
‹g“c‘SGAN@G’jA‰ª‘º_ŽjA”õŒã^“oA¼–{ŒõFA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°A ’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V
ƒEƒTƒMATG“Š—^‚É‚Ä‹}Œƒ‚ÈŠÌy‘f‚Ì㸂ð”F‚ß‚½Ä¶•s—Ç«•nŒŒ.
•S£@‘åiJR‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—ÇA˜a“cŸ–ç
‘½”­«œ‘Žî‚ɑ΂·‚éƒ{ƒ‹ƒeƒ]ƒ~ƒu‚Ìdose intensity‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
‰ª–{Gˆê˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›

 

‘æ49‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï
–¼ŒÃ‰®‘Û‰ï‹cêA–¼ŒÃ‰®A10ŒŽ27“úE29“ú
5”ÔõF‘Ì’·˜rŒ‡Ž¸‚𔺂¤œ‘ˆÙŒ`¬ÇŒóŒQ‚ɑ΂·‚郌ƒiƒŠƒhƒ~ƒh‚ÌŽg—pŒoŒ±.
êm’JˆÀ’ÃŽqAN@Žj˜NA‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A•S£@‘åA•½ˆä@ŠwA“¡’J—m‘¾˜YA‘¾“cŒ’‰îA“ú–ì‰ë”V
R-CHOP—Ö@‚ÅŠ®‘SŠ°‰ð‚𓾂½‘O—§‘BŒ´”­‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–EƒŠƒ“ƒpŽîÇ—á.
ŠÔ•”Œ«Š°, —Ñ—ÇŽ÷, ‹gˆä—R”ü, ŒüˆäŒå, â–{Œb—˜“Þ, ‹à“‡L, —tŽR‘ô–, ‹v•Û—E‹L, •Ÿ“‡—TŽq, ˆä㌒, Žè“‡”Ž•¶

 

‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
–¼ŒÃ‰®‘Û‰ï‹cêA–¼ŒÃ‰®A10ŒŽ14“úE16“ú

OS-1-52
Experience of lenalidomide therapy for multiple myeloma in a community setting in Osaka.
Takaoka Yi‘åã•{϶‰ï’†’Õa‰@jAOhta KAYamamura RAKosaka SAFujitani YAInaba AAMugitani AAKumura TAAoyama YAIchihara HAKoh SAYamane TAKanashima HASakamoto EAHashimura MAYoshii YAHirai MAMomose DAWada KAKoh KRASugano YAOkamoto SATeshima HANakao TAHino M

OS-1-111
Serum cytokine profiles in hemophagocytic syndrome after allogeneic hematopoietic cell transplant.
Koh HAKoh KRANakane TASakamoto EAKatayama TANakamae MATerada YANakamae HAYamane TAHino M

PS-1-104
A rare case of CD7+, CD56+ and Ph-positive early precursor B-ALL.
Yoshida MANakane TAOkamura HABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HAHagihara KANakamae MATerada YANakamae HAHino M
OS-2-4(‹¤“¯Œ¤‹†)
The TARGET system provides more practical and general features compared with the IRIS study.
Tauchi TAKizaki MAOkamoto SAHanaka HATanimoto MAInokuchi KASaburi YAHino MAIsobe YAOshimi KADan KAOhyashiki KAIkeda Y
OS-2-6(‹¤“¯Œ¤‹†)
Dasatinib versus Imatinib in patients with newly diagnosed chronic-phase CML: Japanese subanalysis.
Ogura MANakamae HAFujisawa SAIshizawa KATaniwaki MAUtsunomiya AAMatsue KATamura KAUsuki KATanimoto MAIshida YAAkiyama HASakai RAKasai MAHino MATakeyama KASeriu TABradley-Garelik MBAZhu C
OS-2-10(‹¤“¯Œ¤‹†)
Multi-center clinical study evaluating the CMR/MMR ratio of CML-CP by high-sensitive IS-Q-PCR test.
Nishiwaki KATakahashi NAWakita HAShinohara YATakahara SASano KAMasuoka HAAotsuka NAMatsuura YAHirasawa AANakamura HAKashimura MAFukazawa MATanaka HANakagawa YAMatsue KAItoh KAHatano YAKuroki JANakayama YAIchikawa YAChubachi AANimura TAMotegi MAMugitani AANakane TANakamae HAHino MASawada KAMiyazaki Y
PS-2-147
Cold-AIHA in a case of MDS relapsed after allogeneic bone marrow transplantation.
Okamura HANakane TAYoshida MABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HANakamae MATerada YANakamae HAHino M

PS-2-172
Primary gastric T-cell lymphoma without Human T cell Leukemia Virus Type 1: a case report.
Manabe MAYamane TAInaba AANanno SAInoue AAAimoto MAOkamura HAYoshida MABingo MANishimoto MAHayashi YAKoh HANakane TANakamae MAHagihara KATerada YANakamae HANakamura MAMuguruma KAOhsawa MA
Hino M

PS-2-208
Reversible posterior leukoencephalopathy following acute pancreatitis in a patient with leukemia.
Nishimoto MAKoh HAHayashi YAManabe MABingo MAYoshoda MAOkamura HAHirose AANakamae MAHagihara KANakane TATerada YANakamae HAHino M
OS-3-100
The immunoprofile of patients with CML treated with imatinib, nilotinib or dasatinib.
Hayashi YANakamae HAKatayama TANakane TAKoh HANishimoto MANakamae MAYoshida MABingo MAOkamura HAAimoto MAManabe MAHagihara KANakao YATerada YAHino M
OS-3-157
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders.
Koh HAHino MAOhta KAIino MAUrase FAYamaguchi MAYamanouchi JAUsui NAYoshida MATanimoto MAOhyashiki KAUrabe AATamura KAKanamaru AAMasaoka T

 

‘æ195‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã‘ی𗬃Zƒ“ƒ^[A‘åãA9ŒŽ10“ú
ä`‘ÑŒŒˆÚAŒã‚ɃgƒLƒ\ƒvƒ‰ƒYƒ}”]Ç‚ð”­Ç‚µ‚½œ‘ˆÙŒ`¬ÇŒóŒQ‚Ì‚P—á.
ˆî—tWŽqA¼–{ŒõFAN@G’jA—Ñ@—ÇŽ÷A‰ª‘º_ŽjA ’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VA‰º–쑾˜Y

 

‘æ9‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï
ƒpƒVƒtƒBƒR‰¡•lA‰¡•lA7ŒŽ21“úE23“ú
pŒã8”N‚ðŒo‰ß‚µ, œ‘ŠàŽîÇ‚ð’悵‚ÄÄ”­‚µ‚½ˆÝŠàÇ—á.
ŠÔ•”Œ«Š°, ‹gˆä—R”ü, ŒüˆäŒå, â–{Œb—˜“Þ, ‹à“‡L, ‘O“cˆêÎ, ‹v•Û—E‹L, •Ÿ“‡—TŽq, ˆä㌒, Žè“‡”Ž•¶

 

‘æ15‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘‰ï
ç—¢ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[A‘åãA6ŒŽ30“úE7ŒŽ1“ú
‘¢ŒŒŠ²×–EˆÚAŒãŠ³ŽÒ‚ɑ΂·‚éWT1ƒƒNƒ`ƒ“–Ɖu—Ö@.
•Ûå’¼‹BA‘O“c“N¶AŽRªF‹vA“ú–ì‰ë”VAX–{‘n¢ŽqAŒ´@ˆê^A’†“cA¼“cƒKA’؈五ŽA”ö˜H—S‰îA‰ª@–F

 

‘æ95‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
“sƒzƒeƒ‹ƒjƒ…[ƒAƒ‹ƒJƒCƒbƒNA“òèA6ŒŽ18“ú
”ñŒŒ‰ŽÒŠÔ“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãAŽ©—¥_ŒoáŠQ‚ð’悵‚½HHV6”]‰ŠEÒ‘‰Š‚̈ê—á.
¼–{ŒõFA’†‘O”Ž‹vA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°AN@G’jA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A“ú–ì‰ë”V
HBVŠÖ˜AŒŒ‹…æÃHÇŒóŒQ‚ÌŽ©‘RŠ°‰ð‚É‘±‚«ƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ÌÄ”­‚ð”F‚ß‚½‚—îŽÒ—á.
˜a“cŸ–çiJR‘åã“S“¹•a‰@jA‹g‘º‘ì˜NA›–ìˆÀŠìA‚@‹N—ÇAΓc‰p˜a
“–‰@‚É‚¨‚¯‚é”­ì«–éŠÔŒŒF‘f”AÇŠ³ŽÒ‚ɑ΂·‚éƒGƒNƒŠƒYƒ}ƒu‚ÌŽg—pŒoŒ±.
N@Žj˜Ni¶’·‰ï•{’†•a‰@jA‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›
‹³ˆçu‰‰
Aggressive lymphoma‚ÌŽ¡—Ã`Šî‘b‚©‚çÅV’mŒ©‚Ü‚Å`
.

Ž›“c–FŽ÷

 

‘æ194‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
“Þ—ÇŒ§—§•¶‰»‰ïŠÙA“Þ—ÇA6ŒŽ11“ú
Šà«‘–Œ‰Š‚ɑ΂µ‚Äerlotinib‚ª—LŒø‚Å‚ ‚Á‚½”x‘BŠàpŒãÄ”­Ç—á.
ŠÔ•”Œ«Š°, Œõ‰ª–ÎŽ÷, ”~ì‰Á“ÞŽq, “c’†G“T, ‹g‘º¬‰›, –Ø‘º’B˜Y, •“cŒi•q, H“¡VŽO, •½“cˆêl

 

‘æ65‰ñ“ú–{Œð’ʈãŠw‰ï‘‰ï
ƒƒ‹ƒpƒ‹ƒN‹ž“sA‹ž“sA6ŒŽ4“úE5“ú
EBVÄŠˆ«‚𔺂¤ŒŒ‹…æÃHÇŒóŒQ‚É‘±‚¢‚ÄÄ”­‚ð”F‚ß‚½‚—îƒzƒWƒLƒ“ƒŠƒ“ƒpŽî.
˜a“cŸ–çiJR‘åã“S“¹•a‰@j
“Á•Êu‰‰I
“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŒ»ó.
“ú–ì‰ë”V

 

‘æ97‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï
‹ž‰¤ƒvƒ‰ƒUƒzƒeƒ‹A“Œ‹žA5ŒŽ13“úE15“ú
ˆÝŒ´”­ˆ««ƒŠƒ“ƒpŽî(DLBCL)‚ÉR-CHOP—Ö@‚ðŽ{s‚µŠ°‰ð‚ª“¾‚ç‚ꂽ’¼ŒãA“¯•”ˆÊ‚É‘ŠúˆÝŠà‚ð”F‚ß‚½Ç—á.
^@çéŽõA‘å“cGˆêA…ã—zA”nêŠóˆê˜YAˆäˆêŒ›A•½’Ë‘ñ–çA”‹Œ´Œ‰’ÊAã™—TŽqA™ŽR—S”VA“ú–ì‰ë”V

 

‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·i‹¤“¯Œ¤‹†ˆÈŠOjB

‘æ33‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
ˆ¤•QŒ§Œ§–¯•¶‰»‰ïŠÙA¼ŽRA3ŒŽ9“úE10“ú
PS-1-100
ä`‘ÑŒŒˆÚAŒã‚ɇ•¹‚µ‚½Ž©ŒÈ–Ɖu«bó‘BŽ¾Š³‚Ì1Ç—á.
ˆäã“ÖŽii‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†ªF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ÀA—Ñ@—ÇŽ÷A¼–{ŒõFA‘Š–{Ž÷A”õŒã^“oA‹g‘º‘ì˜NA‰ª‘º_ŽjA‹g“c‘SGAŠÔ•”Œ«Š°AœA£’©¶A’†”ö‹gFAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-1-015
”ñŠ°‰ðŠú‚É“¯Ží‘¢ŒŒŠ²×–EˆÚAiHCTj‚ðŽ{s‚³‚ꂽ”’ŒŒ•aŠ³ŽÒ‚Ì’·Šú¶‘¶‚ÉŠñ—^‚·‚éˆöŽq‚ÌŒŸ“¢.
N@G’ji‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†‘O”Ž‹vA’†ªF•FA—Ñ@—ÇŽ÷A¼–{ŒõFA‘Š–{Ž÷Aˆäã“ÖŽiAŠÔ•”Œ«Š°A”õŒã^“oA‹g“c‘SGA‰ª‘º_ŽjA”~–{—R—¢AˆäãŒb—¢A‘Š–{@—–AœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-2-079
“¯Žíœ‘ˆÚAŒã‚ɉ¡’f«Ò‘‰Š‚ð‡•¹‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a.
ŠÔ•”Œ«Š°i‘åãŽs—§‘åŠwŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FAˆÉ“¡˜a”ŽA‰ª‘º_ŽjA”õŒã^“oA‹g“c‘SGAˆäã“ÖŽiA‘Š–{Ž÷A¼–{ŒõFA—Ñ@—ÇŽ÷AN@G’jA’†‘O”ü‰ÀAŽ›“c–FŽ÷A’†‘O”Ž‹vA’†”ö—²•¶A’†”ö‹gFA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-1-017
“–‰È‚É‚¨‚¯‚éPh—z«ALL‚Ì“¯Ží‘¢ŒŒŠ²×–EˆÚA¬Ñ‹y‚Ñ—\ŒãˆöŽq‚ÌŒŸ“¢.
‹g‘º‘ì˜Ni‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†ªF•FAœA£’©¶AN@G’jA’†‘O”ü‰ÀA‘Š–{@—–AˆäãŒb—¢A‘Š–{Ž÷Aˆäã“ÖŽiA¼–{ŒõFA—Ñ@—ÇŽ÷AŽ›“c–FŽ÷A’†”ö‹gFA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
ŠÅŒìPS-1-07
ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÉWII Fit‚ðŽæ‚è“ü‚ꂽŒø‰Ê‚Æ¡Œã‚̉ۑè.
X씪ç‘ãi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰È•a“jA쌳—¢A™ŽRK—éA‘ºŒû—SŽqA”g•½m”üA‹{–{’qŽqAˆîè…“ÞŽqA‰ºÎ•xKA“ì•”½Ž¡
ŠÅŒìPS-1-09
‘¢ŒŒŠ²×–EˆÚAŒãÄ”­‚µ‚½ˆ««ƒŠƒ“ƒpŽîŠ³ŽÒ‰Æ‘°‚ªÝ‘î—×{‘I‘ðŒã‚É‘ÌŒ±‚µ‚½‚±‚Æ.
’ß“c—Œbi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰È•a“jAŽRèm”üA”g•½m”üAˆîè…“ÞŽqA‹{è‹žŽq
ŠÅŒìPS-2-03
ˆÚA•a“‚É‚¨‚¯‚銳ŽÒˆã—ÎҌ𗬉ï‚ÌŽÀ‘H•ñ.
ŽRèm”üi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@@ŒŒ‰t“à‰È•a“jAŽoì”ü—R‹IA‘½Ž¡”ä´ŽqA”g•½m”üA‹{–{’qŽqA’ß“c—ŒbAˆîè…“ÞŽq
‹¤“¯WS2-18-2
Œ’íƒhƒi[‚©‚ç‚Ì––½ŒŒŠ²×–E̎掞‚ÌŒŒŠÇƒAƒNƒZƒX‚Ì‚½‚߂̃fƒoƒCƒX‚ÉŠÖ‚·‚é‘S‘’²¸.
”¨’†ˆê¶i˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw—AŒŒEŒŒ‰tŽ¾Š³Ž¡—Õ”jA—é–Ø—¥˜NA”M“c—RŽqA“ú–ì‰ë”VA–L“ˆ’“¿A¬Ž›—Ç®A¡‘º‰ëŠ°
‹¤“¯WS2-20-1
–¢•ª‰»‘¢ŒŒŠ²×–E‚ÌŽxŽ”\‚ðŽ‚ƒqƒgœ‘—R—ˆŠÔ—tŒnŠ²×–E‚Ì—\Šú“I•ª—£‚Æ‚»‚Ì‹@”\‰ðÍ.
¼‰ª—R˜aiŠÖ¼ˆã‰È‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŠ²×–E¶•¨ŠwjA²X–Ø@–LA‚‹´¹–çA’†’Ë—²‰îAˆäã‰ë”üA¬ìŒ[‹±A‚‹´—²KAÎì@~A“ú–ì‰ë”VA‰’“c¸º

2010”N
–{”N‚æ‚艉‘è–¼A”­•\ŽÒ‚̇‚Å‹LÚ‚µ‚Ä‚¨‚è‚Ü‚·
ŠeŠw‰ï‚É‚¨‚¯‚鉉‘臘‚Í•M“ªŽÒ‚ðŒÜ\‰¹‡‚Å•À‚ׂè‚è‚Ü‚·
‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·i‹¤“¯Œ¤‹†ˆÈŠOjB
52th American Society of Hematology
OrlandADec 4-7
3551
Factors That Contribute to Long-Term Survival In Patients with Leukemia Not In Remission at Allogeneic Hematopoietic Cell Transplantation

Koh H, Nakamae H, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto K, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M

1180[‹¤“¯Œ¤‹†]
Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey In 10years Project by Japan Society for Hematopoietic Cell Transplantation

Kodera Y, Yamamoto K, Kato S, Harada M, Kanda Y, Hamajima N, Asano S, Ikeda Y, Imamura M, Kawa K, Morishima Y, Nakahata T, Tanimoto M, Dohy H, Tanosaki R, Shiobara S, Kim SW, Nagafuji K, Hino M, Miyamura K, Suzuki R

3852[‹¤“¯Œ¤‹†]
Prospective Isolation and Functional Characterization of Human Bone Marrow-Derived Hematopoietic Stem Cell-Supportive Mesenchymal Stromal Cells

Matsuoka Y, Sasaki Y, Takahashi M, Nakatsuka R, Uemura Y, Inoue M, Ogawa H, Takahashi T, Ishikawa J, Hino M, Sonoda Y

2287[‹¤“¯Œ¤‹†]
Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System.

Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y


‘æ94‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒsƒAƒU’WŠCAŽ ‰êA11ŒŽ6“ú
‰‰‘è”Ô†10
‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–EƒŠƒ“ƒpŽî‚ð”­Ç‚µ‚½“¯Ží‘¢ŒŒŠ²×–EˆÚAƒhƒi[‚Ì1—á.
N@Žj˜Ni•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›Aêm’JˆÀ’ÃŽq
‰‰‘è”Ô†32
ƒvƒŠƒ“—U“±‘Ì“Š—^Œã‚ɃAƒfƒmƒEƒCƒ‹ƒXiAdVj-oŒŒ«äNã÷‰ŠiHCj‚𗈂µ‚½ˆ««ƒŠ
ƒ“ƒpŽî‚Ì2—á.
™ŽR—T”Vi϶‰ï–ì]•a‰@jAã™—TŽq

‘æ72‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï
ƒpƒVƒtƒBƒR‰¡•lA‰¡•lA9ŒŽ24-26“ú
PS-2-152
Autoimmune hemolytic anemia with trisomy X chromosome abnormality.
ŽOõF‘̈Ùí‚ð”F‚ß‚½Ž©ŒÈ–Ɖu«—nŒŒ«•nŒŒ.
‘¾“c’‰Mi•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jA‰v‰ª@—DAŒÃì‰À‰›AŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA“ú–ì‰ë”V
PS-1-27
ƒNƒ[ƒ“•a‚ÆSWEET•a‚ÌŽ¡—ÃŒo‰ß’†‚É‘½”­«œ‘Žî‚ð”­Ç‚µ‚½ˆê—á.
‹à“‡@Li‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹´‘ºŒõ°A‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞAˆäã@Œ’AŽè“‡”Ž•¶
PS-2-37
Early start of Bortezomib may contribute to better survival of Japanese multiple myeloma patients.
‘Šúƒ{ƒ‹ƒeƒ]ƒ~ƒu“Š—^‚Í–{–M‘½”­«œ‘Žî¶‘¶‚É‚æ‚¢‰e‹¿‚ð‹y‚Ú‚·.
¬â‚³‚¨‚èi‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjAŽR‘º—º‰îAN@G’jAˆî—tWŽqA•‰ªNMAŽRªF‹vA“ú–ì‰ë”VA‘¾“cŒ’‰î
OS-2-32
—AŒŒŒã“S‰ßèǂɑ΂·‚éŒoŒû“SƒLƒŒ[ƒgÜDeferasirox‚ÌŽg—pŒoŒ±.
Ž›“c–FŽ÷i‘åãŽs—§‘åŠw‘åŠw‰@ŒŒ‰tŽîᇧŒäŠwjAŽR‘º—º‰îAâ–{Œb—˜“ÞAã–{e•FAŽRªF‹vAÂŽR‘×FA•½ˆä@ŠwAŽè“‡”Ž•¶Aêm’JˆÀ’ÃŽqA‘¾“cŒ’‰îA“ú–ì‰ë”V
PS-1-157
ƒNƒ[ƒ“•aŽ¡—Ã’†‚É”­Ç‚µ‚½ACD13A33‰A«‚Ì‹}«œ‘’P‹…«”’ŒŒ•a‚Ì1—á.
¼–{ŒõFi‘åãŽs—§‘åŠwŒŒ‰t“à‰È‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vAˆäã“ÖŽiA‘Š–{@—–A‘Š–{Ž÷A—Ñ@—ÇŽ÷AN@G’jA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“n•ÓŒ›Ž¡A“ú–ì‰ë”V
PS-1-81
HLAˆê’v“¯–E‚©‚ç‚Ìœ‘ˆÚAŒãÄ”R‚ÌdÇĶ•s—Ç«•nŒŒ‚ɑ΂µA“¯ˆêƒhƒi[‚©‚ç‚ÌRIC-PBSCT‚ðŽ{s‚µ‚½ˆê—á.
—Ñ@—ÇŽ÷i‘åãŽs—§‘åŠw‘åŠw‰@ŒŒ‰tŽîᇧŒäŠwjA’†ªF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ÀA¼–{ŒõFAˆäãŒb—¢Aˆäã“ÖŽiA‘Š–{Ž÷A‘Š–{Ž÷A‹g“c‘SGAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
SH-33
A-68-year-old-man with unconsciousness after influenza virus infection.
ƒCƒ“ƒtƒ‹ƒGƒ“ƒUœëŠ³Œã‚Ɉӎ¯ÁŽ¸‚ɊׂÁ‚½68Î’j«—á.
ŒÃì‰À‰›i•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAêm’JˆÀ’ÃŽqA‹v‘ºŠx‰›AÂŽR‘×FAŽsŒ´O‘PAN@Žj˜NA‘å˜H@„
PS-2-35
Salvage therapy with THALED for refractory or relapsed multiple myeloma.
Ž¡—Ã’ïR«‚ ‚é‚¢‚ÍÄ”­‘½”­«œ‘Žî‚ɑ΂·‚éƒTƒŒƒh‚ð—p‚¢‚½ƒTƒ‹ƒx[ƒW—Ö@.
êm’JˆÀ’ÃŽqi•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›
[‹¤“¯Œ¤‹†]
OS-1-21
Prospective isolation and functional characterization of human marrow-derived MSCs.
Matsuoka Y (Dept. Stem Cell Biol., Kansai Med Univ.), Sasaki Y, Takahashi M, Nakatsuka R, Inoue M, Ogawa H, Takahashi T, Ishikawa J, Hino M, Uemura Y, Sonoda Y
[‹¤“¯Œ¤‹†]
OS-1-42
Efficacy of a new protocol, CAG-G-GO (GO following CAG and G-CSF), for refractory or relapsed AML.
Matsuoka H (Oncology/Hematology, Kobe Univ.), Kurimoto M, Uneda S, Shimanuki M, Hosoi H, Murata S, Nohgawa M, Sakaguchi R, Hino M, Yamane T, Sakamoto C, Ohta K, Mugitani A, Aoyama Y, Sonoki T, Hatanaka K, Nakakuma H
[‹¤“¯Œ¤‹†]
OS-1-161
Chemokines/soluble adhesion molecules in febrile neutropenic with hematologic malignancies.
Ichihara HiDep. of Hematology, Seichokai Fushu Hospitalj, Kumura T, Matsuda M, Itagaki N, Aoyama Y, Kou S, Ishii K, Mugitani A, Tsukaguchi M, Kubota T, Urase F, Maeda Y
[‹¤“¯Œ¤‹†]
OS-2-165
Clonogenic myeloma progenitor cells reside in the CD19-CD38++ plasma cell population.
Hosen N (Dept. of Functional Diagnostic, Osaka Univ.), Kishida S, Matsuoka Y, Ichihara H, Mugitani S, Aoyama Y, Kawakami M, Yamaguchi T, Murakami M, Fuji S, Tamaki H, Nakao T, Oka Y, Hino M, Sugiyama H
[‹¤“¯Œ¤‹†]
Dasatinib compared with imatinib in newly diagnosed chronic myelogenous leukemia in chronic phase.
Nakamae H (Hematology, Graduate School of Medicine, Osaka City Univ.), Shah N, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Bradley-Garelik MB, Zhu C, Baccarani M, Kantarjian H.
[‹¤“¯Œ¤‹†]
OS-3-75
MMSC-1 as a novel target molecule for monoclonal antibody therapy against multiple myeloma.
Hosen N (Dept. of Functional Diagnostic, Osaka Univ.), Kishida S, Matsuoka Y, Ishihara H, Aoyama Y, Mugitani A, Kawakami M, Yamagami T, Murakami M, Tamaki H, Nakao T, Fuji S, Nakajima H, Hino M, Oka Y, Sugiyama H
[‹¤“¯•ñ]
PS-1-75
RIST‚É‚æ‚è—ÇD‚ÈŒo‰ß‚𓾂Ă¢‚éA”­Ç1”N‚ÅŠ¥“®–¬E”]“®–¬•ÂÇ‚ð‚«‚½‚µ‚½CAEBV‚Ì26΂̗«.
ŽR“c‰À¢i‘åã•{—§•êŽqˆã—ÃZƒ“ƒ^[ŒŒ‰tEŽîᇉÈjAˆÀˆä¹”ŽA²“¡^•äA‹ß“¡@“AàV“c–¾‹vAŽž­’è—YAˆäã‰ë”üA‰Í’×R‹IŽqA¼ì³‘¥A‰Ô’J²‹vAŽO‹´@–LA“ú–ì‰ë”VA‰Í@Œh¢

‘æ192‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï—á‰ï
‘åã‘ی𗬃Zƒ“ƒ^[A‹ž“sA9ŒŽ11“ú
‰‰‘è156
ˆâ“`Žq‘g‚ÝŠ·‚¦ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“(rTM)‚ª—LŒø‚Å‚ ‚Á‚½ŽY‰ÈDIC‚Ì3Ç—á.
‹v‘ºŠx‰›i¶’·‰ï•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAÂŽR‘×FAŽsŒ´O‘PAN@Žj˜NAêm
’JˆÀ’ÃŽqA‘ì‚ЂƂÝi“¯@ŽY•wl‰ÈjA s‰ªŒc‰îA–؉º@’eA’†ì¹ŽqA ŽRè‘¥s
‰‰‘è157
œ‘ˆÙŒ`¬ÇŒóŒQ‚ÌŒo‰ß’†‚É”­Ç‚µ‚½Œã“V«ŒŒ—F•aA‚Ì1—á.
‹´‘ºŒõ°i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞA‹à“‡@LAŽè“‡”Ž•¶
‰‰‘è168
POEMSÇŒóŒQ‚É—ÞŽ—‚Ì•a‘Ô‚ð’悵‚½ƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‡•¹MALTƒŠƒ“ƒpŽî‚Ì1—á.
”õŒã^“oi‘åãŽs—§‘åŠwˆãŠw•”•t‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA—Ñ@—ÇŽ÷A‚@‹N—ÇAN@G’jA’†ªF•FA’†‘O”ü‰ÀAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽRªF‹vA“ú–ì‰ë”V

‘æ11‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ï
“Œ‹žƒrƒbƒOƒTƒCƒgA“Œ‹žA7ŒŽ25“ú
‰‰‘è56
õF‘̈Ùít(4;12)(q12;p13)‚ð—L‚·‚éŽá”N”­ÇAML with myelodysplasia-related
changes‚Ì1—á.
ŠÔ•”Œ«Š°i‘åãŽs—§‘åŠwˆãŠw•”ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘ºPmA’†‘ºƒŽqA
•ŸŽR’qŽqA[“cŒb—˜“ÞAˆäã“ÖŽiA“ú–ì‰ë”V

‘æ93‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A‘åãA6ŒŽ19“ú
‰‰‘è40
EDTA‚É‚æ‚錌¬”‰q¯Œ¸­‚ð”F‚ß‚½Œ’íl‚Ì1—á.
N@Žj˜Ni•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›
‰‰‘è21
‘½”­«œ‘Žî‚ÌŒo‰ß’†‚Éplasmablastic transformation‚𗈂µ‚½1—á.
Œüˆä@Œåi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹gˆä—R”üAŠÔ•”Œ«Š°A‹à“‡@LAâ–{Œb—“ÞAŽè“‡”Ž•¶AŒŽ‰ª‘ì”nA•Ÿ“‡—TŽqAˆäã@Œ’
‰‰‘è31
“î•”‘gD‚Ö‚Ì‚Ñ‚Ü‚ñ«Z‚É‚ÄÄ”­‚µ‚½HHV-8(-)HIV(-)Eprimary effusion lymphoma—lƒŠƒ“ƒpŽî‚Ì2—á.
‹g‘º‘ì˜Ni‘åã“S“¹•a‰@ŒŒ‰t“à‰ÈjA‰ª–{Gˆê˜YA›–ìˆÀŠìA˜a“cŸ–ç

‘æ191‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï—á‰ï
ŽÅ—–‰ïŠÙA‹ž“sA6ŒŽ12“ú
‰‰‘è77
‹}«‘Oœ‘«”’ŒŒ•a(APL)‚ɇ•¹‚µ‚½”dŽí«ŒŒŠÇ“à‹ÃŒÅÇŒóŒQ(DIC)‚ɑ΂µƒŠƒRƒ“ƒrƒiƒ“ƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ð—p‚¢‚½2Ç—á‚ÌŒŸ“¢.
ŽsŒ´O‘Pi¶’·‰ï•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAN@Žj˜NAÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA‘¾“c’‰M, ŒÃì‰À‰›
‰‰‘è83
cŠuŒ´”­NHL(DLBCL)‚̉»Šw—Ö@ŒãA‘å“®–¬‰ð—£‚ð”­Ç‚µ‚½1—á.
›–ìˆÀŠìi‘åã“S“¹•a‰@ŒŒ‰t“à‰ÈjA˜a“cŸ–çA‰ª–{Gˆê˜YA‹g‘º‘ì˜NA¬ŽR@mA–p@‹ÎAA“ú–ì‰ë”V
‰‰‘è84
Hyper-CVAD‚ÅŠ°‰ð“±“üŒãAmolecular remission‚É“ž’B‚µ‚½¬lE2A-PBX1—z«ALL‚Ì2—á
›–ìˆÀŠìi‘åã“S“¹•a‰@ŒŒ‰t“à‰ÈjA˜a“cŸ–çA‰ª–{Gˆê˜YA‹g‘º‘ì˜NA“ú–ì‰ë”V

‘æ32‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
ƒAƒNƒgƒVƒeƒB•l¼EƒI[ƒNƒ‰ƒAƒNƒgƒVƒeƒBƒzƒeƒ‹•l¼A•l¼A2ŒŽ19“úA20“ú
PS-1-49
ƒÀŽÕ’f–òiCarvediolj‚É‚æ‚èRƒKƒ“Ü‚É‚æ‚é–òÜ«S‹ØÇ‚ª‰ü‘P‚µA“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ“¾‚½‹}«œ‘«”’ŒŒ•a‚Ì1—á.
@ÂŽR‘×FiŽÐ‰ïˆã—Ö@l¶’·‰ï•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAŽsŒ´O‘PAN@Žj˜NA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽq
ŠÅPS-1-35
‘¢ŒŒ×–EˆÚAŠ³ŽÒ‚ÌŒûo”S–ŒáŠQ‚ɑ΂·‚éƒOƒŠƒZƒŠƒ“ŠÜšu‚Ì—LŒø«.
@Žoì”ü—R‹Ii‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰È•a“jA’†ªF•FA‹{è‹žŽqA“ú–ì‰ë”V
PS-1-95
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɇ•¹‚µ‚½’°ŠÇ”X–E«‹CŽîÇ‚Ì1Ç—á.
@ˆäã“ÖŽii‘åãŽs—§‘åŠwˆãŠw•”ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vA’†ªF•FAN@G’jA’†‘O”ü‰ÀA—Ñ@—ÇŽ÷A¼–{ŒõFA‹g‘º‘ì˜NAˆäãŒb—¢A‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-2-101
46,XY,t(9;12)(q34;q22)‚ð—L‚·‚é–«œ‘‘B«Ž¾Š³‚É“ñ“x‚Ìä`‘ÑŒŒˆÚA‚ðŽ{s‚µ‚½ˆê—á.
@‹à“‡@Li‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°A‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞAˆäã@Œ’AŽè“‡”Ž•¶
ŠÅPS-2-9
‘¢ŒŒ×–EˆÚAŠ³ŽÒ‚ÌHŽ–Žw“±ƒ}ƒjƒ…ƒAƒ‹‚Ìì¬‚ðŽŽ‚Ý‚Ä.
@ŒK–¼“ÖŽqi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰È•a“jA“ˆ˜H»’qA¡ˆä—ÁA‚‹´’¼ŽqA™ŽRK—éAŠâŒ©–¾ŽqA”g•½m”üA’ß“c—ŒbA‹{è‹žŽqA‰ÔŽR‰ÀŽqA“¡–{_‹BA’†‰Æ´—²A’†ªF•FA“ú–ì‰ë”V
ŠÅPS-1-8
‘¢ŒŒ×–EˆÚA‚ð‘I‘ð‚·‚éŠ³ŽÒ‚ւ̈ӎuŒˆ’èŽx‰‡‚ÌŒ»ó‚Ɖۑè.
@{ì”üKi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰È•a“jAŽRèm”üA’ß“c—ŒbA‹{è‹žŽq
PS-2-24
ƒVƒNƒƒXƒ|ƒŠƒ“iCsAj{’ZŠúƒƒ\ƒgƒŒƒLƒZ[ƒgisMTXj‚ðGVHD—\–h‚Æ‚µ‚½”ñT×–Eœ‹ŽE”ñTBI‰º‚Å‚Ìœ‘”ñ”j‰ó“I”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚAiu-RISTj‚ÌŒŸ“¢.
@’†ªF•Fi‘åãŽs—§‘åŠwˆãŠw•”ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ÀA—Ñ@—ÇŽ÷A¼–{ŒõFA‹g‘º‘ì˜NAˆäãŒb—¢Aˆäã“ÖŽiA‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
ŠÅPS-2-30
‘¢ŒŒ×–EˆÚAŠ³ŽÒ‚Ì‘Þ‰@Œã‚Ì–â‘è“_`ŠO—ˆ‚Ƃ̘AŒg‚ðŽŽ‚Ý‚Ä`
@”g•½m”üi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰È•a“jA’ß“c—ŒbA‹{è‹žŽq
PS-2-127
”’ŒŒ‹…’ቺŠ³ŽÒ‚É‚¨‚¯‚éHŽ–“à—e‚ÌŒŸ“¢.
@‰ÔŽR‰ÀŽqi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@‰h—{•”jA–Ñ—˜ŒbŽqA“¡–{_‹BA“åˆä@éA≺—TŽqAÎì‰À‘ãŽqA–ìˆä—œA”d–”ü‰ÀA•ž•”rˆêA’Ë“c’èMAŒK–¼“ÖŽqA“ˆ˜H»’qAŠâŒ©–¾ŽqA”g•½m”üA‹{è‹žŽqA’†ªF•FA“ú–ì‰ë”V
PS-1-12
Ara-C+CY+TBI‚ð‘Oˆ’u‚Æ‚µ‚½”ñŒŒ‰ä`‘ÑŒŒˆÚA‚Ì—\ŒãˆöŽq‚Ì“–‰È‚Å‚ÌŒŸ“¢.
@—Ñ@—ÇŽ÷i‘åãŽs—§‘åŠwˆãŠw•”ŒŒ‰tE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ÀA¼–{ŒõFA‹g‘º‘ì˜NAˆäãŒb—¢Aˆäã“ÖŽiA‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-2-99
õF‘̈Ùít(16;21)(p11;q22)‚ð—L‚µAä`‘ÑŒŒˆÚAŒã2”N‚ÌŒo‰ß‚ÅÄ”­‚𗈂µ‚½‹}«œ‘«”’ŒŒ•a.
@ŠÔ•”Œ«Š°i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹à“‡@LA‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞA•XŽºŒöGA‘¾“cŒ’‰îAˆäã@Œ’AŽè“‡”Ž•¶
PS-1-56
“–‰@‚É‚ÄŽ©‰ÆˆÚA‚ðŽ{s‚µ‚½ƒAƒ~ƒƒCƒh[ƒVƒX‚ɑ΂·‚錟“¢.
@Œüˆä@Œåi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞA‹à“‡@LAŽè“‡”Ž•¶
PS-2-35
“–‰È‚É‚¨‚¯‚鈫«ƒŠƒ“ƒpŽî‚̑΂·‚鎩ŒÈ––½ŒŒŠ²×–EˆÚA‚ÌŒã•ûŽ‹“I‰ðÍ.
@‹gˆä—R”üi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹à“‡@LAŒüˆä@ŒåAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞAˆäã@Œ’
[‹¤“¯Œ¤‹†]
WS-2-11-1
@‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½––½T ×–EƒŠƒ“ƒpŽî330–¼‚̉ðÍ:JSCTŒ¤‹†‰ï“úŠØ‹¤“¯’²¸Œ¤‹†.
@‹à@¬Œ³A—é–Ø—¥˜NAŒá‹½_ŒúA¡‘º‰ëŠ°A˜aŸ†@“ÖA‹g“c@‹ªAÎì—²”VA”¨’†ˆê¶AŽO‰YŸ_A“ú–ì‰ë”VA‘ëàV@~AŽR–{@‹A‘O“c‰ÃMAˆÉ“¤’ÃG“ñA—é–Ø~ŽiA¼–ì‹gGA’·“¡G“ñA‚ã—mˆêAChul Soo KimAŒ´“cŽÀª

2009”N
‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·B
ŠeŠw‰ï‚É‚¨‚¯‚鉉‘臘‚Í•M“ªŽÒ‚ðŒÜ\‰¹‡‚Å•À‚ׂè‚è‚Ü‚·

‘æ92‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒƒ‹ƒpƒ‹ƒN‹ž“sA‹ž“sA12ŒŽ12“ú
N@Žj˜Ni¶’·‰ï•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›A
êm’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›
”xƒ€ƒR[ƒ‹Ç‚ð‡•¹‚µ‚½œ‘ˆÙŒ`¬ÇŒóŒQ‚̈êÇ—á.
‰‰‘è23
ŠÔ•”Œ«Š°i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹à“‡@LA‹gˆä—R”üAŒüˆä@
ŒåAâ–{Œb—˜“ÞAŽè“‡”Ž•¶AŠâˆäŒªˆçA‹v•Û—E‹LA•Ÿ“‡—TŽqAˆäã@Œ’
‘–ŒŽî—l‚̉摜‚ð’悵‚Ä”­Ç‚µAŒo‰ß’†‚É‘½”­«œ‘Žî‚Ö‚Ìis‚ª‚Ý‚ç‚ꂽ‘ŠOŒ`
Ž¿×–EŽî.
‰‰‘è8
‹g‘º‘ì˜Ni‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FAˆäã“ÖŽiAˆäãŒb—¢A¼–{ŒõFA—Ñ@—ÇŽ÷A”~–{—R—¢A’†‘O”ü‰ÀAŽ›“c–FŽ÷A’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
”牺–Iâ|D‰Š—lT×–EƒŠƒ“ƒpŽîiSPTCLj‚Ì3—á.
‰‰‘è19
˜a“cŸ–çiJR‘åã“S“¹•a‰@ŒŒ‰t“à‰ÈjA‰ª–{Gˆê˜YA›–ìˆÀŠì
AraC­—ʗÖ@Œã‚ÌŽc‘¶‰è‹…‚ɑ΂µƒfƒLƒTƒƒTƒ]ƒ““Š—^‚ª’˜Œø‚µAŠ®‘SŠ°‰ð‚ÉŽŠ‚Á‚½‚—îŽÒ‹}«”’ŒŒ•a.
‰‰‘è28
ƒVƒ“ƒ|ƒWƒEƒ€
’†‘O”Ž‹vi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰Èj
‚ ‚È‚½‚È‚ç‚Ç‚¤‚·‚é‘¢ŒŒŠ²×–EˆÚA`HLA“K‡ŒŒ‰ŽÒ‚ª“¾‚ç‚ê‚È‚¢Žž`
2)”ñŒŒ‰ŽÒŠÔœ‘”ñ”j‰ó“I“¯Žíœ‘E––½ŒŒ‘¢ŒŒŠ²×–EˆÚA‚ÌŒ»ó.

‘æ71‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï
‘—§‹ž“s‘Û‰ïŠÙA‹ž“sA10ŒŽ23“úA24“úA25“ú
‹à“‡@Li‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°A‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞAˆäã@Œ’AŽè“‡”Ž•¶
–«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ‚É“¯Ží––½ŒŒŠ²×–EˆÚA‚ðŽ{sŒã“ñŽŸ«”’ŒŒ•a‚ð”­Ç‚µ‚½ˆê—á.
‰‰‘è PS-2-55
‹v‘ºŠx‰›iŽÐ‰ïˆã—Ö@l•{’†•a‰@ŒŒ‰t“à‰ÈjAÂŽR‘×FAŽsŒ´O‘PAN@Žj˜NAêm’JˆÀ’ÃŽq
“–‰@‚É‚¨‚¯‚鎡—Ã’ïR«‘½”­«œ‘Žî‚ɑ΂·‚éBortezomib‚ÌŽ¡—ÃŒoŒ±.
‰‰‘è PS-2-201
¬â‚³‚¨‚èi‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjA‘¾“cŒ’‰îA’†”ö‹gFA‹v‘ºŠx‰›A”‹Œ´Œ‰’ÊAâ–{Œb—˜“ÞA‰ª–{Gˆê˜YA—Ñ@—ÇŽ÷A‘Š–{@—–A”~–{—R—¢AŽ›“c–FŽ÷A•‰ªNMA’†ªF•FAN@G’jA“ú–ì‰ë”V
ƒCƒgƒ‰ƒRƒiƒ][ƒ‹’ŽË–ò‚É‚æ‚éŒoŒ±“IŽ¡—ÂÌEORTC/MSGf’fŠî€‚ÉŠî‚¢‚½—LŒø«‰ðÍ.
‰‰‘è PS-2-220
Ž›“c–FŽ÷i‘åãŽs—§‘åŠwŒŒ‰tŽîᇧŒäŠwjA’†‘O”Ž‹vA‘Š–{@—–A‹à“‡@LAâ–{Œb—˜“ÞAˆäã“ÖŽiA‹g‘º‘ì˜NAˆäãŒb—¢A¼–{ŒõFA—Ñ@—ÇŽ÷AN@G’jA’†ªF•FA’†‘O”ü‰ÀA‚@‹N—ÇAŽRªF‹vA’†”ö‹gFA‘¾“cŒ’‰îAêm’JˆÀ’ÃŽqAŽè“‡”Ž•¶A“ú–ì‰ë”V
Ä”­E“«Bcl-2/IgH—z«‚ë‚Ù‚¤«ƒŠƒ“ƒpŽî‚ɑ΂·‚éCladribine—Ö@.
‰‰‘è OS-3-65
“¡’J—m‘¾˜Ni‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjA‚‹´”ü—R‹IAˆî—tWŽqAŠÔ•”Œ«Š°A¬â‚³‚¨‚èAŽR‘º—º‰îA‘¾“cŒ’‰î
‘¢ŒŒŠíŽ¾Š³‚É”º‚¤”­”M«D’†‹…Œ¸­Ç‚ɑ΂·‚éƒZƒtƒFƒsƒ€‚Ì—LŒø«‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢.
‰‰‘èPS-2-41
ŠÔ•”Œ«Š°i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA•“cWŽiA‹gˆä—R”üAŒüˆä@ŒåAâ–{Œb—˜“ÞA‹à“‡@LA‹v•Û—E‹LA•Ÿ“‡—TŽqAˆäã@Œ’AŽè“‡”Ž•¶
”dŽí«ŒŒŠÇ“à‹ÃŒÅ‚𔺂Á‚½œ‘ŠàŽîÇ‚Ì4—á.
‰‰‘è PS-2-256
Œüˆä@Œåi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞA‹à“‡@LA’†‘º‹§GA•S£@‘åA“ú–ì‰ë”VAŒK]—DŽqAŽá‹·Œ¤ˆêAŽè“‡”Ž•¶
Œã“V«–Ɖu•s‘SÇŒóŒQ‚ɇ•¹‚µ‚½—œóâ|Œ´”­”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚̈ê—á.
‰‰‘èPS-2-105
êm’JˆÀ’ÃŽqAN@Žj˜NAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›
‘½”­«œ‘Žî‚ɑ΂·‚éƒTƒŒƒhƒJƒvƒZƒ‹100‚ÌŽg—pŒoŒ±.
‰‰‘èPS-2-192
ŽR‘º—º‰îi‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjAâ–{Œb—˜“ÞAŽ›“c–FŽ÷Aã–{e•FA¬â‚³‚¨‚èAÂŽR‘×FAŽ†’J•x•vAŽè“‡”Ž•¶Aêm’JˆÀ’ÃŽqA‘¾“cŒ’‰îA“ú–ì‰ë”V
—AŒŒŒã“S‰ßèǂɑ΂·‚éŒoŒûƒLƒŒ[ƒgÜideferasiroxj‚ÌŽg—pŒoŒ±.
‰‰‘è0S-2-142
‹gˆä—R”üi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°AŒüˆä@ŒåAâ–{Œb—˜“ÞA‹à“‡@LAˆäã@Œ’AŽè“‡”Ž•¶
t(9;22;16)(q34;q11;q24)‚𔺂Á‚½–«œ‘«”’ŒŒ•a.
‰‰‘è PS-3-42
Tadanobu OhtaiŽÐ‰ïˆã—Ö@l•{’†•a‰@ŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[j, Kazusuke Oguma, Yoshio Furukawa, Shiro Koh, Hiroyoshi Ichihara, Yasutaka Aoyama, Takeo Kumura, Atsuko Mugitani, Masayuki Hino
Two cases of spur cell anemia with difficulty diagnosis from MDS.
‰‰‘è PS-3-149
‘½Ž{Ý‹¤“¯Œ¤‹†
¼‰ª@Li˜a‰ÌŽRŒ§—§ˆã‰È‘åŠwŒŒ‰t“à‰ÈjAŒI–{”ü˜aA‰Ô‰ªL‰ÀA”ΓcŽu–ƒA“‡ŠÑ‰h–íA׈ä—TŽ÷A‘º“cËŒáA’¼ì‹§°AãŒû@—ÕA“ú–ì‰ë”VAŽRªF‹vAã–{e•FA‘¾“cŒ’‰îAêm’JˆÀ’ÃŽqAÂŽR‘×FA‰€–ØFŽuA’†ŒFGŠì
Ä”­E“«AML‚ɑ΂·‚éCAG—Ö@‚¨‚æ‚ÑG-CSFæsƒQƒ€ƒcƒYƒ}ƒuƒIƒ]ƒKƒ}ƒCƒVƒ“iGOj—Ö@.
‰‰‘èOS-2-2
‘½Ž{Ý‹¤“¯Œ¤‹†
”Ñ“c”ü“ÞŽqiˆ¤’mˆã‰È‘åŠw‘¢ŒŒ×–EˆÚAU‹»Šñ•tuÀjA•Ÿ“cûé_A’r‹T˜a”ŽA‹gŒ´@“NA¬ìŒ[‹±A’JŒûCˆêA‚Œ©º—ÇAˆÀ•”NMA“ú–ì‰ë”VA‰q“¡“O–çA”M“c—RŽqA“c’†~ŽiA—é–Ø—¥˜N
‰ä‚ª‘‚É‚¨‚¯‚錌‰“¯Ží‘¢ŒŒŠ²×–EˆÚA‚Å‚ÌMycophenolate MofetiliMMFjŽg—p‘S‘ŽÀ‘Ô’²¸Œ‹‰Ê•ñ.
‰‰‘è OS-3-106

‘æ189‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã‘ی𗬃Zƒ“ƒ^[A‘åãA9 ŒŽ26“ú
óˆäƒŽuiJR‘åã“S“¹•a‰@ŒŒ‰t“à‰ÈjA‰ª–{Gˆê˜YA›–ìˆÀŠìA˜a“cŸ–ç
Šˆ“®«EBVŠ´õ‚Æ‚ÌŠÖ˜A‚ª‹^‚í‚ꂽCoombs‰A«Ž©ŒÈ–Ɖu«—nŒŒ«•nŒŒ
ŒŒ‰t3 ‰‰‘è115

ŽsŒ´O‘Pi•{’†•a‰@EŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jAÂŽR‘×FA‹v‘ºŠx‰›AN@Žj˜NA‘¾“c’‰MAŒÃì‰À‰›Aêm’JˆÀ’ÃŽq
ƒ{ƒŠƒRƒiƒ][ƒ‹‚ÅQT‰„’·Atorsardes de pointes‚𶂶‚½”’ŒŒ•aÇ—á.
‘æ91‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA“Þ—ÇA6ŒŽ20“ú
‰ª–{Gˆê˜Yi‘åã“S“¹•a‰@EŒŒ‰t“à‰ÈjA›–ìˆÀŠìA˜a“cŸ–ç
ATRA—Ö@‚É‚æ‚銰‰ðŒã8”N–Ú‚ÉÄ”­AATRAEˆŸáåŽ_‚ÌŒð‘Ö“Š—^‚É‚ÄÄ“x•ªŽqŠ°‰ð‚𓾂½‚—î‹}«‘Oœ‘‹…«”’ŒŒ•a.
‘æ91‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA“Þ—ÇA6ŒŽ20“ú
¼–{ŒõFi‘åãŽs—§‘åŠw‘åŠw‰@EŒŒ‰tŽîᇧŒäŠwjA‚@‹N—ÇAN@G’jA’†ªF•FAŽ›“c–FŽ÷A’†‘O”ü‰ÀA’†‘O”Ž‹vAŽRªF‹vA“ú–ì‰ë”V
CCyR‚ÅŒo‰ß’†Amp-CML‚ª‘‰Á‚µ’†•_ŒoZ‚Å‹}«“]‰»‚µ‚½CML‚Ì1—á.
‘æ91‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA“Þ—ÇA6ŒŽ20“ú
‹gˆä—R”üi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[@ŒŒ‰t“à‰ÈjAŒüˆä@ŒåAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞA‹à“‡@LA•y“cŽqAX@G•vAˆäã@Œ’AŽè“‡”Ž•¶
ŠáÇó‚ɑ΂µÉŽq‘̶ŒŸ‚É‚ÄÄ”­‚Æf’f‚µ‚½•@oŒ´”­ˆ««ƒŠƒ“ƒpŽî‚̈ê—á.
‘æ91‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA“Þ—ÇA6ŒŽ20“ú
‘Š–{Ž÷i‘åãŽs‘åEŒŒ‰tŽîᇧŒäŠwjAN@G’jA•S£@‘åA‰ª–{Gˆê˜YAŽçŒû@—–A˜a“cŒb—¢A’†ªF•FA•‰ªNMAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚̓«ƒAƒfƒmƒEƒCƒ‹ƒXoŒŒ«äNã÷‰Š‚ɑ΂·‚écidofovir‚Ì—L—p«‚ÌŒŸ“¢.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ÂŽR‘×Fi¶’·‰ï•{’†•a‰@EŒŒ‰tŽ¾Š³ƒZƒ“ƒ^[jA‹v‘ºŠx‰›AŽsŒ´O‘PAêm’JˆÀ’ÃŽqA•Ä’J@¸A“ú–ì‰ë”V
Žq•êŠÔ“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ‚½Œ´”­«ƒ}ƒNƒƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ÔàVŒ‹‹Mi‘åãŽs‘åEŒŒ‰tŽîᇧŒäŠwjAŽ›“c–FŽ÷A“c’†‚³‚â‚©A•S£@‘åA‘Š–{Ž÷A‰ª–{Gˆê˜YAŽçŒû@—–A˜a“cŒb—¢AN@G’jA’†ªF•FA•‰ªNMA‚@‹N—ÇAŽRªF‹vA‘åàV­•FA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãBKƒEƒCƒ‹ƒX‚É‚æ‚édÇ”x‰Š‚̈ê—á.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ŠâŒ©–¾Žqi‘åãŽs‘åE7ŠK•a“jAŒK–¼“ÖŽqAŽR“c˜a”üA”g•½m”üA‹ŽRŒ³ŽqA’ß“c—ŒbA‹{è‹žŽqA’†ªF•FA•‰ªNMA“ú–ì‰ë”V
‘¢ŒŒŠ²×–EˆÚA‚ÌŒûo”S–ŒáŠQ—\–h‚Æ‚µ‚Ä‚ÌGFOŒoŒûÛŽæ‚ÌŒø‰Ê.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ã–ì^—RŽqi‘åãŽs‘åE7ŠK•a“jA¡ˆä—ÁA‘½Ž¡”ä´ŽqAŽRèm”üA‹{‰º’å”üA”g•½m”üA‹ŽRŒ³ŽqA’ß“c—ŒbA‹{è‹žŽq
‘¢ŒŒŠ²×–EˆÚA‚É‚¨‚¯‚éADL’ቺ‚̉e‹¿—vˆö‚ÌŒŸ“¢-FIM•]‰¿‚ð—p‚¢‚Ä-.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
‡“¯ƒVƒ“ƒ|ƒWƒEƒ€u”ñŒŒ‰PBSCT‚ÉŒü‚¯‚Äv
“ú–ì‰ë”Vi‘åãŽs‘åEŒŒ‰tŽîᇧŒäŠwj
œ‘ˆÚA„ià’ciJMDPj‚É‚¨‚¯‚éŽæ‘g‚ÌŒ»ó‚Æ«—ˆ“W–].
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
•‰ªNMi‘åãŽs‘åEŒŒ‰tŽîᇧŒäŠwjA’†ªF•FAN@G’jA‰ª–{Gˆê˜YA‘Š–{Ž÷A˜a“cŒb—¢A•S£@‘åA‚@‹N—ÇAŽRªF‹vAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽçŒû@—–A”~–{—R—¢A“ú–ì‰ë”V
‰ŠúŽ¡—Õs‰ž«‚Ì’°ŠÇ‹}«GVHD‚ɑ΂·‚éƒXƒeƒƒCƒh“®’—Ö@‚ÌŒŸ“¢.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
’†ªF•Fi‘åãŽs‘åEŒŒ‰tŽîᇧŒäŠwjA•‰ªNMA’†‘O”Ž‹vA‘Š–{Ž÷AN@G’jA•S£@‘åA‰ª–{Gˆê˜YA˜a“cŒb—¢AŽçŒû@—–A”~–{—R—¢AŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
‹}«GVHD‚ɑ΂·‚鉊úŽ¡—ÂƂµ‚ẴXƒeƒƒCƒh‚¨‚æ‚у~ƒRƒtƒFƒm[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹iMMFj•¹—p—Ö@‚̈À‘S«‚¨‚æ‚Ñ—LŒø«‚ÉŠÖ‚·‚錟“¢.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
¼‰Y”üKi‘åãŽs‘åEŒŒ‰t“à‰ÈŠO—ˆjAŒK–¼“ÖŽqA’ß“c—ŒbA‰Í“àƒqƒfŽqA‹{è‹žŽq
‘¢ŒŒŠ²×–EˆÚAŒã‚ÌHŽ–‚ÌŽÀۂɂ‚¢‚Ä.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ŠÔ•”Œ«Š°i϶‰ï’†’Õa‰@EŒŒ‰t“à‰ÈjA‹ž–{”ŽsAŽR‘º—º‰îA“¡’J—m‘¾˜NA¬â‚³‚¨‚èA‘¾“cŒ’‰îA¼“cM•FA¼ì“T—ÇA‘ë“c³—ºA‹à“‡@LAŽè“‡”Ž•¶AŽçŒû@—–A“ú–ì‰ë”V
‘¢ŒŒ×–EˆÚA‘O‚ÌŒûo“àŠ´õŒ¹ƒXƒNƒŠ[ƒjƒ“ƒO‚ÌŒŸ“¢.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
ŽçŽRˆç”üi‘åãŽs‘åEŒŒ‰t“à‰ÈjA{ì”üKA‘ºŒû—SŽqA‘å“c–ƒˆßŽqAŠp@^‘ãA’ß“c—ŒbA”g•½m”üA‹{è‹žŽq
ˆÚAŒãŠ³ŽÒ‚Ì•s–°Çó‚ɑ΂·‚éƒAƒƒ}ƒeƒ‰ƒs[‚ÌŒø‰Ê.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
•àVÊŽqi‘—§‚ª‚ñƒZƒ“ƒ^[’†‰›•a‰@EŠ²×–EˆÚA‰ÈjAŽRŒû‘ñ—mA‹àX•½˜aAŽR‰º‘ì–çA‰P‹nŒ›—SA–òŽtŽ›˜aºA’|“à@mA“ì’J‘×mAŽÄŽR_•FA“ú–ì‰ë”VAX“àK”üA˜e@–[ŽqA‹›“ˆL•FA“¡“c_”VA‚¼@‘×A›Á@“ú³A”öèŒhŽ¡A¼Î‰péA‹Êˆä‰ÀŽqA‹´–ì@‘A‚–ì–í“ÞA¼‹´‰ÀŽqA“ú‚“¹OA‰i“ˆ‹M”ŽA•xŽR‡Ž¡A’r‹T˜a”ŽA‹{˜eCˆêA“à“c’¼”VA_“c‘PLA•Ÿ“c—²_
‘æˆêŠ°‰ðŠú(CR1)‹}«œ‘«”’ŒŒ•a(AML)‚ɑ΂·‚铯ŽíˆÚA‚ðŠÜ‚ß‚½Ž¡—ÂɊւ·‚é—Õ°Œˆ’f•ªÍi’†ŠÔ‰ðÍj.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
”‹Œ´›’‘¾˜YA‹à@¬Œ³A¬¼P•FAŒã“¡“N–çAã“c‹±“TAˆÉ“¡r˜NA“ú–ì‰ë”VAŠp“ìˆê‹MA“c–ìè—²“ñAX@Tˆê˜YAã@¹LA’J–{“N–çA“c“‡Œ¦ŽqA•Ÿ“cûéLA‚ã—mˆêiRISTŒ¤‹†ƒOƒ‹[ƒvj
ƒNƒ‰ƒhƒ‹ƒrƒ“‚¨‚æ‚уuƒXƒ‹ƒtƒ@ƒ“‚ð‘Oˆ’u‚Æ‚µ‚½HLA“K‡ŒŒ‰ŽÒŠÔƒ~ƒjˆÚA‚É‚¨‚¯‚éGVHD—\–h‚ÉŠÖ‚·‚郉ƒ“ƒ_ƒ€‰»‘æII‘ŠŽŽŒ±FƒVƒNƒƒXƒ|ƒŠƒ“’P“Ƒ΃^ƒNƒƒŠƒ€ƒX’P“ÆiRIST0301j.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
ŽRèGli‹à‘ò‘åŠwE×–EˆÚAŠwjA“ú–ì‰ë”VAŒÃì’B—YAX‰º„‹vA‰F“s‹{äoA¡‘º‰ëŠ°A‹S’Ë^mAV’×mŽi˜YAŠ}ˆä³°A“c“ˆŽŽjA”~Œ´‹v”ÍA“‡èçqA’JŒûCˆêA¡‘º@–LA’†”öáÁ“ñ
C3‚ðŽw•W‚Æ‚µ‚½ƒVƒNƒƒXƒ|ƒŠƒ“‚É‚æ‚é‹}«GVHD—\–h–@‚ÌŒŸ“¢F‘¼Ž{Ý‹¤“¯—Õ°ŽŽŒ±‚̬Ñ.
‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïAŽD–yA2ŒŽ5“úA6“ú

2008”N
‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·B

ŠeŠw‰ï‚É‚¨‚¯‚鉉‘臘‚Í•M“ªŽÒ‚ðŒÜ\‰¹‡‚Å•À‚ׂè‚è‚Ü‚·

50th American Society of Hematology
San FransiscoADec 6-9
[‹¤“¯Œ¤‹†]
1170
Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC). for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan

Kim SW, Fukuda T, Hagiwara S, Komatsu T, Goto T, Ueda Y, Ito T, Hino M, Sunami K, Tanosaki R, Mori S, Kami M, Tajima K, Takaue Y


‘¾“c’‰Mi¶’·‰ï•{’†•a‰@“à‰ÈjA‰ª“c@Œ’AŒÃì‰À‰›AŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA“ú–ì‰ë”VA‘O‘qrŽ¡
TCRˆâ“`ŽqÄ\¬‚ð”F‚߃Šƒ“ƒpŽî‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½¶‰º• •”Œ´”­adenocarcinoma‚̈ê–UŒŸ—á.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
¬â‚³‚¨‚èi‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjA‘¾“cŒ’‰îAŽçŒû@—–A”‹Œ´Œ‰’ÊA‹v‘ºŠx‰›A’†”ö‹gFAâ–{Œb—˜“ÞA‰ª–{Gˆê˜YAœA£’©¶A‰Í–쌪ˆê˜YAÂŽR‘×FAŽR‘º—º‰îA—Ñ@—ÇŽ÷A‹à“‡@LA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
LˆæR¶Ü•s‰ž‚Ì”­”M«D’†‹…Œ¸­Ç‚ɑ΂·‚éŒoŒ±“IŽ¡—ÂƂµ‚ẴCƒgƒ‰ƒRƒiƒ][ƒ‹’ŽË–ò‚Ì—L—p«‚ɂ‚¢‚Ä.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
â–{Œb—˜“Þi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‘¾“cŒ’‰îAŽçŒû@—–AN@G’jA’†ªF•FA•‰ªNMAŽ›“c–FŽ÷A˜a“cŒb—¢A•S£@‘åA‘Š–{Ž÷A¬â‚³‚¨‚èAŽR‘º—º‰îAŠÔ•”Œ«Š°A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
‘¢ŒŒŠíŽ¾Š³Ž¡—Ã’†Š³ŽÒ‚Ì”­”M«D’†‹…Œ¸­Ç‚Ìf’fŽ¡—Âɂ¨‚¯‚éƒvƒƒJƒ‹ƒVƒgƒjƒ“‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
Ž›“c–FŽ÷i‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†‘O”Ž‹vAŽçŒû@—–A‹à“‡@LAâ–{Œb—˜“ÞA‘Š–{Ž÷A˜a“cŒb—¢AN@G’jA’†ªF•FA•‰ªNMA‚@‹N—ÇAŽRªF‹vA’†”ö‹gFAêm’JˆÀ’ÃŽqA‘¾“cŒ’‰îAŽè“‡”Ž•¶A“ú–ì‰ë”V
‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–E«ƒŠƒ“ƒpŽî‚ÌCHOP—Ö@‚É‚¨‚¯‚éRelative Dose IntensityiRDIj‚Ì—\Œã‚ւ̉e‹¿.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
’†”ö—²•¶i‘åãŽs—§‘åŠwŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈA‘åãŽs—§‘åŠw•ªŽq•a‘Ô–ò—ŠwjAŽRªF‹vA•Ð㔺ŽqA²Žç—F”ŽAŠâ”ö@—mA“ú–ì‰ë”V
ƒGƒNƒ\ƒ“13‚ÉV‹Kƒiƒ“ƒZƒ“ƒX•ÏˆÙiTrp499Stopj‚ð”F‚ß‚½ƒvƒŒƒJƒŠƒNƒŒƒCƒ“Œ‡–RÇ.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
“¡’J—m‘¾˜Ni‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[ŒŒ‰t“à‰ÈjA‹à“‡@LA‹gˆä—R”üAŒüˆä@ŒåA—Ñ@—ÇŽ÷Aâ–{Œb—˜“ÞAŽè“‡”Ž•¶
“–‰È‚É‚¨‚¯‚é–«œ‘«”’ŒŒ•a‚ɑ΂·‚郃Vƒ‹Ž_ƒCƒ}ƒ`ƒjƒuŽ¡—ìÑ.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
ŠÔ•”Œ«Š°i‘åã•{϶‰ï’†’Õa‰@ŒŒ‰t“à‰ÈjA“¡’J—m‘¾˜NA¬â‚³‚¨‚èAŽR‘º—º‰îA‘¾“cŒ’‰îAXì@‹MAZ’J[OAˆäã@Œ’AŽè“‡”Ž•¶
Œo‹CŠÇŽx”x¶ŒŸ‚É‚Äf’fŠm’肵AŽ©‰Æ––½ŒŒŠ²×–EˆÚA‚ª—LŒø‚Å‚ ‚Á‚½ŒŒŠÇ“à‘å×–EŒ^‚a×–EƒŠƒ“ƒpŽîÇ—á.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
êm’JˆÀ’ÃŽqi¶’·‰ï•{’†•a‰@ŒŒ‰t“à‰ÈjAŽsŒ´O‘PAÂŽR‘×FA‹v‘ºŠx‰›AŒÃì‰À‰›A‘¾“c’‰MA‘¾“c„OA“ú–ì‰ë”VA’Jì@’A‘O‘qrŽ¡A‰Ôˆä@~
‹}‘¬‚ȃAƒ~ƒƒCƒh[ƒVƒX‚Ìis‚ð”F‚ß‚½‘½”­«œ‘Žî.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
ΈäˆêŒciŽs—§ŠÝ˜a“cŽs–¯•a‰@ŒŒ‰t“à‰ÈjAŠÔ•”Œ«Š°A‰®–Ø•q–çAŽè“‡”Ž•¶A‰iâX–õÍA–Ø‘º‰pŽkA‰Y£•¶–¾A—Ñ@–M—YAŽÄ–ì@Œ«A’ËŒû^’mŽqAŒj“c’B–çAêm’JˆÀ’ÃŽqA–kŽR@“™A–쑺¹ì
‚—îŽÒaggressive”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂·‚éR-VNCOP-B—Ö@.‘æ2‘ŠŒ¤‹†.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
ŠÝ–{—TŽŸiŠÖ¼ˆã‰È‘åŠw•‘®–‡•û•a‰@ŒŒ‰tEŽîᇓà‰ÈjAŽRªF‹vA‘¾“cŒ’‰îA“¡“c^–çA“c“ˆŒ’ˆê˜YAX@áÁˆê˜YA’†”ö—²•¶A‚@‹N—ÇA–p@‹ÎAA¬â‚³‚¨‚èAŽR‘º—º‰îA“òì—´ˆêA“ú–ì‰ë”VA•ŸŒ´Ž‘û¶
–«ŠúCML‚É‚¨‚¯‚éƒCƒ}ƒ`ƒjƒuŽ¡—Â̌»ó.
‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
‹ž“sA10ŒŽ10-12“ú
‹{–{“Þ’ÃŽqi‘åãŽs—§‘匌‰t“à‰ÈE‘¢ŒŒŠ²×–EˆÚA‰ÈjA¬ì‹g•FA’†ªF•FA˜a“c@Œb—¢AN@G’jA•‰ªNMAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãA‚“x‚Ì•Ö”é‚Ɠ«• ’É‚Å”­Ç‚µ‚½”dŽí«…“—‘Ñóáv]ƒEƒCƒ‹ƒX(VZV)Š´õǂ̈ê—á.
‘æ185‰ñ“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åãA6ŒŽ7“ú
‘Š–{Ž÷i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FAN@G’jA•‰ªNMAÔàVŒ‹‹MAŽçŒû@—–A˜a“cŒb—¢AŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
’°ŠÇGVHDŽ¡—Ã’†‚ÉEBƒEƒCƒ‹ƒXŠÖ˜AˆÚAŒãƒŠƒ“ƒp‘B«Ž¾Š³(PTLD)‚É‚æ‚鬒°úE‚𗈂µ‚½‹}«œ‘«”’ŒŒ•a‚̈ê—á.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
ŠâŒ©–¾Žqi‘åãŽs‘匌‰t“à‰È•a“ŠÅŒìŽtjAŽçŽRˆç”üA”g•½m”üA‘OŒ´ŽpŽqA‹ŽRŒ³ŽqA‘Š–{Ž÷A•‰ªNMA“ú–ì‰ë”VA’ß“c—ŒbA‹{è‹žŽq
‘¢ŒŒŠ²×–EˆÚA‚Ì”S–ŒáŠQ‚ɑ΂µ‚ÄGFO“Š—^‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
N@G’ji‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA‚@‹N—ÇA’†ªF•FA•‰ªNMAŽçŒû@—–A‘Š–{Ž÷A˜a“cŒb—¢AÔàVŒ‹‹MAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽRªF‹vA“ú–ì‰ë”V
ƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒhƒpƒ‹ƒX—Ö@‚ª’˜Œø‚µ‚½“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãIdiopathic Pneumonia Syndrome‚É‚¨‚¯‚éTh1ATh2ƒTƒCƒgƒJƒCƒ“‚ÌŒŸ“¢.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
’ß“c—Œbi‘åãŽs‘åŠw‚ª‚ñŠÅŒìê–åŠÅŒìŽtjA‘OŒ´ŽpŽqA‹ŽRŒ³ŽqA‹{è‹žŽq
‘¢ŒŒ×–EˆÚAŠ³ŽÒƒTƒ|[ƒgƒ`[ƒ€‚Ì\’z.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
Ž›“c–FŽ÷i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAŽRªF‹vAN@G’jA’†ªF•FA•‰ªNMAŽçŒû@—–A‘Š–{Ž÷AÔàVŒ‹‹MA˜a“cŒb—¢A’†‘O”Ž‹vA‚@‹N—ÇA“ú–ì‰ë”V
‘¢ŒŒŠíˆ««Ž¾Š³‚ɑ΂·‚éIntravenous Busulfan 8mg/kg+Fludarabine 180mg/m2+TBI 4Gy‚É‚æ‚霑”ñ”j‰ó“Iä`‘ÑŒŒˆÚAiRICBTj‚ÌŒŸ“¢.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
’†ªF•Fi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vA‘Š–{Ž÷Aã–{e•FAÔàVŒ‹‹MA˜a“cŒb—¢AN@G’jA•‰ªNMAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
S‹@”\’ቺ5Ç—á‚ɑ΂·‚霑”ñ”j‰ó“I“¯Ží‘¢ŒŒŠ²×–EˆÚAiRISTjŒã‚ÌS‹@”\‚¨‚æ‚ÑŽ©—¥_Œo‹@”\‚̉ðÍ.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
˜a“cŒb—¢i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAâ–{Œb—˜“ÞAN@G’jA’†ªF•FA•‰ªNMAŽçŒû@—–A‘Š–{Ž÷AÔàVŒ‹‹MAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
‘¢ŒŒŠ²×–EˆÚAŒã‚ÌAMPH-BŽ¡—Ã’†‚ÉV‹K”­Ç‚µ‚½ƒgƒŠƒRƒXƒ|ƒƒ“ŒŒÇ‚Ì2—á.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
ÂŽR‘×F(¶’·‰ï•{’†•a‰@ŒŒ‰t“à‰ÈjA”¨’†ˆê¶A•Ä’J@¸A¼–{“N˜YA‹›“ˆL•FA‰ª–{‰ëŽiAŽR‘º—º‰îAìã@ŠwA‹Ê’uLÆA‰E‹ž’¼ÆAã“cGŽŸAŽR–{–¢‰›A’†‘º@ŒOA”’ì—R”üŽqA¼–{—R”üA“¡‘ãŽu•ÛA‹ß“¡^—ŽqA¼“c—EŽ™A’JŠ_“àˆè—]A‹Ê’urŽ¡
ŒŒ‰tŽ¾Š³f—ÂɌg‚í‚éˆãŽtEŠÅŒìŽt‚ÌE‹Æ«ƒXƒgƒŒƒXE—}‚¤‚ÂŽÚ“x‚ÌŒ»‹µ.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú
[‘½Ž{Ý‹¤“¯Œ¤‹†]
“‡èçqAˆêŒË’C•vA•lŒûŒ³—mA“n•Ó@VAΓcG”VA‹gŒ´—²•vAX–{@“NA‹›“ˆL•FA‘«—§‘sˆêAŒ¢Ž”ŠxŽjAàV“c–¾‹vA‰ª@GŽŸAˆÉ“¡@–žA“ú–ì‰ë”VAæ|“c~–çA“à“c@‘ìA¬Ž›—Ç®
T×–E”ñœ‹ŽNIMA•sˆê’vŒŒ‰ŽÒŠÔˆÚA’·Šú¶‘¶—á‚É‚¨‚¯‚é–«GVHD‚ÌŒŸ“¢.
‘æ30‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
‘åãA2ŒŽ29“ú-3ŒŽ1“ú

2007”N
‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·B
ŠeŠw‰ï‚É‚¨‚¯‚鉉‘臘‚Í•M“ªŽÒ‚ðŒÜ\‰¹‡‚Å•À‚ׂè‚è‚Ü‚·
ŽsŒ´O‘Pi¶’·‰ï•{’†•a‰@jA‘¾“c’‰MAŒÃì‰À‰›AÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA“ú–ì‰ë”V
INF-ƒÀ“Š—^Œãˆ««•nŒŒ‚ð‡•¹‚µ‚½Ç—á.
‘æ88‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“sA11ŒŽ24“ú
•S£@‘åi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAN@G’jA’†ªF•FA•‰ªNMAŽçŒû@—–A‘Š–{Ž÷A˜a“cŒb—¢AÔàVŒ‹‹MAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
–«œ‘‘B«Ž¾Š³‚ɔ畆è÷—±‹…“÷Žî‚ð‡•¹‚µ‚½ˆê—á.
‘æ88‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“sA11ŒŽ24“ú
ŠÔ•”Œ«Š°i϶‰ï’†’Õa‰@jA‰ª–{Gˆê˜YA¬â‚³‚¨‚èAŽR‘º—º‰îA‘¾“cŒ’‰îAi“¡Šì—\A–؉ºŠìŒõA’F@—zˆêA‹à“‡@LAŽè“‡”Ž•¶
ƒƒVƒ‹Ž_ƒCƒ}ƒ`ƒjƒu‘—Ê‚ª–³Œø‚Å‚ ‚Á‚½t(9;12)Œ^–«œ‘«”’ŒŒ•a.
‘æ88‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“sA11ŒŽ24“ú
Koh H, Koh KR, Hagihara K, Nakane T, Takeoka Y, Kanashima H, Sakamoto H, Nakamae M, Ichihara H, Terada Y, Nakamae H, Ohta K, Yamane T, Watanabe T, Hino M
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia: result of a single center study.
13th International Conference on Human Retrovirology HTLV and Related Viruses, Hakone, 22-25 May
Sakamoto E, Ohta K, Nishiki S, Terada Y, Moriguchi R, Nakao Y, Teshima H, Mugitani A, Hino M
Intravenous Itraconazole for empiric antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.
3rd Trends in Medical Mycology, Torino, 28-31 October
Koh KR, Nakamae H, Ohta K, Li HZ, Koh H, Nakane T, Takeoka Y, Hirose A, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Yamane T, Hino M
Possible involvement of ƒÁƒÂ-T cells in the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
Terada Y, Nakamae H, Nakane T, Koh H, Takeoka Y, Moriguchi R, Aimoto M, Akazawa Y, Wada E, Kanashima H, Sakamoto E, Koh KR, Yamane T, Ohta K, Nakao Y, Teshima H, Hino M
The impact of relative dose intensity (RDI) of CHOP on outcome of diffuse large B-cell lymphoma: results of a single center study.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
Ichinohe TShimazaki C, Hamaguchi M, Watanabe A, Ishida H, Yoshihara T, Morimoto A, Uoshima N, Adachi S, Inukai T, Sawada A, Oka K, Itoh M, Hino M, Kanda J, Uchiyama T, KoderaY
Long-term survival after HLA-haploidentical stem cell transplantation from non-inherited maternal antigen-mismatched family donors: impact of chronic graft-versus-host-disease.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
ÂŽR‘×Fi¶’·‰ï•{’†•a‰@jA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›Aêm’JˆÀ’ÃŽqAŽsŒ´‘POA“ú–ì‰ë”V
Žs’†•a‰@“ü‰@’†‚ÌŒŒ‰tŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚é”­”M«D’†‹…Œ¸­Ç‚ÌŒã•ûŽ‹“I‰ðÍ.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
‘¾“c’‰Mi¶’·‰ï•{’†•a‰@jAŽsŒ´‘POAŒÃì‰À‰›AÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”VA¼–ì‹gG
ˆ««ƒŠƒ“ƒpŽî‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½‰E‘lŒa•”Œ´”­ˆ««Žîá‡.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
‚@‹N—Çi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vA‘¾“cŒ’‰îA—›@ƒÍA’†ªF•FA•‰ªNMAœA£’©¶A”‹Œ´Œ‰’ÊA‹à“‡@LAâ–{Œb—˜“ÞA’†‘O”ü‰ÀAŽ›“c–FŽ÷A’†”ö‹gFAŽRªF‹vA“ú–ì‰ë”V
–«GVHD”­ÇŽž‚Ì––½ŒŒTƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒgA–Ôó×–E‚¨‚æ‚ÑŒŒ´ƒTƒCƒgƒJƒCƒ“‚Ì“®‘Ô‰ðÍ.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
N@G’jii‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAâ–{Œb—˜“ÞA’†ªF•FA•‰ªNMAŽçŒû@—–A‘Š–{Ž÷A˜a“cŒb—¢AÔàVŒ‹‹MAŽ›“c–FŽ÷A’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚Ì”ñŠ´õ«’†•_Œo‡•¹Ç‚ÌŽ©Œ±—á‚ÌŒŸ“¢.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
Ž›“c–FŽ÷i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FAN@G’jAŽçŒû@—–A‘Š–{Ž÷AÔàVŒ‹‹MA˜a“cŒb—¢A’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA’†”ö‹gFA“ú–ì‰ë”V
‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–E«ƒŠƒ“ƒpŽî‚ÌCHOP—Ö@‚É‚¨‚¢‚ÄRelative Dose Intensity(RDI)‚ªŽ¡—×\Œã‚É—^‚¦‚é‰e‹¿.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
ŒÃì‰À‰›i¶’·‰ï•{’†•a‰@jA‘¾“c’‰MAÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqAŽsŒ´‘POA“ú–ì‰ë”V
ATLƒLƒƒƒŠƒAŒo‰ß’†‚É”­•a‚µ‚½”]Œ´”­T×–E«ƒŠƒ“ƒpŽî.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
êm’JˆÀ’ÃŽqi¶’·‰ï•{’†•a‰@jAÂŽR‘×FA‹v‘ºŠx‰›AŒÃì‰À‰›AŽRªF‹vA“ú–ì‰ë”V
‘½”­«œ‘Žî—á‚É‚¨‚¯‚éƒTƒŠƒhƒ}ƒCƒh‚ÌŠ³ŽÒ–ž‘«“x.
‘æ69‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ49‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ï
‰¡•lA10ŒŽ11“ú-13“ú
‰ª–{Gˆê˜Yi϶‰ï’†’Õa‰@jA¬â‚³‚¨‚èAŽR‘º—º‰îAŠÔ•”Œ«Š°A‘¾“cŒ’‰îA’†“‡‰plA‚’J‹ïŽjA“ú–ì‰ë”V
Ä”­Žž‚ÉS‘Ÿ‚É‹‘åŽîᎂðŒ`¬‚µ‚½”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚Ì1—á.
‘æ183‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA_ŒËA9ŒŽ1“ú
ã–ì—m—Si‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA•‰ªNMA’†ªF•FAN@G’jA‘Š–{Ž÷A˜a“cŒb—¢AÔàVŒ‹‹MAŽ›“c–FŽ÷A“ú–ì‰ë”V
”­ÇŽž‚Éԉ苅‚Ì’˜‚µ‚¢Œ¸­‚ð”F‚ß‚½”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚Ì1—á.
‘æ183‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA_ŒËA9ŒŽ1“ú
‰ºŽR@½i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAN@G’jA’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞAŽsŒ´O‘PAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ÌIdiopathic Pneumonia Syndrome (IPS)‚É”º‚¤dÇ‚Ñ‚Ü‚ñ«”x–EoŒŒ(DAH)‚ɑ΂µƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒhiCY)ƒpƒ‹ƒX—Ö@‚ª’˜Œø‚µ‚½¬lT×–E”’ŒŒ•aƒŠƒ“ƒpŽîiATLL)‚Ì1—á.
‘æ182‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA5ŒŽ26“ú
‰ª–{Gˆê˜Yi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjAN@G’jAŽ›“c–FŽ÷A’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞA‹à“‡@LAŽsŒ´O‘PA’†‘O”ü‰ÀA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚA‘Šú‚ÉŒŒ‹…æÃHÇŒóŒQ‚ð”­Ç‚µ‚½ALL‚Ì1—á.
‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA•Ÿ‰ªA2ŒŽ16“úA17“ú
N@G’ji‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA”‹Œ´Œ‰’ÊA‹à“‡@LA’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞA’†‘O”ü‰ÀAŽsŒ´O‘PA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
¬l‚s×–E”’ŒŒ•a/ƒŠƒ“ƒpŽîiATL/Lj‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚAiallo-HSCTj‚ÌŒŸ“¢.
‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA•Ÿ‰ªA2ŒŽ16“úA17“ú
Ž›“c–FŽ÷i‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vA’†ªF•FAN@G’jA•‰ªNMAâ–{Œb—˜“ÞA‹à“‡@LAŽsŒ´O‘PA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
isŠú”’ŒŒ•a‚ɑ΂·‚éintravenous busulfan(Buslufex 8mg/kg)+CY120mg/kg+TLI 7.5Gy‚ð—p‚¢‚½modified myeloablative conditioning‚É‚æ‚铯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŒoŒ±.
‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA•Ÿ‰ªA2ŒŽ16“úA17“ú
’†ªF•Fi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†‘O”Ž‹vAN@G’jAâ–{Œb—˜“ÞA•‰ªNMA‹à“‡@LA’†‘O”ü‰ÀAŽsŒ´O‘PA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
“–‰È‚É‚¨‚¯‚é”ñTBIE”ñATG‚Å‚Ìfludarabine(Flu)‚ð—p‚¢‚½”ñŒŒ‰ŽÒŠÔœ‘”ñ”j‰ó“I“¯Ží‘¢ŒŒŠ²×–EˆÚA(u-RIST)‚̉ðÍ.
‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA•Ÿ‰ªA2ŒŽ16“úA17“ú
‹à@¬Œ³A“ú–ì‰ë”Vi‘åãŽs‘匌‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA”¨’†ˆê¶Aã“c‹±“TA“c–ìè—²“ñAœAì@½AX@Tˆê˜YA’†£ˆê‘¥AˆÉ“¡r˜NA“‡èçqA‰Í‡‘׈êAŠp“ìˆê‹MA’†‘O”Ž‹vA‹Ê’urŽ¡A…’J’m—¢Aã@¹LA’·“¡GŽiA’JŒûCˆêA‚ã—mˆêAŒ´“cŽÀª
ƒNƒ‰ƒhƒ‹ƒrƒ“AƒuƒXƒ‹ƒtƒ@ƒ“ATBI 4Gy‚ð—p‚¢‚½HLA“K‡”ñŒŒ‰ŽÒŠÔœ‘ƒ~ƒjˆÚAF‘½Ž{Ý‹¤“¯—Õ°‘æI‘ŠŽŽŒ±iRIST0305j.
‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA•Ÿ‰ªA2ŒŽ16“úA17“ú

2006”N
‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²——‚¢‚½‚¾‚¯‚Ü‚·B
Koh K-R,Nakamae H,Ohta K,Koh H,Nakane T,Nakamae M,Kanashima H,Hagihara K,Sakamoto E,Terada Y,Takeoka Y,Hirose A,Yamane T,Hino M
Preferential Th2 polarization at the onset of thrombotic microangiopathy (TMA): Immunoligical comparison of TMA versus acute GVHD in terms of peripheral T cell subsets, dendritic cell subsets and cytokine profiles.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Nakane T,Nakamae H,Kamoi H,Koh H,Takeoka Y,Sakamoto E,Kanashima H,Ichihara H,Nakamae M,Koh K-R,Yamane T,Hino M
Decreased serum levels of surfactant protein D (SP-D) prior transplant is associated with the development of bronchiolitis obliterans (BO) and idiopathic pneumonia syndrome (IPS) following allogeneic hematopoietic stem cell transplantation.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Nakamae H, Nakane T, Koh H, Takaoka Y, Sakamoto E, Kanashima H, Ichihara H, Nakamae N, Koh K-R, Yamane T, Hino M
Non-TBI, Non-ATG Containing Fludarabine-Based Regimen for Unrelated Allogeneic Reduced Intensity Transplantation.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Sakamoto E, Nakamae H, Koh K-R, Yamane T, Hino M
Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor. Session Type
  48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Miyawaki S,Ohtake S,Fujisawa S,Kiyoi H,Shinagawa K,Usui N,Miyamura K,Nishimura M,Miyazaki Y,Nishii K,Nagai T,Yamane T,Taniwaki M,Takahashi M,Yagasaki F,Kimura Y,Asou N,Honda S,Ohnishi K,Naoe T,Ohno R
Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose Ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Ohtake S,Miyawaki S,Fujita H,Miki H,Shinagawa K,Usui N,Miyamura K,Nishimura M,Miyazaki Y,Nishii K,Nagai T,Yamane T,Taniwaki M,Takahishi M,Yagasaki F,Kimura Y,Asou N,Honda S,Ohnishi K,Naoe T,Ohno R
Randomized clinical trial of induction therapy comparing intesified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML 201 study).
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°AŽ›“c–FŽ÷A•½ˆä@ŠwAŽè“‡”Ž•¶
VAD—Ö@’†‚Évasospastic angina‚𗈂µ‚½‘½”­«œ‘Žî‚Ì1—á.
‘æ86‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA˜a‰ÌŽRA11ŒŽ18“ú
ŽsŒ´O‘PAN@G’jA’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞA‹à“‡@LA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
”DP‚É‚æ‚èdlj»‚µ‚½“«ITP‚ɑ΂µ“EäB‚ª—LŒø‚Å‚ ‚Á‚½1—á.
‘æ86‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA˜a‰ÌŽRA11ŒŽ18“ú
â–{Œb—˜“ÞAN@G’jA’†ªF•FA•‰ªNMA‹à“‡@LA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”VA‘åàV­•FA•Ÿ“‡—TŽqA¼ì—²”VA‘º£‡Æ
–«œ‘«”’ŒŒ•a‚ÆGastrointestinal stromal tumor‚ð‚Ù‚Ú“¯Žž‚É”­Ç‚µ‚Ä‚¢‚½2Ç—á.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
’†‘O”ü‰ÀA‰Á“¡—²KA’†–{“N–çAâ–{Œb—˜“ÞA‘“c‚³‚ä‚èAŠ™“c‹IŽqAš“ß°‰›A‰H“¡•¶•FA–k콈ê
G-CSF‚É‚æ‚éD’†‹…‚̉^“®§Œä:MAP kinase‚Ì–ðŠ„.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
•‰ªNMA’†‘O”Ž‹vAŽRªF‹vA‚@‹N—ÇA‘¾“cŒ’‰îA’†ªF•FAN@G’jAâ–{Œb—˜“ÞA”‹Œ´Œ‰’ÊA‹à“‡@LA’†‘O”ü‰ÀA“ú–ì‰ë”V
ƒXƒeƒƒCƒh’ïR«‹}«GVHD‚ɑ΂·‚éƒ~ƒRƒtƒFƒm[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹(MMF)‚ÌŒø‰Ê‚ÌŒŸ“¢.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
N@G’jA’†‘O”Ž‹vA’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞA”‹Œ´Œ‰’ÊA’†‘O”ü‰ÀA‚@‹N—ÇA‘¾“cŒ’‰îA“cŒEFsAŽRªF‹vA˜kŸº‰p‹@A“ú–ì‰ë”V
“¯Žíœ‘ˆÚAŒã‚ɃEƒCƒ‹ƒX”x‰Š‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½IPS‚ð”­Ç‚µ‚½ALL‚̈ê—á.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
êm’JˆÀ’ÃŽqA–kŽR@“™A‹›“ˆL•FAŽè“‡”Ž•¶A–쑺¹ìA’·’Jì@–«A—Ñ@–M—Y
‘½”­«œ‘Žî•aŠú‘w•Ê‰»‚ÌÄŒŸ“¢.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
ÂŽR‘×FAŽR‘º—º‰îA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA“ú–ì‰ë”VA˜a“c@—´A’†ì¹Žq
”DP‘OŠú‚Éf’f‚³‚êCAG—Ö@‚É‚ÄŠ°‰ð‚ÉŽŠ‚茒펙‚ðoŽY‚µ“¾‚½‹}«œ‘«”’ŒŒ•a‚Ì1Ç—á.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
ŠÔ•”Œ«Š°A•½ˆä@ŠwA—Ñ@—ÇŽ÷AŽ›“c–FŽ÷Aã“c@ÂA‘åì´FAˆäã@Œ’AŽè“‡”Ž•¶
‰ŠÇ«’°Ž¾Š³‘œ‚ð’悵‚Ä”­Ç‚µ‚½CAEBV‚̈ê—á.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
‘¾“c’‰MAŒÃì‰À‰›AÂŽR‘×FA‹v‘ºŠx‰›Aêm’JˆÀ’ÃŽqA”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
”M”­‚ðŽå‘i‚ÉŒo‰ß‚µdel(7)(q22q32)‚ÌõF‘̈Ùí‚ðŽ¦‚µ‚½”ñ’èŒ^MDSÇ—á.
‘æ68‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ48‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA•Ÿ‰ªA10ŒŽ6-8“ú
â–{Œb—˜“ÞAN@G’jA’†ªF•FA•‰ªNMA‹à“‡@LA“ú–ì‰ë”VA–p@‹ÎAA‰Á–Η‰pA¼@Mˆê
@–«œ‘‘B«Ž¾Š³Ž¡—Ã’†‚Étoxic shock like syndrome‚𔺂¤‰óŽ€«‹Ø–Œ‰Š‚ð‡•¹‚µ‚½1—á.
‘æ179‰ñ“ú–{“à‰ÈŠw‹ß‹E’n•û‰ïA_ŒËA6ŒŽ10“ú
N@G’jA’†ªF•FA•‰ªNMAâ–{Œb—˜“ÞA”‹Œ´Œ‰’ÊA’†‘O”ü‰ÀA’†‘O”Ž‹vA‚@‹N—ÇA‘¾“cŒ’‰îA“cŒEFsAŽRªF‹vA“ú–ì‰ë”V
@ä`‘ÑŒŒˆÚAŒã‚Éatypical RPLS(reversible posterior leukoencephalopathy syndrome)‚ð”­Ç‚µ‚½MDS‚Ì1—á.
‘æ28‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA“Œ‹žA2ŒŽ24“ú-25“ú
’†ªF•FA’†‘O”Ž‹vAŠ›ˆä@”ŽA‘¾“cŒ’‰îAŽRªF‹v@A“ú–ì‰ë”V
“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã•ÂÇ«‹CŠÇŽx‰ŠiBOj”­Ç—\‘ªˆöŽq‚Æ‚µ‚Ä‚ÌŒŒ´SP-DASP-AAKL-6”Z“x‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
‘æ28‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA“Œ‹žA2ŒŽ24“ú-25“ú
â–{Œb—˜“ÞA‘¾“cŒ’‰îA’†‘O”Ž‹vAŽÄ“cåŽqAŽ›“c–FŽ÷AŽRªF‹vA“ú–ì‰ë”V
@‘¢ŒŒŠ²×–EˆÚAŽžD’†‹…Œ¸­Šú‚É‚¨‚¯‚銴õǂɑ΂·‚éƒJƒ‹ƒoƒyƒlƒ€‚Ì—LŒø«.
‘æ28‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA“Œ‹žA2ŒŽ24“ú-25“ú
ŽRªF‹vAœA£’©¶A’†“ˆN”ŽA”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA‚@‹N—ÇA‘¾“cŒ’‰îA•½ˆä@ŠwA’†”ö‹gFAêm’JˆÀ’ÃŽqAŽè“‡”Ž•¶A“ú–ì‰ë”V
@non-Hodgkin's lymphoma‚ɑ΂·‚é‘å—ʉ»Šw—Ö@•¹—pŽ©‰Æ––½ŒŒŠ²×–EˆÚA.
‘æ28‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA“Œ‹žA2ŒŽ24“ú-25“ú
‚@‹N—ÇA’†‘O”Ž‹vA‘¾“cŒ’‰îAN@G’jA’†ªF•FA’†‘O”ü‰ÀA”‹Œ´Œ‰’ÊAâ–{Œb—˜“ÞAŽ›“c–FŽ÷A•‰ªNMAœA£’©¶A“cŒEFsAŽRªF‹vA“ú–ì‰ë”V
@“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚Ì‹}«GVHD”­ÇŽž‚ÆTMA”­ÇŽž‚Ì––½ŒŒTƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg‚¨‚æ‚ÑŒŒ´ƒTƒCƒgƒJƒCƒ“‚Ì“®‘Ô‰ðÍ‚Æ—Õ°“IˆÓ‹`.
‘æ28‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA“Œ‹žA2ŒŽ24“ú-25“ú
–؉ºŠìŒõA•ì‡•vAŠâ“cN”ŽA¬¼‰pŽ÷A–kžŠ•q–çA‰œ@_ŽqA‹´–{@–±A“ú–ì‰ë”V
@’·ŠúŠÔŽ‘±‚µ‚½Á‰»ŠíÇó‚𔺂¤ŸT•a‚ðŠ¿•û–ò‚ƃZƒƒgƒjƒ“ƒmƒ‹ƒAƒhƒŒƒiƒŠƒ“Ä‹zŽû‘jŠQ–ò•¹—p‚ʼnü‘P‚µ‚½Ç—á.
‘æ10‰ñ“ú–{S—Óà‰ÈŠw‰ïA“Œ‹žA1ŒŽ21-22“ú

2005”N
Nakamae R,Yamane T,Hagihara K,Takeoka Y,Sakamoto E,Nakane T,Nakamae M,Koh K-R,Ohta K,Hino M
@Risk factor analysis for thrmobotic microangiopathy after reduced intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
@47th Annual Meeting of the American Society of Hematology
Atlanta, 10-13 Decmber
Miyamura K, Ohnishi K, Naoe T, Takeuchi H, Yoshiki N, Yagasaki F, Fujisawa S, Kimura Y, Motoji T, Imai K, Yamane T, Yoshida S, Miyawaki S, Saburi Y, Kitamura K, Ohno R (JALSG)
Triphasic exponential decline of BCR-ABL transcripts during imatinib therapy for chronic myelogenous leukemia.
47th Annual Meeting of the American Society of Hematology
Atlanta, 10-13 Decmber
¬â‚³‚¨‚èA’†”ö‹gFAœA£’©¶A‹à“‡@LAŽ†’J•x•vA’†‘O”Ž‹vA“ú–ì‰ë”V
@R¶•¨Ž¿—LŒø‚ÌŒŒ‹…æÃHÇŒóŒQ‚ªæs‚µ‚½ˆ««ƒŠƒ“ƒpŽî‚̈êÇ—á.
‘æ84‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘å’ÃA12ŒŽ10“ú
’†ªF•FA“cŒEFsA•‰ªNMAâ–{Œb—˜“ÞA”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA‘¾“cŒ’‰îA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
@‘½”­ßŠO•a•Ï‚ð‚Æ‚à‚È‚¤‰”­isŠúˆ««ƒŠƒ“ƒpŽî‚Ì1—á.
‘æ84‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘å’ÃA12ŒŽ10“ú
’†”ö‹gFA‹à“‡@LAœA£’©¶A¬â‚³‚¨‚èAŽ†’J•x•vA“ú–ì‰ë”V
@•s–¾”M‚̊ӕʂɑ΂·‚ésIL2 receptor‚Ì—L—p«‚ɂ‚¢‚Ä.
‘æ178‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‹ž“sA12ŒŽ3“ú
–؉ºŠìŒõA“cŒEFsA¼–{‹±ˆêA“ú–ì‰ë”V
@ŒŒ´’†Calprotectin‚Ì‘¢ŒŒŠíŽ¾Š³‚É‚¨‚¯‚鑪’èˆÓ‹`‚ÌŒŸ“¢.
‘æ25‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°‰»Šw‰ï”N‰ï˜A‡‘å‰ï
•Ÿ‰ªA11ŒŽ17-20“ú
–؉ºŠìŒõA¬¼‰pŽ÷AŠâ“cN”ŽA–kžŠ•q–çA‰œ@_ŽqA‹´–{@–±
@ŒJ‚è•Ô‚·šq“f‚ðŒ_‹@‚ɈݎîᇂÌf’f‚³‚ꂽˆÝá‘‘¢ÝÇ—á.
‘æ13‰ñ—×{•a°‹¦‰ï‘S‘Œ¤‹†‰ïA“Œ‹žA11ŒŽ17“ú
’†”ö—²•¶AKaushansky Kenneth
@ƒgƒƒ“ƒ{ƒ|ƒGƒ`ƒ“‚Í“]ŽÊˆöŽqFOXO3a‚Ì•sŠˆ«‰»‚¨‚æ‚Ñp27KIP1‚Ì”­Œ»—}§‚ð’Ê‚¶‚Ä‹Šj‹…‘¢ŒŒ‚ð‘£i‚·‚é.
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
’†“ˆN”ŽA•½ˆä@ŠwA‰®–Ø•q–çAŽè“‡”Ž•¶Aˆäã@Œ’A•½Î—¥ŽqAˆäŒû‘¾˜YAâ–{@˜j
@“ÁˆÙ‚È”’ŒŒ‰»‚ðŽ¦‚µ‚½Anaplastic large cell lymphoma‚̈ê—á.
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
’†‘O”Ž‹vA”‹Œ´Œ‰’ÊAŽ›“c–FŽ÷Aâ–{Œb—˜“ÞA•‰ªNMA’†ªF•FA’†‘O”ü‰ÀA‚@‹N—ÇA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@“–‰È‚É‚¨‚¯‚铯ŽíˆÚAŒãTMA‚̃ŠƒXƒNƒtƒ@ƒNƒ^[‚ÌŒã•ûŽ‹“IŒŸ“¢.
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
‘¾“c’‰MAŒÃì‰À‰›A^@çéŽõAÂŽR‘×FAŽR‘º—º‰îAêm’JˆÀ’ÃŽqA’†‘O”Ž‹vA‚@‹N—ÇA‘¾“cŒ’‰îAŽRªF‹vA“cŒEFsA“ú–ì‰ë”V
@R‚ª‚ñÜŽ¡—ÃŒã‚Ì‘¢¸‹@”\‚Ì’ÇÕ‚Æ“¯ŽíˆÚAŒã‚Ì”DP‚ÅŒ’Ž™‚𓾂½”’ŒŒ•aÇ—á.
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
êm’JˆÀ’ÃŽqA‘¾“c’‰MAÂŽR‘×FAŽR‘º—º‰îA^@çéŽõA¬â‚³‚¨‚èA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@‘½”­«œ‘Žî‚ɑ΂·‚éƒTƒŠƒhƒ}ƒCƒhŽ¡—Â̗հ“IŒŸ“¢
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
•Ÿ“‡—TŽqA‘åàV­•FAˆäã@Œ’A“ú–ì‰ë”VAã“c^ŠìŽq
@ƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚É‚¨‚¯‚éCyclooxygenase-2‚Ì”­Œ».
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
•‰ªNMA’†¼Œ’ŽjA“ú–ì‰ë”VA’†‘O”Ž‹vA”‹Œ´Œ‰’ÊAâ–{Œb—˜“ÞA’†ªF•FAN@G’jA’†‘O”ü‰ÀA–q“c—
@ƒŠƒ“ƒpŽî—l‹u]Çilymphomatoid papulosisj‚̈ê—á.
‘æ67‰ñ“ú–{ŒŒ‰tŠw‰ïE‘æ47‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‡“¯‘‰ïA‰¡•lA9ŒŽ17E18“ú
^@çéŽõA•Ä“c@åAÂŽR‘×FAŽR‘º—º‰îAêm’JˆÀ’ÃŽqAˆÀ“¡Œ’Ž¡A’†“ˆ‘דTA‹à@Žç—Ç
@lHŒÄ‹zŠíŠÇ—’†‚Ìmidazolam“Š—^‚É‚æ‚è‹}«ŠÌ•s‘S‚ð”­Ç‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ÌÇ—á.
‘æ177‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA9ŒŽ10“ú
’†ªF•FA’†‘O”Ž‹vAâ–{Œb—˜“ÞA•‰ªNMA”‹Œ´Œ‰’ÊA‘¾“cŒ’‰îA‚@‹N—ÇA“cŒEFsAŽRªF‹vA“ú–ì‰ë”V
@Š°‰ð“±“ü’†‚É”]”^á‡‚ð‡•¹‚µ‚½AML‚ɑ΂µ“¯Ží––½ŒŒŠ²×–EˆÚA‚ðŽ{s‚µ“¾‚½1—á.
‘æ83‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘åãA6ŒŽ11“ú
â–{Œb—˜“ÞA’†ªF•FA•‰ªNMAœA£’©¶A”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA’·’J쑾˜YA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@L-asparaginase‚ªˆêŽž“I‚É—LŒø‚Å‚ ‚Á‚½nasal NK/T-cell lmphoma.
‘æ176‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ4“ú

2004”N
¬â‚³‚¨‚èA’†”ö‹gFA鑺®“oAŽÄ“cåŽqA‹à“‡@LAŽ†’J•x•vi‚í‚©‚±‚¤‰ï•a‰@jA¼ŒûC•½A“ú–ì‰ë”V
@Ž©ŒÈ–Ɖu«ŠÌ‰Š‚ÌŒo‰ß’†A‚“x‚̔ČŒ‹…Œ¸­‚𗈂µ‚½Ç—á.
‘æ175‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‹ž“sA12ŒŽ18“ú
’†ªF•FA’†‘O”Ž‹vAŽ›“c–FŽ÷A’†‘O”ü‰ÀA”‹Œ´Œ‰’ÊA’·’J쑾˜YA‚@‹N—ÇA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@––½ŒŒ‘¢ŒŒŠ²×–E̎掞‚̇•¹Ç—\‘ª‚ɑ΂·‚éS”“®‰ðÍ‚Ì—Õ°“IˆÓ‹`.
‘æ27‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ïA‰ªŽRA12ŒŽ16E17“ú
”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA’·’J쑾˜YAŽ›“c–FŽ÷A•‰ªNMA’†ªF•FA‚@‹N—ÇA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@CML‚ɇ•¹‚µ‚½“]ˆÚ«‘å’°Šà‚ɑ΂µ‚Ää`‘ÑŒŒƒ~ƒjˆÚA‚ðŽ{s‚µ‚½1—á.
‘æ27‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ïA‰ªŽRA12ŒŽ16E17“ú
•‰ªNMAœA£’©¶A’†ªF•FAâ–{Œb—˜“ÞA”‹Œ´Œ‰’ÊA’†‘O”Ž‹vA’·’J쑾˜YAŽRªF‹vA“ú–ì‰ë”V
@‚—î‚Ì•ƒei75Îj‚æ‚蓯Žíœ‘ˆÚA‚ðŽ{s‚µ‚½PhõF‘Ì—z«‹}«”’ŒŒ•a‚Ì1—á
‘æ82‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï@‹ž“sA12ŒŽ11“ú
ÂŽR‘×FAŽR‘º—º‰îA^@çéŽõA‘¾“c’‰MAêm’JˆÀ’ÃŽqi•{’†•a‰@jA“ú–ì‰ë”V
@––½ŒŒ’†‚ÉCD10—z«T×–E‚ð”F‚ß‚½Angioimmunoblast T cell lymphoma
‘æ82‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï@‹ž“sA12ŒŽ11“ú
ΈäˆêŒcAŽR–{‹`®A–쑺¹ìA–kŽR@“™A—Ñ@–M—YAêm’JˆÀ’ÃŽqA“¡–ì—TŽqA‰®–Ø•q–çAŽè“‡”Ž•¶AŒj“c’B–çA‰Y£•¶–¾A–k“‡O”V
@‚—îŽÒaggressive”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂·‚éVNCOP-B—Ö@—LŒø«‚ƈÀ‘S«‚ÉŠÖ‚·‚錟“¢‘æ2•ñ
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
ÂŽR‘×FAŽR‘º—º‰îA^@çéŽõA‘¾“c’‰MAêm’JˆÀ’ÃŽqA“ú–ì‰ë”V
@––½ŒŒ’†‚ÉCD10—z«T×–E‚ð”F‚ß‚½Angioimmunoblastic T-cell lymphoma
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
“¡–ì—TŽqA‘åàV­•FA•½ŽR“¹•FA––•ï„‹vAFŠ™–F”üA”’ˆäLKAˆÉ‘q‹`OA“ú–ì‰ë”VAã“c^ŠìŽq
@Diffuse large B-cell lymphoma‚É‚¨‚¯‚鉊Ç×–EZ‚Æ—\Œã‚ÌŠÖŒW
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
¬â‚³‚¨‚èA‰H“¡•¶•FAŠ™“c‹IŽqAâ–{Œb—˜“ÞA’·’J쑾˜YA–Ø‘º˜NŽqA“ú–ì‰ë”VA–k콈ê
@ƒqƒg’P‹…‚É‚¨‚¢‚Äè÷—±‹…ƒRƒƒj[ŽhŒƒˆöŽq‚ÍLPS‚É‚æ‚éŽîᇉ󎀈öŽq‚ÌŽY¶‚ðSTAT3‚ÌŠˆ«‰»‚ð‰î‚µ‚ħŒä‚·‚é
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
‘¾“c’‰Mi¶’·‰ï•{’†•a‰@jA^@çéŽõAÂŽR‘×FAŽR‘º—º‰îAêm’JˆÀ’ÃŽqA’·’J쑾˜YA’†‘O”Ž‹vA‚@‹N—ÇA‘¾“cŒ’‰îAŽRªF‹vA“cŒEFsA“ú–ì‰ë”V
@Ž©ŒÈ–Ɖu«—nŒŒ«•nŒŒ‚ð‡•¹‚µ‹}«”’ŒŒ•a‰»Žž‚É46,XY,+9,der(9;18)(p10;q10)‚ÌŠjŒ^ˆÙí‚ðŽ¦‚µ‚½MDSÇ—á
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
à_–ØŽìŒbAã@¹OA_“c‘PLA˜a‹C@“ÖAŽRªF‹vA‹›“ˆL•FA’†ˆä–M‹vAˆÀ•”NMAã“c‹±“TAˆäã“O–çAŒá‹½_ŒúA“ú‚“¹OA—Ñ@F¹Aˆî–{Œ«OA“’’nWˆê˜YA–L“ˆ’“¿A¬—Ñ’¼Ž÷Aˆ°“c—²ŽiA”¨’†ˆê¶A’†”ö^“ñA‹{˜dŽO˜YA’JŒûCˆê
@‹}«ƒŠƒ“ƒp‹…«”’ŒŒ•a‚ɑ΂·‚霑”ñ”j‰ó“IˆÚA‚Ì—LŒø«F33—á‚Ì‘½Ž{Ý‹¤“¯Œã•ûŽ‹“IŒ¤‹†
‘æ66‰ñ“ú–{ŒŒ‰tŠw‘‰ïE‘æ46‰ñ“ú–{—Õ°ŒŒ‰tŠw‘‰ïA‹ž“sA9ŒŽ17E18E19“ú
¬¼ŽqA‘弈êmAŽ›àV@•A“cŒEFsAŽRªF‹vA“ú–ì‰ë”V
@ŠeŽíŒŒ‰tŽ¾Š³‚É‚¨‚¯‚é‰Â—n‰»Œ^RCAS1‘ª’è‚ÌŒŸ“¢
‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïA“Œ‹žA9ŒŽ3E4E5“ú
–؉ºŠìŒõi¶’·‰ïˆ¤•—•a‰@jA“cŒEFsA•Ÿˆä@“OAŽRªF‹vA“ú–ì‰ë”V
@‘¢ŒŒŠíŽ¾Š³‚É‚¨‚¯‚ébiotin‘ª’èˆÓ‹`‚̉”\«‚ɂ‚¢‚Ä
‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïA“Œ‹žA9ŒŽ3E4E5“ú
‰®–Ø•q–çi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†“‡N”ŽA•½ˆä@ŠwAŽè“‡”Ž•¶
@‰óás«”^”çǂɇ•¹‚µ‚½MDS‚ÉŒŒ‰ŽÒŠÔ“¯Ží––½ŒŒˆÚA‚ðŽ{s‚µ‚½1—á.
@‘æ81‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘åãA7ŒŽ3“ú
¬â‚³‚¨‚èi‚í‚©‚±‚¤‰ï•a‰@jA’†”ö‹gFA^@çéŽõAŽÄ“cåŽqA‹à“‡@LAŽ†’J•x•vA•‰ªNMA“ú–ì‰ë”V
@Š°‰ð“±“ü—Ö@‚É‚æ‚錌¬”ÂŒ¸­Šú‚ÉŒŒð«Ã–¬‰Š‚ð‚«‚½‚µ‚½‹}«œ‘«”’ŒŒ•a‚Ì1Ç—á.
‘æ81‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘åãA7ŒŽ3“ú
”‹Œ´Œ‰’Êi‘åãŽs—§‘åŠwjA•‰ªNMAœA£’©¶A’†‘O”Ž‹vA’·’J쑾˜YA‘¾“cŒ’‰îA“cŒEFsAŽRªF‹vA“ú–ì‰ë”VA’†”ö‹gF
@69΂̂—îAMLŠ³ŽÒ‚ÉŽ{s‚µ‚½ä`‘ÑŒŒƒ~ƒjˆÚA.
‘æ173‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ5“ú
’Ë–{—R‰À(‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹g‰ªŽéA¼ŽR@—TA¬¼Œ[•vA•‰ªNMAŽè“‡”Ž•¶A²“¡—˜•FA‘Oì’¼‹PAˆäã@Œ’
@Subcutaneous paniculitis-like T-cell lymphoma‚Ì1—á.
‘æ173‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ5“ú
^@çéŽõi‚í‚©‚±‚¤‰ï•a‰@jA’†”ö‹gFA‰Z¶‹±ÍAV•Û‹MŽmAŒ´“c”Ž‰ë
@DŽ_‹…‘‰Á‚𔺂¤ŠÔŽ¿«”x‰Š‚𕹔­‚µAƒXƒeƒƒCƒh‚É‚æ‚鎡—ª’˜Œø‚·‚é‚àŒ¸—Ê’†‚É‹}Œƒ‚Ȉ«‰»‚ð”F‚ß‚½MDS‚Ì1—á.
‘æ173‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ5“ú
’†”ö‹gFi‚í‚©‚±‚¤‰ï•a‰@jAŽÄ“cåŽqA¬â‚³‚¨‚èA‹à“‡@LAŽ†’J•x•vA“ú–ì‰ë”V
@Ž©‘R‰ñ•œ‚ðŠm”F‚µ“¾‚½‚“x‚ÌŒŒ¬”ÂŒ¸­Ç‚Ì3—á.
‘æ173‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ5“ú
ŠÔ•”Œ«Š°i˜aòŽs—§•a‰@jA˜@’rF•vA”gŒËŽ‹KA¬¼r²A´…‘וvA‰Í£‹g—YA¼‰º°•FA¼–{³‹I
@ATG—Ö@Œã‚ɌŌ`Šà‚ð”­Ç‚µ‚½Ä¶•s—Ç«•nŒŒ‚Ì3—á.
‘æ173‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ5“ú
ŽÄ“cåŽqi‘åãŽs—§‘åŠwjAâ–{Œb—˜“ÞA’†‘O”Ž‹vA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@“–‰È‚É‚¨‚¯‚éFebrile neutropenia‚ɑ΂·‚éR¶•¨Ž¿Ž¡—Â̗հ‰ðÍ.
‘æ78‰ñ“ú–{Š´õÇŠw‰ï‘‰ïA“Œ‹žA4ŒŽ6“úA7“ú

2003”N
“ú–ì‰ë”VA–q“c—A‘¾“cŒ’‰îA”‹Œ´Œ‰’ÊA‘¾“c’‰MAŽRªF‹vAêm’JˆÀ’ÃŽq
@G-CSF‚ð—p‚¢‚½“¯Ží––½ŒŒŠ²×–EˆÚAÌŽæŒã14ƒ–ŒŽ‚É‹}«œ‘«”’ŒŒ•a‚ð”­Ç‚µ‚½Ç—á
‘æ26‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA‰¡•lA12ŒŽ19“ú|20“ú
Ž›“c–FŽ÷A’†‘O”Ž‹vAÔ–x”ü‰ÀAÂŽR‘×FA’·’J쑾˜YAŽR‘º—º‰îA”‹Œ´Œ‰’ÊA’†“ˆN”ŽA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@ƒAƒ“ƒgƒ‰ƒTƒCƒNƒŠƒ“Œn–òÜ‚É‚æ‚é‹}«S“Å«‚̃Aƒ“ƒMƒIƒeƒ“ƒVƒ“IIŽó—e‘Ì‘jŠQÜiƒoƒ‹ƒTƒ‹ƒ^ƒ“j‚É‚æ‚é—\–hŒø‰Ê
‘æ26‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA‰¡•lA12ŒŽ19“ú|20“ú
ÂŽR‘×FA’†‘O”Ž‹vAŽR‘º—º‰îA’·’J쑾˜YAŽ›“c–FŽ÷A”‹Œ´Œ‰’ÊA’†“ˆN”ŽA‘¾“cŒ’‰îAŽRªF‹vA“ú–ì‰ë”V
@œ‘”ñ”j‰ó“I‘Oˆ’u‚ð—p‚¢‚½”ñŒŒ‰ŽÒŠÔœ‘ˆÚA‚Ì‚SÇ—á
‘æ26‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA‰¡•lA12ŒŽ19“ú|20“ú
ŽR‘º—º‰îAŽRªF‹vAÂŽR‘×FA^@çéŽõA“‡@‰xŽqAŽ›“c–FŽ÷A’†‘O”Ž‹vA’·’J쑾˜YA–q“c—A‘¾“cŒ’‰îA“ú–ì‰ë”V
@”ñŠ°‰ðŠú”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ÉNST‚ðŽ{s‚µ‚½4—á
‘æ26‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïA‰¡•lA12ŒŽ19“ú|20“ú
‹´–{‰K–¤A’†”ö‹gFA^@çéŽõAœA£’©¶AŽ†’J•x•vAŽRªF‹vA“‡@‰xŽqA‹à“‡@LA“ú–ì‰ë”V
@ƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19Š´õ‚ð”­Ç‚·‚é‚Æ“¯ŽžŠú‚Éœ‘ˆÙŒ`¬ÇŒóŒQ‚ɈÚs‚µ‚½Ä¶•s—Ç«•nŒŒ‚̈ê—á
‘æ172‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA˜a‰ÌŽRA12ŒŽ20“ú
Nakamae H, Terada Y, Akahori M, Aoyama Y, Hasegawa T, Yamamura R, Ohta
K, Yamane T, Hino M
@Angiotensin II receptor blocker prevents acute cardiotoxicity following CHOP
5th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Ichinohe T, Uchiyama T, Shimazaki S, Tamaki S, Watanabe A, Hamaguchi M,
Hino M, Adachi S, Endoh M, Uoshima N, Yoshihara T, Hatanaka K, Fujii H, Kawa
K, Gondo H, Kawanishi K, Maruya E, Saji H, Kodera Y
@Outcome of non-T-cell-depleted hematopoietic stem cell transplantation
between HLA-haploidentical non-inherited natural antigen (NIMA)-mismatched
family members linked with long-term feto-maternal microchimerism
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Yamane t, Aoyama Y, Nakamae H, Hasegawa T, Yamamura R, Sakamoto C,
Terada Y, Koh G, Ohta K, Hino M
@Non-myeloablative hematopoietic stem cell transplantation for hematological
malignancies (abstract)
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Ohta K, Makita K, Mugitani A, Hagiwara K, Ohta T, Yamane T, Hino M
@Acute myelogenous leukemia in a donor after granulocyte-colony stimulating
factor primed peripheral blood stem cell harvestiabstract)
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
‰®–Ø•q–çAŽRªF‹v
@ŒŒ‰tŽ¾Š³‚Ì•ªŽq•W“I—Ö@|‚b‚l‚k‚ɑ΂·‚éImatinib‚ÌŽ¡—ìтð’†S‚É|
‘æ‚W‚O‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA_ŒËA12ŒŽ6“ú
^@çéŽõA‹´–{‰K–¤A’†”ö‹gFAœA£’©¶AŽ†’J•x•v
ATL‚ÌŒo‰ß’†‚É×–E«–Ɖu•s‘S‚É‚æ‚銴õǂ𕹔­‚µ‚½‚RÇ—á
‘æ‚W‚O‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA_ŒËA12ŒŽ6“ú
•‰ªNMAŽè“‡”Ž•¶A‰®–Ø•q–çA‹à“‡@L
@’nŒÅ‚ߗÖ@’†‚É‘½”­«‚̉ŠÇ«ŠÌ‹UŽîᇂ𶂶‚½‹}«‘Oœ‘«”’ŒŒ•a
‘æ‚W‚O‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA_ŒËA12ŒŽ6“ú
’†“ˆN”ŽA‘¾“cŒ’‰îAŽR‘º—º‰îAÂŽR‘×FA’·’J쑾˜YA’†‘O”Ž‹vAŽ›“c–FŽ÷A”‹Œ´
Œ‰’ÊAŽRªF‹vA“ú–ì‰ë”V
@S–Œ”X–E‚ð‡•¹‚µ‚½–«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ‚Ì‚P—á
‘æ‚W‚O‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA_ŒËA12ŒŽ6“ú
–؉ºŠìŒõA“cŒEFsAŽRªF‹vA“ú–ì‰ë”V
@‘¢ŒŒŠíŽîᇫŽ¾Š³‚É‚¨‚¯‚éRP53R‘Ì‘ª’è‚Ì—L—p«‚ÌŒŸ“¢
‘æ50‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïAL“‡A10ŒŽ29“ú-10ŒŽ31“ú
“ú–ì‰ë”VAŽRªF‹v
@ˆÚAˆã—Ã
‘æ50‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïAL“‡A10ŒŽ29“ú-10ŒŽ31“ú
’†“ˆN”ŽA”‹Œ´Œ‰’ÊAŽ›“c–FŽ÷AŽR‘º—º‰îAÂŽR‘×FA’†‘O”Ž‹vA’·’J쑾˜YA‘¾“c
Œ’‰îAŽRªF‹vA“cŒEFsA“ú–ì‰ë”V
@Helicobacter pylori œ‹ÛŽ¡—Âɂæ‚éITPŽ¡—Âɂ¨‚¯‚é‹»–¡‚ ‚éÇ—á
‘æ171‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA9ŒŽ27“ú
–q“c—Aêm’JˆÀ’ÃŽqA”ö¼–rŽqA‘¾“c’‰MA¼–Ø‚³‚¨‚èA”‹Œ´Œ‰’ÊAŽRªF‹vA“ú
–ì‰ë”V
@‘Sg‚̃AƒXƒyƒ‹ƒMƒ‹ƒXÇðÇ‚ð‹N‚±‚µA‹}Œƒ‚ÈŒo‰ß‚ð‚½‚Ç‚Á‚½ATL‚Ì–UŒŸ—á
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
’J–{“N–çA‰Í–ì‰Ã•¶A“ú–ì‰ë”VAã@¹LA‹{˜dŽO˜YA•õÎ@^A’JŒûCˆêA‰Í@Œh
¢AŒ´“cŽÀª
@Œ’ílƒhƒi[‚É‚¨‚¯‚é––½ŒŒŠ²×–E‚ÌÄ“®ˆõ
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
êm’JˆÀ’ÃŽqA–q“c—A‘¾“c’‰MA¼–Ø‚³‚¨‚èA’†”ö‹gFA‰®–Ø•q–çA•‰ªNMAœA
£’©¶A”‹Œ´Œ‰’ÊAŽRªF‹vA“ú–ì‰ë”V
@Ph—z«ALL5—á‚É‚¨‚¯‚éSTI571‚ÌŽg—pŒoŒ±
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
’·’Jì@–«A¼ì­ŸA–쑺¹ìA“cŒEFsA––œA@ŒªA¼‹½ŸNA—Ñ@–M—YA‘q“c‹`
”V
@ITP‚ɑ΂·‚éƒXƒeƒƒCƒhŽ¡—Â͜—ʂɉe‹¿‚ð‚¨‚æ‚Ú‚·‚©
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
‘¾“c’‰MA”‹Œ´Œ‰’ÊA¼–Ø‚³‚¨‚èA–q“c—Aêm’JˆÀ’ÃŽqA’·’J쑾˜YA’†‘O”Ž‹vA
ÂŽR‘×FA‘¾“cŒ’‰îAŽRªF‹vA“cŒEFsA“ú–ì‰ë”V
@’˜–¾‚È• ’ÉA• …’™—¯‚É‚Ä”­Ç‚µŒŒ¬”‘‘½‚ðŽ¦‚µ‚½C1ƒCƒ“ƒqƒrƒ^[Šˆ«’ቺ‚É‚æ
‚éAngioedema‚̈ê—á
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
‰H“¡•¶•FA—é–ØŒ«ˆêA‰Á“¡—²KA¼–Ø‚³‚¨‚èAÔ–x”ü‰ÀAâ–{Œb—˜“ÞA’·’J쑾˜YA
ã–{e•FAŽRªF‹vA¬–¸”ü’m‘¥A“ú–ì‰ë”VA–k콈ê
@G-CSF“Š—^‚É‚æ‚éƒqƒgD’†‹…‚ÌRituximabˆË‘¶«ADCCŠˆ«‚Ì‘‹­
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
ŽRªF‹vAÂŽR‘×FAã–{e•FA’†‘O”Ž‹vA’·’J쑾˜YAŽR‘º—º‰îA^@çéŽõAŽ›“c
–FŽ÷A‘¾“cŒ’‰îA“ú–ì‰ë”V
@‘¢ŒŒŠíˆ««Žîᇂɑ΂·‚霑”ñ”j‰ó“I‘¢ŒŒŠ²×–EˆÚA
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
‘¾“cŒ’‰îA’†‘O”Ž‹vA“‡@‰xŽqAœA£’©¶A’†‰Æ´—²AÂŽR‘×FA’·’J쑾˜YAŽRª
F‹vA“ú–ì‰ë”V
@ƒqƒgœ‘ƒXƒgƒ[ƒ}×–E‚ɑ΂·‚éAra-C‚Ì’¼Ú“IŽhŒƒì—p
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
’·’J쑾˜YA—é–ØŒ«ˆêAã–{e•FA¼–Ø‚³‚¨‚èAÔ–x”ü‰ÀA‘¾“cŒ’‰îA“ú–ì‰ë”VA–k
콈ê
@ƒqƒgD’†‹…‚É‚¨‚¯‚éIAP family‚Ì”­Œ»F–«D’†‹…«”’ŒŒ•a×–E‚É‚¨‚¯‚écIAP2‚Ì
‰ßè”­Œ»
‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ45‰ñ“ú–{—Õ°ŒŒ‰tŠw‰ï‘‰ïA‘åãA8ŒŽ28“ú
^@çéŽõAÂŽR‘×FAã–{e•FA’·’J쑾˜YA’†‘O”Ž‹vAŽ›“c–FŽ÷A‘¾“cŒ’‰îAŽRª
F‹vA“cŒEFsA“ú–ì‰ë”V
@”ñƒXƒeƒƒCƒhŒnÁ‰Š’Á’ÉÜ‚É‚æ‚鑽”­«‰º•”Á‰»ŠÇ’×á‡‚ð‡•¹‚µ‚½‹}«œ‘’P‹…
«”’ŒŒ•a‚Ì‚P—á
‘æ79‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘åãA7ŒŽ12“ú
’†”ö‹gFAŽ†’J•x•vA‹´–{‰KŒÈA^@çéŽõAœA£’©¶
@STI571‚É‚æ‚è3“x–Ú‚Ì×–Eˆâ“`Šw“IŠ®‘SŠ°‰ð‚É“ž’B‚µ‚½CML‚Ì1—á
‘æ79‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ïA‘åãA7ŒŽ12“ú
Ž›“c–FŽ÷A‘¾“cŒ’‰îAÂŽR‘×FAã–{e•FA’†‘O”Ž‹vA’·’J쑾˜YA^@çéŽõAŽRª
F‹vA“cŒEFsA“ú–ì‰ë”V
@“¯Ží––½ŒŒŠ²×–EˆÚAŒã‚ÉäXE—¼‘¤t‚ÉŽîᎌ`¬‚𔺂Á‚ÄÄ”­‚µ‚½‹}«œ‘«”’
ŒŒ•a‚̈ê—á
‘æ170‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ14“ú
•‰ªNMAŽR‘º—º‰îA›–ìˆÀŠìAŠâè@¹AX‰ª@~
@Š°‰ð“±“ü—Ö@’†‚Éall-transƒŒƒ`ƒmƒCƒ“Ž_‚É‚æ‚é”]ˆ³˜´i‚𶂶‚½‹}«œ‘«”’ŒŒ•a
iAML M3j‚̈êÇ—á
‘æ170‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ïA‘åãA6ŒŽ14“ú